Merge pull request 'rio: extract claims from 2026-02-27-theiaresearch-metadao-claude-code-founders' (#801) from extract/2026-02-27-theiaresearch-metadao-claude-code-founders into main

Co-authored-by: m3taversal <m3taversal@gmail.com>
Co-committed-by: m3taversal <m3taversal@gmail.com>

agents/vida/musings/research-2026-03-12.md

@@ -0,0 +1,142 @@
+---
+status: seed
+type: musing
+stage: developing
+created: 2026-03-12
+last_updated: 2026-03-12
+tags: [glp-1, value-based-care, medicare-advantage, drug-economics, prevention-economics, research-session]
+---
+
+# Research Session: GLP-1 Agonists and Value-Based Care Economics
+
+## Research Question
+
+**How are GLP-1 agonists interacting with value-based care economics — do cardiovascular and organ-protective benefits create net savings under capitation, or is the chronic use model inflationary even when plans bear full risk?**
+
+## Why This Question
+
+**Priority justification:** This follows the gap flagged in the March 10 session ("GLP-1 interaction with MA economics") and directly tests the attractor state thesis. If the most important new drug class is inflationary even under capitated models, the "prevention-first system that profits from health" faces a serious complication.
+
+**Connections to existing KB:**
+- Existing claim rates GLP-1 net cost impact as "inflationary through 2035" — but this was written from a system-wide perspective, not from the capitated plan perspective where downstream savings accrue to the same entity bearing drug costs
+- MA economics research from March 10 showed MA is VBC in form but misaligned in practice — how does GLP-1 prescribing behavior differ under genuine full risk vs. coding-arbitrage MA?
+- The attractor state thesis depends on prevention being economically viable under aligned payment — GLP-1s are the largest test case
+
+**What would change my mind:**
+- If capitated plans are actively embracing GLP-1s AND showing improved MLR, that strengthens the attractor state thesis
+- If even capitated plans are restricting GLP-1 access due to cost, that complicates the "aligned incentives → better outcomes" story
+- If cardiovascular/organ-protective benefits are large enough to offset drug costs within 3-5 years under capitation, the "inflationary through 2035" claim needs updating
+
+## What I Found
+
+### The Core Finding: GLP-1 Economics Are Payment-Model-Dependent
+
+The existing KB claim ("inflationary through 2035") is correct at system level but misleading at payer level. The answer to whether GLP-1s are inflationary depends on WHO is paying and OVER WHAT TIME HORIZON:
+
+**System-level:** Inflationary. CBO projects $35B additional federal spending over 2026-2034. Volume growth outpaces price compression. This is what the existing claim captures.
+
+**Risk-bearing payer level:** Potentially cost-saving. Value in Health modeling shows Medicare net savings of $715M over 10 years when multi-indication benefits are counted. Aon employer data shows medical cost growth reverses after 12 months of sustained use. The SELECT trial exploratory analysis shows 10% reduction in ALL-CAUSE hospitalizations — the single largest cost driver.
+
+**The temporal dimension is key:** Aon data shows costs go UP 23% in year 1 (drug costs dominate), then grow only 2% vs. 6% for non-users after 12 months. Short-term payers see only costs; long-term risk-bearers capture savings. This directly maps to the VBC payment model question.
+
+### Five Key Tracks
+
+**Track 1: Multi-Organ Protection (Beyond Weight Loss)**
+
+GLP-1s are no longer just weight loss drugs. Three major organ-protection trials:
+- SELECT: 20% CV event reduction, 10% fewer all-cause hospitalizations, 11% fewer hospital days
+- FLOW: 24% reduction in major kidney events, 29% reduction in CV death, slowed eGFR decline by 1.16 mL/min/year (delays dialysis at $90K+/year)
+- MASH Phase 3: 62.9% resolution of steatohepatitis vs. 34.3% placebo
+
+Plus unexpected signals: Aon reports 50% lower ovarian cancer incidence and 14% lower breast cancer in female users (preliminary but striking).
+
+The multi-organ protection reframes GLP-1s from "weight management drug" to "metabolic disease prevention platform." The cost-benefit calculation changes dramatically when you add kidney protection ($2,074/subject avoided CKD), liver protection ($28M MASH savings in Medicare), and cancer risk reduction on top of CV benefits.
+
+CLAIM CANDIDATE: GLP-1 agonists protect at least three major organ systems (cardiovascular, renal, hepatic) through mechanisms partially independent of weight loss, making them the first drug class to address metabolic syndrome as a unified disease rather than treating its components separately.
+
+**Track 2: Adherence — The Binding Constraint**
+
+The economics only work if patients STAY ON the drug. They mostly don't:
+- Non-diabetic obesity: 32.3% persistent at 1 year, ~15% at 2 years
+- Diabetic: 53.5% at 1 year, ~30% at 2 years
+- Weight regain after stopping: average 9.69 kg, all weight lost reversed after 1.7 years
+
+This creates a paradox: chronic use makes GLP-1s expensive, but discontinuation eliminates the downstream savings that justify the cost. The economics only work if adherence is sustained AND the payer captures downstream savings.
+
+At $245/month (Medicare deal), 12 months of GLP-1 therapy costs $2,940 per patient. If 64.8% discontinue and regain weight (eliminating downstream benefits), the plan loses $2,940 × 0.648 = ~$1,905 per enrolled patient on non-responders. The adherent 35.2% must generate enough savings to cover both their own drug costs AND the sunk costs of non-completers.
+
+CLAIM CANDIDATE: GLP-1 cost-effectiveness under capitation requires solving the adherence paradox — the drugs are only cost-saving for sustained users, but two-thirds of patients discontinue within a year, creating sunk drug costs with no downstream benefit offset.
+
+**Track 3: MA Plans Are Restricting, Not Embracing**
+
+Near-universal prior authorization for GLP-1s under MA (up from <5% in 2020-2023 to ~100% by 2025). This is MA plans actively managing short-term costs, NOT embracing prevention.
+
+This directly contradicts the simple version of the attractor state thesis: "align incentives and prevention follows." MA plans ARE theoretically incentivized to prevent costly downstream events. But they still restrict GLP-1 access because:
+1. Short-term budget pressure overrides long-term savings expectations
+2. Adherence uncertainty means most patients won't generate savings
+3. Member turnover means plans may not capture downstream benefits
+4. The VBC is in form only — coding arbitrage dominates actual strategy (March 10 finding)
+
+CLAIM CANDIDATE: Medicare Advantage plans' near-universal prior authorization for GLP-1s demonstrates that capitation alone does not align incentives for prevention — short-term cost management, adherence uncertainty, and member turnover create structural resistance to preventive drug coverage even under full risk.
+
+**Track 4: Policy Is Moving Faster Than Expected**
+
+Three converging policy developments are reshaping the landscape:
+1. **Trump/Novo/Lilly deals:** $245/month for Medicare ($50 OOP), $350 general (TrumpRx). ~82% below list price.
+2. **CMS BALANCE Model:** First federal payment model explicitly designed to test GLP-1 + VBC interaction. Requires lifestyle interventions alongside medication. Adjusts capitation rates for obesity. Launches May 2026 (Medicaid), January 2027 (Part D).
+3. **International generics:** Canada patents expired January 2026. China has 17+ generics in Phase 3. Prices could reach $40-50/month internationally by 2028.
+
+The price trajectory is the single most important variable. At $245/month, cost-effectiveness depends on adherence and downstream savings. At $50/month (international generic prices), GLP-1s are unambiguously cost-effective under ANY payment model. The question is how fast prices converge.
+
+**Track 5: Counter-Evidence — Sarcopenia Risk**
+
+The strongest safety argument against broad GLP-1 deployment in the Medicare population:
+- 15-40% of weight lost is lean body mass (muscle, not fat)
+- Elderly adults already lose 12-16% of muscle mass with aging
+- Weight cycling (start GLP-1 → lose muscle → stop → regain fat but NOT muscle → worse body composition) is the most common outcome given 64.8% discontinuation
+- Sarcopenic obesity (high fat + low muscle) affects 10-20% of older adults and increases falls, fractures, disability
+
+This is genuinely concerning: the same drug that prevents CV events may cause sarcopenic disability. For the Medicare population specifically, the net health effect is ambiguous until the sarcopenia risk is better quantified.
+
+### Population-Level Signal
+
+US obesity prevalence declined from 39.9% (2022) to 37.0% (2025) — first population-level decline in recent years. If causally attributable to GLP-1s, this is the largest pharmaceutical impact on a population health metric since vaccines. But the equity concern is real: GLP-1 access skews wealthy/insured.
+
+## Key Surprises
+
+1. **CBO vs. ASPE divergence is enormous.** CBO says $35B additional cost; ASPE says $715M net savings. Both are technically correct but answer different questions. Budget scoring structurally disadvantages prevention.
+
+2. **Diabetes prevention is the largest economic lever, not cardiovascular.** Per-subject savings from avoided T2D ($14,431) dwarf avoided CV events ($1,512), even in a CV outcomes trial.
+
+3. **MA plans are restricting, not embracing.** Near-universal PA for GLP-1s means capitation alone doesn't create prevention incentives. This challenges the simple attractor state thesis.
+
+4. **The temporal cost curve is the key insight.** Costs up 23% in year 1, then slow to 2% growth vs. 6% for non-users. Payment model structure determines whether you see the costs or the savings.
+
+5. **50% ovarian cancer reduction in female GLP-1 users.** If confirmed, this is an entirely new dimension of benefit not captured in any current analysis.
+
+6. **The BALANCE model combines medication + lifestyle.** CMS is explicitly testing whether the combination solves the adherence problem. This is a more sophisticated intervention than simple drug coverage.
+
+## Belief Updates
+
+**Belief 3 (structural misalignment): COMPLICATED.** The GLP-1 + VBC interaction reveals a subtler misalignment than I'd assumed. Capitation creates the THEORETICAL incentive for prevention, but short-term budget pressure, adherence uncertainty, and member turnover create PRACTICAL barriers. The attractor state may require not just payment alignment but also adherence solutions and long-term risk pools.
+
+**Belief 4 (atoms-to-bits boundary): REINFORCED.** The GLP-1 story is partly an atoms-to-bits story — continuous monitoring (CGMs, wearables) could identify the right patients and track adherence, turning GLP-1 prescribing from population-level gambling into targeted, monitored intervention. The BALANCE model's lifestyle component could be delivered through the sensor stack + AI middleware.
+
+**Existing GLP-1 claim needs scope qualification.** "Inflationary through 2035" is correct at system level but incomplete. The claim should be scoped: system-level inflationary, but potentially cost-saving under risk-bearing payment models for targeted high-risk populations with sustained adherence. The price trajectory (declining toward $50-100/month by 2030) may also move the inflection point earlier.
+
+## Follow-up Directions
+
+### Active Threads (continue next session)
+- **GLP-1 adherence interventions under capitation:** What works to improve persistence? Does care coordination, lifestyle coaching, or CGM monitoring improve adherence rates? This is the bottleneck for the entire VBC cost-savings thesis. Look for: BALANCE model early results, Devoted Health or other purpose-built MA plans' GLP-1 protocols, digital health adherence interventions.
+- **Sarcopenia quantification in Medicare GLP-1 users:** The muscle loss risk is theoretical but plausible. Look for: real-world outcomes data on fracture/fall rates in GLP-1 users >65, next-gen compounds claiming muscle preservation, any population-level sarcopenia signal in the Aon or FLOW datasets.
+- **CBO scoring methodology and prevention bias:** The $35B vs. $715M divergence is a structural problem beyond GLP-1s. Look for: analyses of how CBO scoring systematically undervalues prevention, comparisons with other preventive interventions facing the same bias, proposals to reform scoring methodology.
+
+### Dead Ends (don't re-run these)
+- **Tweet monitoring this session:** All feeds empty. No content from @EricTopol, @KFF, @CDCgov, @WHO, @ABORAMADAN_MD, @StatNews. Don't rely on tweet feeds as primary source material.
+- **Compounded semaglutide landscape:** Looked briefly — the compounding market is a legal/regulatory mess but doesn't connect meaningfully to the VBC economics question. Not worth pursuing further unless policy changes significantly.
+
+### Branching Points (one finding opened multiple directions)
+- **Aon cancer signal (50% ovarian cancer reduction):** Two directions: (A) pursue as a novel GLP-1 benefit claim that changes the multi-indication economics, or (B) wait for independent replication before building on observational data from an industry consultant. **Recommendation: B.** The signal is too preliminary and the observational design too prone to confounding (healthier/wealthier women may both use GLP-1s and have lower cancer rates). Flag for monitoring but don't extract claims yet.
+- **BALANCE model as attractor state test:** Two directions: (A) analyze the model design now and extract claims about its structure, or (B) wait for early results (post-May 2026 Medicaid launch) to evaluate whether the combined medication + lifestyle approach actually works. **Recommendation: A for structure, B for outcomes.** The design itself (medication + lifestyle + payment adjustment) is an extractable claim. The outcomes data needs to wait.
+
+SOURCE: 12 archives created across 5 tracks

agents/vida/research-journal.md

@@ -13,3 +13,21 @@
 
 **Sources archived:** 18 across three tracks (8 Track 1, 5 Track 2, 5 Track 3)
 **Extraction candidates:** 15-20 claims across MA economics, senior care infrastructure, and international benchmarks
+
+## Session 2026-03-12 — GLP-1 Agonists and Value-Based Care Economics
+
+**Question:** How are GLP-1 agonists interacting with value-based care economics — do cardiovascular and organ-protective benefits create net savings under capitation, or is the chronic use model inflationary even when plans bear full risk?
+
+**Key finding:** GLP-1 economics are payment-model-dependent in a way the existing KB claim doesn't capture. System-level: inflationary (CBO: $35B additional spending). Risk-bearing payer level: potentially cost-saving (ASPE/Value in Health: $715M net savings over 10 years for Medicare). The temporal cost curve is the key insight — Aon data shows costs up 23% in year 1, then grow only 2% vs. 6% for non-users after 12 months. Short-term payers see costs; long-term risk-bearers capture savings. But MA plans are RESTRICTING access (near-universal PA), not embracing prevention — challenging the simple attractor state thesis that capitation → prevention.
+
+**Pattern update:** This session deepens the March 10 pattern: MA is value-based in form but short-term-cost-managed in practice. The GLP-1 case is the strongest evidence yet — MA plans have theoretical incentive to cover GLP-1s (downstream savings) but restrict access (short-term cost avoidance). The attractor state thesis needs refinement: payment alignment is NECESSARY but NOT SUFFICIENT. You also need adherence solutions, long-term risk pools, and policy infrastructure (like the BALANCE model).
+
+**Cross-session pattern emerging:** Two sessions now converge on the same observation — the gap between VBC theory (aligned incentives → better outcomes) and VBC practice (short-term cost management, coding arbitrage, access restriction). The attractor state is real but the transition path is harder than I'd assumed. The existing claim "value-based care transitions stall at the payment boundary" is confirmed but the stall is deeper than payment — it's also behavioral (adherence), institutional (MA business models), and methodological (CBO scoring bias against prevention).
+
+**Confidence shift:**
+- Belief 3 (structural misalignment): **further complicated** — misalignment persists even under capitation because of short-term budget pressure, adherence uncertainty, and member turnover. Capitation is necessary but not sufficient for prevention alignment.
+- Belief 4 (atoms-to-bits): **reinforced** — continuous monitoring (CGMs, wearables) could solve the GLP-1 adherence problem by identifying right patients and tracking response, turning population-level prescribing into targeted monitored intervention.
+- Existing GLP-1 claim: **needs scope qualification** — "inflationary through 2035" is correct at system level but incomplete. Should distinguish system-level from payer-level economics. Price trajectory (declining toward $50-100/month internationally) may move inflection point earlier.
+
+**Sources archived:** 12 across five tracks (multi-organ protection, adherence, MA behavior, policy, counter-evidence)
+**Extraction candidates:** 8-10 claims including scope qualification of existing GLP-1 claim, VBC adherence paradox, MA prevention resistance, BALANCE model design, multi-organ protection thesis

domains/entertainment/beast-industries-5b-valuation-prices-content-as-loss-leader-model-at-enterprise-scale.md

@@ -0,0 +1,36 @@
+---
+type: claim
+domain: entertainment
+secondary_domains: [internet-finance]
+description: "Beast Industries' $5B valuation validates that investors price integrated content-to-product systems where media operates at loss to drive CPG revenue"
+confidence: likely
+source: "Fortune, MrBeast Beast Industries fundraise coverage, 2025-02-27"
+created: 2026-03-11
+---
+
+# Beast Industries $5B valuation validates content-as-loss-leader model at enterprise scale
+
+Beast Industries' $5B valuation in its 2025 fundraise represents market validation that the content-as-loss-leader model scales to enterprise size. The valuation is based on projected revenue growth from $899M (2025) to $1.6B (2026) to $4.78B (2029), with media (YouTube + Amazon) projected to represent only 1/5 of total sales by 2026—down from approximately 50% in 2025.
+
+The economic structure reveals the loss-leader mechanism: the media business produced similar revenue to Feastables (~$250M) but operated at an ~$80M loss, while Feastables generated $250M revenue with $20M+ profit. This inversion—where the larger revenue stream is unprofitable—demonstrates that content functions as customer acquisition infrastructure rather than a primary revenue source.
+
+The competitive advantage is structural: Feastables achieves zero marginal cost customer acquisition through content distribution, compared to traditional CPG companies like Hershey's and Mars spending 10-15% of revenue on advertising. Feastables' presence in 30,000+ retail locations (Walmart, Target, 7-Eleven) shows this model translates to physical retail distribution at scale, not just direct-to-consumer sales.
+
+Investors are explicitly pricing the integrated system (content → audience → products) rather than content revenue alone. The $4.78B 2029 revenue projection, if realized, would make a YouTube creator larger than many traditional entertainment companies—but with revenue primarily from CPG products rather than media. This represents a structural shift in how creator economics scale beyond direct monetization.
+
+## Evidence
+- Beast Industries raising at $5B valuation with revenue trajectory: $899M (2025) → $1.6B (2026) → $4.78B (2029)
+- Media business projected at 1/5 of total revenue by 2026, down from ~50% in 2025
+- Media business: ~$250M revenue, ~$80M loss; Feastables: $250M revenue, $20M+ profit
+- Feastables in 30,000+ retail locations with zero marginal cost customer acquisition vs traditional CPG 10-15% ad spend
+- Five verticals: software (Viewstats), CPG (Feastables, Lunchly), health/wellness, media, video games
+
+---
+
+Relevant Notes:
+- [[the media attractor state is community-filtered IP with AI-collapsed production costs where content becomes a loss leader for the scarce complements of fandom community and ownership]]
+- [[creator-brand-partnerships-shifting-from-transactional-campaigns-to-long-term-joint-ventures-with-shared-formats-audiences-and-revenue]]
+- [[fanchise management is a stack of increasing fan engagement from content extensions through co-creation and co-ownership]]
+
+Topics:
+- [[domains/entertainment/_map]]

domains/entertainment/creator-brand-partnerships-shifting-from-transactional-campaigns-to-long-term-joint-ventures-with-shared-formats-audiences-and-revenue.md

@@ -34,6 +34,12 @@ This claim is rated experimental because:
 
 The claim describes an emerging pattern and stated industry prediction rather than an established norm.
 
+
+### Additional Evidence (extend)
+*Source: [[2025-02-27-fortune-mrbeast-5b-valuation-beast-industries]] | Added: 2026-03-12 | Extractor: anthropic/claude-sonnet-4.5*
+
+Beast Industries represents the structural endpoint of creator-brand integration: full vertical ownership rather than partnership. The company owns five verticals (software via Viewstats, CPG via Feastables and Lunchly, health/wellness, media, video games) with Feastables in 30,000+ retail locations, demonstrating that creator-owned brands achieve traditional retail distribution at scale. The $5B valuation suggests investors view fully integrated creator-owned product companies as more valuable than partnership models, as the creator captures all margin rather than splitting with brand partners. This extends the partnership trajectory from transactional campaigns → joint ventures → full creator ownership of the product vertical.
+
 ---
 
 Relevant Notes:

domains/entertainment/the media attractor state is community-filtered IP with AI-collapsed production costs where content becomes a loss leader for the scarce complements of fandom community and ownership.md

@@ -290,6 +290,12 @@ Entertainment is the domain where TeleoHumanity eats its own cooking.
 
 The crystallization of 'human-made' as a premium label adds a new dimension to the scarcity analysis: not just community and ownership, but verifiable human provenance becomes scarce and valuable as AI content becomes abundant. EY's guidance that companies must 'keep what people see and feel recognizably human—authentic faces, genuine stories and shared cultural moments' to build 'deeper trust and stronger brand value' suggests human provenance is becoming a distinct scarce complement alongside community and ownership. As production costs collapse toward compute costs (per the non-ATL production costs claim), the ability to credibly signal human creation becomes a scarce resource that differentiates content. Community-owned IP may have structural advantage in signaling this provenance because ownership structure itself communicates human creation, while corporate content must construct proof through external verification. This extends the attractor claim by identifying human provenance as an additional scarce complement that becomes valuable in the AI-abundant, community-filtered media landscape.
 
+
+### Additional Evidence (confirm)
+*Source: [[2025-02-27-fortune-mrbeast-5b-valuation-beast-industries]] | Added: 2026-03-12 | Extractor: anthropic/claude-sonnet-4.5*
+
+Beast Industries' $5B valuation and revenue trajectory ($899M → $1.6B → $4.78B by 2029) with media projected at only 1/5 of revenue by 2026 provides enterprise-scale validation of content-as-loss-leader. The media business operates at ~$80M loss while Feastables generates $250M revenue with $20M+ profit, demonstrating that content functions as customer acquisition infrastructure rather than primary revenue source. The $5B valuation prices the integrated system (content → audience → products) rather than content alone, representing market validation that this attractor state is real and scalable. Feastables' presence in 30,000+ retail locations (Walmart, Target, 7-Eleven) shows the model translates to physical retail distribution, not just direct-to-consumer. This is the first enterprise-scale validation of the loss-leader model where media revenue is subordinate to product revenue.
+
 ---
 
 Relevant Notes:

domains/health/CMS 2027 chart review exclusion targets vertical integration profit arbitrage by removing upcoded diagnoses from MA risk scoring.md

@@ -34,6 +34,12 @@ The broader 2027 rate environment compounds the pressure into a three-pronged sq
 
 This is a proxy inertia story. Since [[proxy inertia is the most reliable predictor of incumbent failure because current profitability rationally discourages pursuit of viable futures]], the incumbents who built their MA economics around coding optimization will struggle to shift toward genuine quality competition. The plans that never relied on coding arbitrage (Devoted, Alignment, Kaiser) are better positioned.
 
+
+### Additional Evidence (extend)
+*Source: [[2026-02-23-cbo-medicare-trust-fund-2040-insolvency]] | Added: 2026-03-12 | Extractor: anthropic/claude-sonnet-4.5*
+
+(extend) The trust fund insolvency timeline creates intensifying pressure for MA payment reform through the 2030s. With exhaustion now projected for 2040 (12 years earlier than 2025 estimates), MA overpayments of $84B/year become increasingly unsustainable from a fiscal perspective. Reducing MA benchmarks could save $489B over the decade, significantly extending solvency. The chart review exclusion is one mechanism in a broader reform trajectory: either restructure MA payments or accept automatic 8-10% benefit cuts for all Medicare beneficiaries starting 2040. The political economy strongly favors MA reform over across-the-board cuts, meaning chart review exclusions will likely be part of a suite of MA payment reforms driven by fiscal necessity rather than ideological preference.
+
 ---
 
 Relevant Notes:

domains/health/medicare-fiscal-pressure-forces-ma-reform-by-2030s-through-arithmetic-not-ideology.md

@@ -0,0 +1,40 @@
+---
+type: claim
+domain: health
+description: "Trust fund exhaustion timeline combined with MA overpayments creates mathematical forcing function for structural reform independent of political control"
+confidence: likely
+source: "CBO Medicare projections (2026), MA overpayment analysis"
+created: 2026-03-11
+depends_on:
+  - medicare-trust-fund-insolvency-accelerated-12-years-by-tax-policy-demonstrating-fiscal-fragility.md
+---
+
+# Medicare fiscal pressure forces MA reform by 2030s through arithmetic not ideology
+
+The convergence of three fiscal dynamics creates a mathematical forcing function for Medicare Advantage reform within the 2030s, independent of which party controls government:
+
+1. **Trust fund exhaustion by 2040** — triggering automatic 8-10% benefit cuts without Congressional action
+2. **MA overpayments of $84B/year ($1.2T/decade)** — accelerating trust fund depletion
+3. **Locked-in demographics** — working-age to 65+ ratio declining from 2.8:1 to 2.2:1 by 2055
+
+Reducing MA benchmarks could save $489B over the decade, significantly extending trust fund solvency. The arithmetic creates intensifying pressure through the late 2020s and 2030s: either reform MA payment structures or accept automatic benefit cuts starting in 2040.
+
+This is not an ideological prediction but a fiscal constraint. The 2055→2040 solvency collapse in under one year demonstrates how little fiscal margin exists. MA reform becomes the path of least resistance compared to across-the-board benefit cuts affecting all Medicare beneficiaries.
+
+## Why This Forces Action
+
+Politicians face a choice between:
+- **Option A:** Reform MA overpayments (affects ~50% of beneficiaries, mostly through plan changes)
+- **Option B:** Accept automatic 8-10% benefit cuts for 100% of Medicare beneficiaries in 2040
+
+The political economy strongly favors Option A. The fiscal pressure builds continuously through the 2030s as the exhaustion date approaches, creating windows for reform regardless of partisan control.
+
+---
+
+Relevant Notes:
+- medicare-trust-fund-insolvency-accelerated-12-years-by-tax-policy-demonstrating-fiscal-fragility.md
+- CMS 2027 chart review exclusion targets vertical integration profit arbitrage by removing upcoded diagnoses from MA risk scoring
+- value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk
+
+Topics:
+- domains/health/_map

domains/health/medicare-trust-fund-insolvency-accelerated-12-years-by-tax-policy-demonstrating-fiscal-fragility.md

@@ -0,0 +1,43 @@
+---
+type: claim
+domain: health
+description: "CBO projection collapsed from 2055 to 2040 in under one year after tax legislation, revealing Medicare's structural vulnerability to revenue changes"
+confidence: proven
+source: "Congressional Budget Office projections (March 2025, February 2026) via Healthcare Dive"
+created: 2026-03-11
+---
+
+# Medicare trust fund insolvency accelerated 12 years by single tax bill demonstrating fiscal fragility of demographic-dependent entitlements
+
+The Medicare Hospital Insurance Trust Fund's projected exhaustion date collapsed from 2055 (March 2025 CBO estimate) to 2040 (February 2026 revised estimate) — a loss of 12 years of solvency in under one year. The primary driver was Republicans' "Big Beautiful Bill" (signed July 2025), which lowered taxes and created a temporary deduction for Americans 65+, reducing Medicare revenues from taxing Social Security benefits alongside lower projected payroll tax revenue and interest income.
+
+This demonstrates Medicare's extreme fiscal sensitivity: one tax bill erased over a decade of projected solvency. The speed of collapse reveals how thin the margin is between demographic pressure and fiscal sustainability.
+
+## Consequences and Timeline
+
+By law, if the trust fund runs dry, Medicare is restricted to paying out only what it takes in. This triggers automatic benefit reductions starting at **8% in 2040**, climbing to **10% by 2056**. No automatic solution exists — Congressional action is required.
+
+The 2040 date creates a 14-year countdown for structural Medicare reform, with fiscal pressure intensifying through the late 2020s and 2030s regardless of which party controls government.
+
+## Demographic Lock-In
+
+The underlying pressure is locked in by demographics already born:
+- Baby boomers all 65+ by 2030
+- 65+ population: 39.7M (2010) → 67M (2030)
+- Working-age to 65+ ratio: 2.8:1 (2025) → 2.2:1 (2055)
+- OECD old-age dependency ratio: 31.3% (2023) → 40.4% (2050)
+
+These are not projections but demographic certainties.
+
+## Interaction with MA Overpayments
+
+MA overpayments ($84B/year, $1.2T/decade) accelerate trust fund depletion. Reducing MA benchmarks could save $489B, significantly extending solvency. The fiscal collision: demographic pressure + MA overpayments + tax revenue reduction = accelerating insolvency that forces reform conversations within the 2030s.
+
+---
+
+Relevant Notes:
+- the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline
+- value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk
+
+Topics:
+- domains/health/_map

domains/health/the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline.md

@@ -31,6 +31,12 @@ The fundamental tension in healthcare economics: medicine can now cure diseases
 
 The composition of spending shifts dramatically: less on chronic disease management (diabetes complications, repeat cardiovascular events, lifelong hemophilia factor), more on curative interventions (gene therapy, personalized vaccines), prevention (MCED screening, GLP-1s), and new care categories. Per-capita health outcomes improve substantially, but per-capita spending also increases. The deflationary equilibrium is real but 15-20 years away, not 5-10.
 
+
+### Additional Evidence (extend)
+*Source: [[2026-02-23-cbo-medicare-trust-fund-2040-insolvency]] | Added: 2026-03-12 | Extractor: anthropic/claude-sonnet-4.5*
+
+(extend) The Medicare trust fund fiscal pressure adds a constraint layer to the cost curve dynamics. While new capabilities create upward cost pressure through expanded treatment populations, the trust fund exhaustion timeline (now 2040, accelerated from 2055 by tax policy changes) creates a hard fiscal boundary. The convergence of demographic pressure (working-age to 65+ ratio declining to 2.2:1 by 2055), MA overpayments ($1.2T/decade), and reduced tax revenues means automatic 8-10% benefit cuts starting 2040 unless structural reforms occur. This fiscal ceiling will force coverage and payment decisions in the 2030s independent of technology trajectories, potentially constraining the cost curve expansion that new capabilities would otherwise enable.
+
 ---
 
 Relevant Notes:

domains/internet-finance/SPL-404-enables-fungible-NFT-swap-revenue-for-DAOs-by-bridging-governance-tokens-and-NFT-liquidity-on-Solana.md

@@ -0,0 +1,29 @@
+---
+type: claim
+domain: internet-finance
+description: "SPL 404 is a Solana token standard that creates bidirectional swaps between fungible governance tokens and NFTs, letting DAOs earn secondary revenue from swap activity without direct NFT treasury sales."
+confidence: experimental
+source: "Rio; FutureDAO Champions NFT Collection proposal (2024-07-18, passed 2024-07-22)"
+created: 2026-03-12
+depends_on:
+  - "MetaDAO is the futarchy launchpad on Solana where projects raise capital through unruggable ICOs governed by conditional markets creating the first platform for ownership coins at scale"
+---
+
+# SPL 404 enables fungible-NFT swap revenue for DAOs by bridging governance tokens and NFT liquidity on Solana
+
+SPL 404 is a Solana token standard that allows bidirectional swaps between fungible tokens and NFTs. For DAOs, this creates a monetization path that doesn't require direct NFT sales from the treasury: instead, when community members swap their governance tokens (e.g., $FUTURE) into NFT form or back, the protocol earns revenue from the swap mechanics. Secondary market royalties then compound on top.
+
+FutureDAO's Champions NFT Collection proposal (passed July 2024) illustrates this architecture in practice. Of the $10,000 design budget, $3,000 was earmarked for non-artistic technical work — $1,000 for smart contract development and $2,000 for metadata integration — required specifically to enable SPL 404 swap mechanics. The proposal projected two revenue streams: SPL 404 swap fees and secondary market royalties. Neither stream requires the DAO to sell NFTs directly; revenue flows from market activity rather than treasury disposition.
+
+This matters for DAO treasury design. Traditional NFT monetization requires either initial sales (one-time, often fraught with launch mechanics) or secondary royalties (declining in enforcement reliability post-Blur). SPL 404 adds a third path: perpetual swap revenue tied to the governance token's own liquidity. As long as members convert between token and NFT form, the swap mechanism generates revenue.
+
+The limitation is that SPL 404 swap revenue is indirect and hard to project — it depends on community demand for the NFT form specifically. If members prefer holding the fungible token, swap volume is minimal regardless of collection quality.
+
+---
+
+Relevant Notes:
+- [[MetaDAO is the futarchy launchpad on Solana where projects raise capital through unruggable ICOs governed by conditional markets creating the first platform for ownership coins at scale]] — FutureDAO runs on MetaDAO's futarchy infrastructure; SPL 404 extends the token utility layer
+- [[MetaDAOs Autocrat program implements futarchy through conditional token markets where proposals create parallel pass and fail universes settled by time-weighted average price over a three-day window]] — the governance mechanism that approved this SPL 404-enabled NFT spend
+
+Topics:
+- [[_map]]

domains/internet-finance/futarchy-excels-at-relative-selection-but-fails-at-absolute-prediction-because-ordinal-ranking-works-while-cardinal-estimation-requires-calibration.md

@@ -29,6 +29,12 @@ Contributing factors to prediction failure: play-money environment created no do
 ## Challenges
 This was a play-money experiment, which is the primary confound. Real-money futarchy may produce different calibration through actual downside risk. The 84-day measurement window may have been too short for TVL impact to materialize. ETH price volatility during the measurement period confounded project-specific performance attribution.
 
+
+### Additional Evidence (extend)
+*Source: [[2024-11-25-futardio-proposal-launch-a-boost-for-hnt-ore]] | Added: 2026-03-12 | Extractor: anthropic/claude-sonnet-4.5*
+
+ORE's HNT-ORE boost proposal demonstrates futarchy's strength in relative selection: the market validated HNT as the next liquidity pair to boost relative to other candidates (ISC already had a boost at equivalent multiplier), but the proposal does not require absolute prediction of HNT's future price or utility—only that HNT is a better strategic choice than alternatives. The proposal passed by market consensus on relative positioning (HNT as flagship DePIN project post-HIP-138), not by predicting absolute HNT performance metrics.
+
 ---
 
 Relevant Notes:

domains/internet-finance/futarchy-markets-can-price-cultural-spending-proposals-by-treating-community-cohesion-and-brand-equity-as-token-price-inputs.md

@@ -0,0 +1,38 @@
+---
+type: claim
+domain: internet-finance
+description: "Futarchy governance can evaluate and approve non-financial cultural expenditures when proposers successfully frame community cohesion and brand benefits as positive token price signals, expanding the scope of what market governance can decide."
+confidence: experimental
+source: "Rio; FutureDAO Champions NFT Collection proposal (2024-07-18, passed 2024-07-22)"
+created: 2026-03-12
+depends_on:
+  - "MetaDAOs Autocrat program implements futarchy through conditional token markets where proposals create parallel pass and fail universes settled by time-weighted average price over a three-day window"
+  - "coin price is the fairest objective function for asset futarchy"
+---
+
+# futarchy markets can price cultural spending proposals by treating community cohesion and brand equity as token price inputs
+
+Futarchy governance selects proposals by whether conditional markets expect them to increase token price. This creates an implicit question for cultural spending: can markets price "soft" benefits like community cohesion, brand presence, and social identity into a token price signal?
+
+FutureDAO's Champions NFT proposal provides a concrete test case. The proposal requested $10,000 for NFT artwork design — with the primary stated value case being community cohesion ("PFPs for community members to represent themselves") and Solana ecosystem presence ("FutureDAO's notoriety across the Solana ecosystem"), not direct financial ROI. Revenue projections were explicitly indirect: SPL 404 swap fees and secondary market royalties, both dependent on emergent community demand. Despite this soft value framing, the proposal passed futarchy governance on July 22, 2024.
+
+This indicates that futarchy markets can evaluate cultural spending when participants believe brand and community effects will flow through to token price. The mechanism works because the objective function (token price) is broad enough to incorporate any factor that market participants believe matters — including social capital, community retention, and ecosystem reputation. Futarchy doesn't require direct financial return from a proposal; it requires only that participants believe the proposal increases expected token value.
+
+The implication for DAO governance design is significant: futarchy is not limited to quantifiable ROI decisions. It can govern brand investments, cultural initiatives, and community spending — anywhere the market believes soft benefits translate to token appreciation. This expands futarchy's applicable scope beyond the financial optimization use cases it was originally theorized for.
+
+The risk is that cultural proposals introduce systematic bias: participants who value community belonging may persistently overestimate the token-price impact of cultural spending, creating a selection pressure for feel-good proposals over productive ones.
+
+## Challenges
+
+The single data point is limited. One passed proposal doesn't establish a reliable pattern. Cultural proposals that fail futarchy governance (and thus go unobserved in public records) would provide the necessary counter-evidence to calibrate how often futarchy actually validates cultural versus financial spending.
+
+---
+
+Relevant Notes:
+- [[MetaDAOs Autocrat program implements futarchy through conditional token markets where proposals create parallel pass and fail universes settled by time-weighted average price over a three-day window]] — the mechanism that priced and approved this cultural spending proposal
+- [[coin price is the fairest objective function for asset futarchy]] — the broad objective function that makes cultural pricing possible
+- [[redistribution proposals are futarchys hardest unsolved problem because they can increase measured welfare while reducing productive value creation]] — adjacent challenge: welfare-increasing but value-neutral proposals
+- [[futarchy-governed DAOs converge on traditional corporate governance scaffolding for treasury operations because market mechanisms alone cannot provide operational security and legal compliance]] — limits of futarchy for operational decisions
+
+Topics:
+- [[_map]]

entities/entertainment/beast-industries.md

@@ -0,0 +1,33 @@
+---
+type: entity
+entity_type: company
+name: "Beast Industries"
+domain: entertainment
+secondary_domains: [internet-finance]
+status: active
+founded: "~2020"
+founder: "Jimmy Donaldson (MrBeast)"
+key_metrics:
+  valuation: "$5B (2025 fundraise)"
+  revenue_2025: "$899M (projected)"
+  revenue_2026: "$1.6B (projected)"
+  revenue_2029: "$4.78B (projected)"
+  feastables_revenue: "$250M"
+  feastables_profit: "$20M+"
+  media_loss: "~$80M"
+  retail_locations: "30,000+"
+tracked_by: clay
+created: 2026-03-11
+---
+
+# Beast Industries
+
+Beast Industries is MrBeast's (Jimmy Donaldson) integrated media and consumer products company, operating five verticals: software (Viewstats), CPG (Feastables, Lunchly), health/wellness, media (YouTube + Amazon), and video games. The company raised capital at a $5B valuation in 2025, with projected revenue growth from $899M (2025) to $4.78B (2029). The business model treats content as customer acquisition infrastructure rather than primary revenue source, with media projected to represent only 1/5 of total sales by 2026.
+
+## Timeline
+- **2025-02-27** — Raised capital at $5B valuation with revenue projections: $899M (2025) → $1.6B (2026) → $4.78B (2029)
+- **2025** — Feastables generated $250M revenue with $20M+ profit; media business similar revenue but ~$80M loss
+- **2025** — Feastables distributed through 30,000+ retail locations (Walmart, Target, 7-Eleven)
+
+## Relationship to KB
+Beast Industries provides enterprise-scale validation of [[the media attractor state is community-filtered IP with AI-collapsed production costs where content becomes a loss leader for the scarce complements of fandom community and ownership]]. The $5B valuation represents market pricing of the integrated content-to-product model, where media operates at a loss to generate zero marginal cost customer acquisition for high-margin CPG products.

entities/internet-finance/futara.md

@@ -0,0 +1,27 @@
+---
+type: entity
+entity_type: company
+name: "FUTARA"
+domain: internet-finance
+status: failed
+platform: futardio
+tracked_by: rio
+created: 2026-03-11
+key_metrics:
+  funding_target: "$50,000"
+  launch_date: "2026-03-04"
+  close_date: "2026-03-04"
+  outcome: "refunding"
+---
+
+# FUTARA
+
+FUTARA was a futarchy-governed fundraise on futard.io that launched and failed on the same day (2026-03-04). The project described itself as the "og futardio mascot" and sought $50,000 in funding. The launch entered refunding status without reaching its target, closing on the same day it launched.
+
+## Timeline
+- **2026-03-04** — Launched on futard.io with $50,000 funding target
+- **2026-03-04** — Closed and entered refunding status (failed)
+
+## Relationship to KB
+- [[futardio]] — platform where launch occurred
+- Example of failed futarchy-governed fundraise on MetaDAO infrastructure

entities/internet-finance/helium.md

@@ -0,0 +1,22 @@
+---
+type: entity
+entity_type: company
+name: "Helium"
+domain: internet-finance
+status: active
+tracked_by: rio
+created: 2026-03-11
+---
+
+# Helium
+
+## Overview
+Helium is a decentralized wireless networking protocol and flagship DePIN (Decentralized Physical Infrastructure Network) project on Solana. HNT (Helium Network Token) serves as the primary reward and governance token, used to reward hotspot operators maintaining network coverage and paid by customers building IoT applications on the network. Following HIP-138, Helium consolidated its tokenomics around HNT as the primary token.
+
+## Timeline
+- **2024-11-25** — Integrated into ORE liquidity network through [[ore-launch-hnt-boost]] proposal for HNT-ORE liquidity boost
+- **2024-11-28** — [[ore-launch-hnt-boost]] passed, establishing HNT-ORE as Tier 3 liquidity pair in ORE's boost system
+
+## Relationship to KB
+- [[ore]] — liquidity integration partner
+- Referenced as "flagship DePIN project" in ORE's strategic positioning for real-world asset liquidity

entities/internet-finance/island-futardio-fundraise.md

@@ -0,0 +1,51 @@
+---
+type: entity
+entity_type: decision_market
+name: "Island: Futardio Fundraise"
+domain: internet-finance
+status: failed
+parent_entity: "[[island]]"
+platform: futardio
+proposer: "xpmaxxer"
+proposal_url: "https://www.futard.io/launch/FpFytak8JZwVntqDh9G95zqXXVJNXMxRFUYY959AXeZj"
+proposal_date: 2026-03-04
+resolution_date: 2026-03-05
+category: fundraise
+summary: "Island.ag attempted to raise $50K for DeFi loyalty + hotel booking platform, reached only $250 before entering refunding status"
+tracked_by: rio
+created: 2026-03-11
+key_metrics:
+  funding_target: "$50,000"
+  total_committed: "$250"
+  token_symbol: "CGa"
+  token_mint: "CGaDW7QYCNdVzivFabjWrpsqW7C4A3WSLjdkH84Pmeta"
+  autocrat_version: "v0.7"
+---
+
+# Island: Futardio Fundraise
+
+## Summary
+
+Island.ag launched a futarchy-governed fundraise on Futardio seeking $50,000 to build a DeFi loyalty program combined with a hotel booking platform. The project proposed to help crypto users discover yields while earning Island Points redeemable for luxury hotel discounts. The raise failed dramatically, attracting only $250 in commitments (0.5% of target) before closing in refunding status after one day.
+
+## Market Data
+
+- **Outcome:** Failed (refunding)
+- **Proposer:** xpmaxxer
+- **Funding Target:** $50,000
+- **Total Committed:** $250 (0.5% of target)
+- **Duration:** 1 day (2026-03-04 to 2026-03-05)
+- **Token:** CGa
+- **Platform:** Futardio v0.7
+
+## Significance
+
+This fundraise represents one of the weakest market validations on the Futardio platform to date. The 200:1 gap between target and commitments suggests either fundamental skepticism about the DeFi-travel loyalty thesis, concerns about founder credibility (solo founder with hospitality background but limited crypto track record), or timing issues in the market cycle. The project's positioning as "extremely lean" with vibe-coded development and 80% marketing spend may have signaled insufficient technical depth for a capital-intensive two-sided marketplace.
+
+The failure provides a data point on what Futardio's permissionless launch model filters out: projects that cannot attract even minimal community validation fail quickly and cleanly, with automatic refunds protecting early participants.
+
+## Relationship to KB
+
+- [[futardio]] — fundraise platform
+- [[island]] — parent entity
+- [[MetaDAO]] — governance infrastructure provider

entities/internet-finance/island.md

@@ -0,0 +1,28 @@
+---
+type: entity
+entity_type: company
+name: Island
+domain: internet-finance
+status: failed
+founded: 2026
+platform: Solana
+tracked_by: rio
+created: 2026-03-11
+key_metrics:
+  funding_target: "$50,000"
+  total_committed: "$250"
+  outcome: "refunding"
+---
+
+# Island
+
+Island.ag was a proposed DeFi loyalty program and hotel booking platform designed to offer luxury hotel discounts to crypto users. The project combined direct hotel partnerships with gamified experiences (raffles for luxury stays) to create a loyalty system for DeFi protocols. Users would earn Island Points by depositing into partner protocols, which could be redeemed for hotel discounts or raffle entries. The project aimed to position crypto users as high-spending business travelers to hotels while providing yield discovery and protocol exposure services.
+
+## Timeline
+
+- **2026-03-04** — [[island-futardio-fundraise]] failed: Raised $250 of $50,000 target through Futardio launch, entered refunding status
+- **2026-03-05** — Fundraise closed in refunding status
+
+## Relationship to KB
+
+Island represents an attempt to bridge DeFi yield aggregation with real-world travel rewards, testing whether loyalty mechanics can drive protocol deposits when yields are below double digits. The project's failure to reach minimum funding threshold ($250 of $50K target) suggests limited market validation for the DeFi-travel loyalty thesis at this stage.

entities/internet-finance/milo-ai-agent.md

@@ -0,0 +1,32 @@
+---
+type: entity
+entity_type: company
+name: "MILO AI Agent"
+domain: internet-finance
+status: failed
+founded: 2026
+platform: futardio
+tracked_by: rio
+created: 2026-03-11
+key_metrics:
+  funding_target: "$250,000"
+  total_committed: "$200"
+  launch_date: "2026-03-03"
+  close_date: "2026-03-04"
+  outcome: "refunding"
+---
+
+# MILO AI Agent
+
+MILO is a mobile AI real estate agent built for the Charleston, Berkeley, and Dorchester County markets in South Carolina. Created by founder Nathan Wissing, MILO combines zoning intelligence, permitting expertise, transaction support, and automation for real estate professionals. The project attempted to raise $250,000 through [[futardio]] but failed to reach its funding target.
+
+## Timeline
+
+- **2026-03-03** — Launched fundraise on [[futardio]] with $250K target for hyper-local AI real estate agent serving Lowcountry SC market
+- **2026-03-04** — Fundraise closed in refunding status with only $200 committed (0.08% of target)
+
+## Relationship to KB
+
+- [[futardio]] — launch platform
+- Example of failed futarchy-governed fundraise with minimal market interest
+- Represents vertical AI agent approach (real estate-specific vs general purpose)

entities/internet-finance/ore-launch-hnt-boost.md

@@ -0,0 +1,47 @@
+---
+type: entity
+entity_type: decision_market
+name: "ORE: Launch a boost for HNT-ORE?"
+domain: internet-finance
+status: passed
+parent_entity: "[[ore]]"
+platform: "futardio"
+proposal_url: "https://www.futard.io/proposal/2QUxbiMkDtoKxY2u6kXuevfMsqKGtHNxMFYHVWbqRK1A"
+proposal_date: 2024-11-25
+resolution_date: 2024-11-28
+category: "strategy"
+summary: "Proposal to launch liquidity boost for HNT-ORE pair and formalize three-tier boost multiplier system"
+tracked_by: rio
+created: 2026-03-11
+---
+
+# ORE: Launch a boost for HNT-ORE?
+
+## Summary
+Proposal to integrate Helium Network Token (HNT) into ORE's liquidity network by launching a boost for the HNT-ORE pair and formalizing a three-tier boost multiplier system. The proposal positions ORE as a liquidity hub for real-world assets on Solana, with HNT as a flagship DePIN integration following Helium's HIP-138 tokenomics consolidation.
+
+## Market Data
+- **Outcome:** Passed
+- **Proposal Account:** 2QUxbiMkDtoKxY2u6kXuevfMsqKGtHNxMFYHVWbqRK1A
+- **Proposal Number:** 1
+- **DAO Account:** EttCec7x4r227dbQ8BYUVtqizDdD6T3WQHGHWKdzJrCc
+- **Proposer:** proPaC9tVZEsmgDtNhx15e7nSpoojtPD3H9h4GqSqB2
+- **Autocrat Version:** 0.3
+- **Created:** 2024-11-25
+- **Completed:** 2024-11-28
+
+## Proposal Details
+The proposal introduces HNT-ORE boost at the same multiplier as ISC-ORE (Tier 3) and formalizes a three-tier boost system:
+- **Tier 1:** Vanilla ORE stake
+- **Tier 2:** Critical liquidity pairs (SOL-ORE, USDC-ORE)
+- **Tier 3:** Extended liquidity pairs (ISC-ORE, HNT-ORE, future additions)
+
+Boosts apply to kTokens representing Kamino vault shares managing concentrated liquidity positions on Orca. Future proposals can adjust multipliers by tier rather than individual pairs.
+
+## Significance
+This proposal demonstrates futarchy pricing strategic partnerships and network positioning. The market validated ORE's narrative of becoming "the central hub" for real-world asset liquidity on Solana by approving integration with Helium, a flagship DePIN project. The three-tier system represents governance simplification through abstraction — future proposals can target tiers rather than individual pairs, reducing complexity while maintaining control.
+
+## Relationship to KB
+- [[ore]] — parent entity
+- [[MetaDAOs Autocrat program implements futarchy through conditional token markets where proposals create parallel pass and fail universes settled by time-weighted average price over a three-day window]] — governance mechanism
+- [[futarchy-markets-can-price-cultural-spending-proposals-by-treating-community-cohesion-and-brand-equity-as-token-price-inputs]] — strategic evaluation through conditional markets

entities/internet-finance/ore.md

@@ -0,0 +1,22 @@
+---
+type: entity
+entity_type: company
+name: "ORE"
+domain: internet-finance
+status: active
+tracked_by: rio
+created: 2026-03-11
+---
+
+# ORE
+
+## Overview
+ORE is a DeFi protocol on Solana positioning itself as a liquidity hub for real-world assets (RWAs) and DePIN tokens. The protocol uses a three-tier boost multiplier system to incentivize liquidity provision, with concentrated liquidity positions managed through Kamino vaults on Orca. ORE's strategic goal is to become the central unit of account for tokenized commodities and DePIN credits in the Solana ecosystem.
+
+## Timeline
+- **2024-11-25** — [[ore-launch-hnt-boost]] proposed: Launch HNT-ORE liquidity boost to integrate Helium into ORE liquidity network
+- **2024-11-28** — [[ore-launch-hnt-boost]] passed: Approved three-tier boost system (vanilla stake / critical pairs / extended pairs) and HNT-ORE boost at Tier 3 multiplier
+
+## Relationship to KB
+- [[MetaDAOs Autocrat program implements futarchy through conditional token markets where proposals create parallel pass and fail universes settled by time-weighted average price over a three-day window]] — governance mechanism
+- [[futarchy-markets-can-price-cultural-spending-proposals-by-treating-community-cohesion-and-brand-equity-as-token-price-inputs]] — strategic partnership evaluation through futarchy

entities/internet-finance/sanctum-offer-investors-early-unlocks-cloud.md

@@ -0,0 +1,39 @@
+---
+type: entity
+entity_type: decision_market
+name: "Sanctum: Should Sanctum offer investors early unlocks of their CLOUD?"
+domain: internet-finance
+status: failed
+parent_entity: "[[sanctum]]"
+platform: "futardio"
+proposer: "proPaC9tVZEsmgDtNhx15e7nSpoojtPD3H9h4GqSqB2"
+proposal_url: "https://www.futard.io/proposal/C61vTUyxTq5SWwbrTFEyYeXpGQLKhRRvRrGsu6YUa6CX"
+proposal_account: "C61vTUyxTq5SWwbrTFEyYeXpGQLKhRRvRrGsu6YUa6CX"
+proposal_date: 2025-08-20
+resolution_date: 2025-08-23
+category: "treasury"
+summary: "Proposal to allow investors immediate unlock of vested CLOUD by forfeiting 35% to Team Reserve"
+tracked_by: rio
+created: 2026-03-11
+---
+
+# Sanctum: Should Sanctum offer investors early unlocks of their CLOUD?
+
+## Summary
+This proposal would have empowered the Sanctum Team to offer investors immediate unlocks of their vesting CLOUD tokens in exchange for forfeiting 35% of their holdings to the Team Reserve. With 9% of token supply unlocking monthly over 24 months from investors, the mechanism could have increased the Team Reserve by up to 27 million CLOUD while reducing token overhang. The team committed not to redistribute forfeited tokens for at least 24 months.
+
+## Market Data
+- **Outcome:** Failed
+- **Proposer:** proPaC9tVZEsmgDtNhx15e7nSpoojtPD3H9h4GqSqB2
+- **Platform:** Futardio (MetaDAO Autocrat v0.3)
+- **DAO Account:** GVmi7ngRAVsUHh8REhKDsB2yNftJTNRt5qMLHDDCizov
+- **Completed:** 2025-08-23
+
+## Significance
+This proposal represents an alternative approach to the token vesting hedgeability problem: rather than allowing investors to maintain nominal lockups while hedging exposure through derivatives, it forces an explicit forfeit-for-liquidity trade-off. The 35% forfeit rate creates a real cost for early liquidity, making the alignment mechanism meaningful rather than cosmetic. The proposal's failure despite potential treasury benefits suggests futarchy markets face adoption friction even for economically rational proposals when they require sophisticated financial reasoning from participants.
+
+## Relationship to KB
+- [[sanctum]] - parent entity governance decision
+- [[time-based-token-vesting-is-hedgeable-making-standard-lockups-meaningless-as-alignment-mechanisms-because-investors-can-short-sell-to-neutralize-lockup-exposure-while-appearing-locked]] - alternative mechanism to hedging
+- [[futarchy-adoption-faces-friction-from-token-price-psychology-proposal-complexity-and-liquidity-requirements]] - demonstrates complexity friction
+- [[MetaDAOs-futarchy-implementation-shows-limited-trading-volume-in-uncontested-decisions]] - low volume uncontested decision pattern

entities/internet-finance/seekervault-futardio-fundraise.md

@@ -0,0 +1,50 @@
+---
+type: entity
+entity_type: decision_market
+name: "SeekerVault: Futardio Fundraise"
+domain: internet-finance
+status: failed
+parent_entity: "[[seekervault]]"
+platform: "futardio"
+proposer: "gbflarcos, Beardkoda"
+proposal_url: "https://www.futard.io/launch/7AMzZD3JZ15FCX2eoC17KgJD5Ywum9J5i7E9BAbgc2vi"
+proposal_date: 2026-03-08
+resolution_date: 2026-03-09
+category: "fundraise"
+summary: "Fundraise for encrypted backup layer targeting 150K+ Solana Seeker phone users"
+key_metrics:
+  funding_target: "$50,000"
+  total_committed: "$2,095"
+  outcome: "refunding"
+  token_symbol: "J4r"
+  token_mint: "J4rMkvf4qwJgX2nK3ueeL4E423chSG2jVqgk5LAGmeta"
+tracked_by: rio
+created: 2026-03-11
+---
+
+# SeekerVault: Futardio Fundraise
+
+## Summary
+SeekerVault attempted to raise $50,000 through Futardio to build encrypted decentralized backup infrastructure for the 150,000+ Solana Seeker phones. The project positioned itself as replacing Google Drive/iCloud with Walrus + Seal storage, with a roadmap including AI agent vaults, creator content stores, and data marketplace. The raise attracted only $2,095 (4.2% of target) before entering refunding status.
+
+## Market Data
+- **Outcome:** Failed (Refunding)
+- **Proposers:** gbflarcos, Beardkoda
+- **Funding Target:** $50,000
+- **Total Committed:** $2,095
+- **Duration:** 1 day (2026-03-08 to 2026-03-09)
+- **Token:** J4r (J4rMkvf4qwJgX2nK3ueeL4E423chSG2jVqgk5LAGmeta)
+
+## Significance
+This fundraise demonstrates the challenge of raising capital for infrastructure plays even with clear product-market fit thesis (150K captive users). The 4.2% subscription rate suggests either:
+1. Market skepticism about execution capability (two-person team, ambitious multi-phase roadmap)
+2. Unclear value capture mechanism (SKV token utility described but not compelling)
+3. Competition concerns (despite claiming "zero competition")
+4. Timing mismatch (dApp Store listing still "in review")
+
+The pitch emphasized multiple revenue streams (subscriptions, creator economy tax, marketplace fees) but may have suffered from scope ambiguity — backup tool vs. AI agent infrastructure vs. creator platform vs. data marketplace.
+
+## Relationship to KB
+- [[seekervault]] — parent entity, fundraise attempt
+- [[futardio]] — platform used for raise
+- [[MetaDAO]] — futarchy governance infrastructure

entities/internet-finance/seekervault.md

@@ -27,6 +27,7 @@ The project proposed combining Walrus protocol for decentralized storage with Se
 - **2026-03-04** — Launched fundraise on Futardio targeting $75,000 for 6-month runway
 - **2026-03-05** — Fundraise closed in refunding status with only $1,186 committed (1.6% of target)
 
+- **2026-03-08** — Futardio fundraise launched targeting $50,000 for 6-month runway to build encrypted backup for 150K+ Solana Seeker phones; raised $2,095 before refunding
 ## Relationship to KB
 - [[futardio]] — fundraising platform
 - Example of failed futarchy-governed fundraise with extreme undersubscription

entities/internet-finance/test-dao-testing-indexer-changes.md

@@ -0,0 +1,37 @@
+---
+type: entity
+entity_type: decision_market
+name: "Test DAO: Testing indexer changes"
+domain: internet-finance
+status: failed
+parent_entity: "[[test-dao]]"
+platform: "futardio"
+proposer: "BF8hxzzR4KuVxfsyAUFyy26E6y2GhsSZgBoUQrygwof1"
+proposal_url: "https://www.futard.io/proposal/35mgLHTJYhyEWjsLHDd4jZNQ6jwuZ4E214TUm1hA8vB2"
+proposal_date: 2025-07-02
+resolution_date: 2025-07-02
+category: "mechanism"
+summary: "Test proposal for indexer changes on futardio platform"
+tracked_by: rio
+created: 2026-03-11
+---
+
+# Test DAO: Testing indexer changes
+
+## Summary
+Test proposal to validate indexer changes on the futardio platform. The proposal description appears truncated ("This is"), suggesting this was a technical test rather than a substantive governance decision.
+
+## Market Data
+- **Outcome:** Failed
+- **Proposer:** BF8hxzzR4KuVxfsyAUFyy26E6y2GhsSZgBoUQrygwof1
+- **Proposal account:** 35mgLHTJYhyEWjsLHDd4jZNQ6jwuZ4E214TUm1hA8vB2
+- **DAO account:** GCSGFCRfCRQDbqtPLa6bV7DCJz26NkejR182or8PNqRw
+- **Autocrat version:** 0.3
+- **Proposal number:** 2
+
+## Significance
+This appears to be a technical test proposal for platform infrastructure rather than a substantive governance decision. The truncated description and "test" naming convention indicate this was used to validate indexer functionality on the futardio platform.
+
+## Relationship to KB
+- [[test-dao]] - parent organization
+- [[futardio]] - platform hosting the decision market

entities/internet-finance/theia-research.md

@@ -40,6 +40,7 @@ Onchain liquid token fund managed by Felipe Montealegre. Invests in companies bu
 - **2026-02-12** — Published 2025 Annual Letter. Five-phase investment loop: moat analysis → multiples → prediction → Kelly sizing → Bayesian updating. Noah Goldberg promoted to equity partner, Thomas Bautista hired.
 - **2026-02-17** — Published "The Investment Manager of the Future." LLMs invert 80/20 ratio of execution vs analysis.
 
+- **2026-02-27** — Felipe Montealegre publicly endorsed MetaDAO's value proposition for "Claude Code founders" who can "raise capital in days so they can ship in weeks," framing it as operational reality rather than narrative (14.9K views, 78 likes)
 ## Competitive Position
 - **Unique positioning**: Only known institutional fund explicitly building investment thesis around futarchy governance as a moat
 - **Token governance focus**: Launched Token Transparency Framework with Blockworks. Describes "Lemon Problem in Token Markets" — the structural issue of quality tokens being indistinguishable from scams

entities/internet-finance/xpmaxxer.md

@@ -0,0 +1,26 @@
+---
+type: entity
+entity_type: person
+name: xpmaxxer
+domain: internet-finance
+status: active
+roles:
+  - founder
+affiliations:
+  - Island
+tracked_by: rio
+created: 2026-03-11
+---
+
+# xpmaxxer
+
+Founder of Island.ag, a failed DeFi loyalty and hotel booking platform. Background in hospitality industry operations before entering crypto. Currently manages personal capital across Solana DeFi protocols.
+
+## Timeline
+
+- **2026-03-04** — Launched [[island-futardio-fundraise]] seeking $50K for DeFi-travel loyalty platform, raised only $250 before refunding
+
+## Relationship to KB
+
+- [[island]] — founded company
+- [[futardio]] — used platform for fundraise attempt

inbox/archive/2020-12-00-da-costa-active-inference-discrete-state-spaces.md

@@ -7,9 +7,14 @@ date: 2020-12-01
 domain: ai-alignment
 secondary_domains: [critical-systems]
 format: paper
-status: unprocessed
+status: null-result
 priority: medium
 tags: [active-inference, tutorial, discrete-state-space, expected-free-energy, variational-free-energy, planning, decision-making]
+processed_by: theseus
+processed_date: 2026-03-11
+enrichments_applied: ["structured exploration protocols reduce human intervention by 6x because the Residue prompt enabled 5 unguided AI explorations to solve what required 31 human-coached explorations.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
+extraction_notes: "Technical reference paper for discrete-state active inference. Extracted two core claims about the VFE/EFE distinction and the unification of existing frameworks under free energy minimization. One enrichment connecting formal active inference theory to the existing Residue prompt claim. This provides mathematical foundation for implementing EFE-based research direction selection in KB architecture."
 ---
 
 ## Content

inbox/archive/2022-03-09-imf-costa-rica-ebais-primary-health-care.md

@@ -7,9 +7,14 @@ date: 2022-03-09
 domain: health
 secondary_domains: []
 format: report
-status: unprocessed
+status: null-result
 priority: high
 tags: [costa-rica, ebais, primary-health-care, international-comparison, spending-efficiency, blue-zone]
+processed_by: vida
+processed_date: 2026-03-11
+enrichments_applied: ["medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md", "pace-demonstrates-integrated-care-averts-institutionalization-through-community-based-delivery-not-cost-reduction.md", "the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
+extraction_notes: "Two new claims extracted: (1) Costa Rica as proof that prevention-first primary care at national scale achieves peer outcomes at fraction of US cost, (2) geographic empanelment as the structural mechanism enabling population health management. Three enrichments: extends the 10-20% medical care claim with strongest international counterfactual, extends PACE claim with national-scale comparison, confirms healthcare attractor state but challenges whether technology is prerequisite vs accelerant. Key insight: EBAIS-PACE comparison reveals same clinical model, wildly different scale — difference is political economy not care design."
 ---
 
 ## Content
@@ -58,3 +63,12 @@ tags: [costa-rica, ebais, primary-health-care, international-comparison, spendin
 PRIMARY CONNECTION: [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]
 WHY ARCHIVED: First international health system deep-dive in the KB. Costa Rica is the strongest counterfactual to US healthcare spending.
 EXTRACTION HINT: The EBAIS-PACE comparison is where the real insight lives. Same model, same concept — wildly different scale. What's different? Political economy, not clinical design.
+
+
+## Key Facts
+- Costa Rica life expectancy: 81.5 years (female), 76.7 years (male) — second in Americas
+- Costa Rica healthcare spending: 1/10 per capita vs US, below world average as % of income
+- EBAIS introduced 1994, covers 5 million population
+- EBAIS team composition: doctor, nurse, technical assistant, medical clerk, pharmacist
+- EBAIS districts show 8% lower child mortality, 2% lower adult mortality, 14% decline in communicable disease deaths
+- Nicoya Peninsula is one of 5 global Blue Zones, but Costa Rica's health outcomes are national not regional

inbox/archive/2023-02-00-pmc-cost-effectiveness-homecare-systematic-review.md

@@ -7,9 +7,14 @@ date: 2023-02-01
 domain: health
 secondary_domains: []
 format: paper
-status: unprocessed
+status: null-result
 priority: high
 tags: [home-health, cost-effectiveness, facility-care, snf, hospital, aging, senior-care]
+processed_by: vida
+processed_date: 2026-03-11
+enrichments_applied: ["continuous health monitoring is converging on a multi-layer sensor stack of ambient wearables periodic patches and environmental sensors processed through AI middleware.md", "the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness.md", "value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
+extraction_notes: "Extracted three claims about home health cost advantage, SNF margin bifurcation as transition signal, and RPM market growth. Applied enrichments to three existing claims about continuous monitoring, healthcare attractor state, and value-based care transitions. The 52% cost differential for heart failure home care is the strongest extractable finding—it represents structural cost advantage, not marginal improvement. SNF bifurcation (36% deeply unprofitable, 34% profitable) is a clear signal of industry restructuring rather than uniform decline. RPM growth data provides the technology enablement layer that makes home-based care clinically viable."
 ---
 
 ## Content
@@ -51,3 +56,11 @@ tags: [home-health, cost-effectiveness, facility-care, snf, hospital, aging, sen
 PRIMARY CONNECTION: [[continuous health monitoring is converging on a multi-layer sensor stack of ambient wearables periodic patches and environmental sensors processed through AI middleware]]
 WHY ARCHIVED: Fills the care delivery layer gap — KB has claims about insurance/payment structure but not about where care is actually delivered and how that's changing.
 EXTRACTION HINT: The cost differential (52% for heart failure) is the most extractable finding. Pair with RPM growth data to show the enabling technology layer.
+
+
+## Key Facts
+- 94% of Medicare beneficiaries prefer post-hospital care at home vs. nursing homes
+- Home health interventions typically more cost-efficient than institutional care across multiple conditions
+- When homecare compared to hospital care: cost-saving in 7 studies, cost-effective in 2, more effective in 1
+- 71 million Americans expected to use some form of RPM by 2025
+- AI in RPM: $1.96B (2024) → $8.43B (2030), 27.5% CAGR

inbox/archive/2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes.md

@@ -0,0 +1,40 @@
+---
+type: source
+title: "Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW Trial)"
+author: "New England Journal of Medicine"
+url: https://www.nejm.org/doi/abs/10.1056/NEJMoa2403347
+date: 2024-05-29
+domain: health
+secondary_domains: []
+format: paper
+status: unprocessed
+priority: high
+tags: [glp-1, semaglutide, CKD, kidney-disease, FLOW-trial, organ-protection]
+---
+
+## Content
+
+The FLOW trial — the first dedicated kidney outcomes trial with a GLP-1 receptor agonist. N=3,533 patients with type 2 diabetes and chronic kidney disease randomized to semaglutide vs. placebo. Median follow-up 3.4 years (stopped early at prespecified interim analysis due to efficacy).
+
+Key findings:
+- Primary composite endpoint (major kidney disease events): 24% lower risk with semaglutide (HR 0.76; P=0.0003)
+- Kidney-specific components: HR 0.79 (95% CI 0.66-0.94)
+- Cardiovascular death: HR 0.71 (95% CI 0.56-0.89) — 29% reduction
+- Major cardiovascular events: 18% lower risk
+- Annual eGFR slope less steep by 1.16 mL/min/1.73m2 in semaglutide group (P<0.001) — slower kidney function decline
+- FDA subsequently expanded semaglutide (Ozempic) indications to include T2D patients with CKD
+
+Additive benefits when used with SGLT2 inhibitors (separate analysis in Nature Medicine).
+
+## Agent Notes
+**Why this matters:** CKD is among the most expensive chronic conditions to manage, with dialysis costing $90K+/year per patient. Slowing kidney decline by 1.16 mL/min/1.73m2 annually could delay or prevent dialysis for many patients. This is where the downstream savings argument for GLP-1s is strongest — preventing progression to end-stage renal disease has massive cost implications.
+**What surprised me:** The trial was stopped early for efficacy — the effect was so large that continuing would have been unethical. The 29% reduction in cardiovascular death (in a kidney trial!) suggests these benefits are even broader than expected.
+**What I expected but didn't find:** No cost-effectiveness analysis within this paper. No comparison of cost of semaglutide vs. cost of delayed dialysis. The economic case needs to be constructed separately.
+**KB connections:** Connects to Value in Health Medicare study (CKD savings component = $2,074/subject). Also connects to the multi-indication benefit thesis — GLP-1s working across CV, metabolic, kidney, and liver simultaneously.
+**Extraction hints:** Potential claim: "Semaglutide reduces kidney disease progression by 24% and delays dialysis onset, creating the largest per-patient cost savings of any GLP-1 indication because dialysis costs $90K+/year."
+**Context:** NEJM publication — highest evidence tier. First GLP-1 to get FDA indication for CKD in T2D patients. This is a foundational trial for the multi-organ benefit thesis.
+
+## Curator Notes (structured handoff for extractor)
+PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
+WHY ARCHIVED: Kidney protection is where GLP-1 downstream savings are largest per-patient — dialysis prevention is the economic mechanism most favorable to the VBC cost-saving thesis
+EXTRACTION HINT: Focus on the economic implications of slowed kidney decline for capitated payers, not just the clinical endpoint

inbox/archive/2024-07-18-futardio-proposal-approve-budget-for-champions-nft-collection-design.md

@@ -6,7 +6,13 @@ url: "https://www.futard.io/proposal/BU8kQ7ECq8CJ9BHUZfYsjHFKPMGsF6oJn5d6b1tArdw
 date: 2024-07-18
 domain: internet-finance
 format: data
-status: unprocessed
+status: processed
+processed_by: rio
+processed_date: 2026-03-12
+claims_extracted:
+  - "SPL-404-enables-fungible-NFT-swap-revenue-for-DAOs-by-bridging-governance-tokens-and-NFT-liquidity-on-Solana"
+  - "futarchy-markets-can-price-cultural-spending-proposals-by-treating-community-cohesion-and-brand-equity-as-token-price-inputs"
+enrichments: []
 tags: [futardio, metadao, futarchy, solana, governance]
 event_type: proposal
 ---

inbox/archive/2024-08-01-jmcp-glp1-persistence-adherence-commercial-populations.md

@@ -0,0 +1,51 @@
+---
+type: source
+title: "Real-world Persistence and Adherence to GLP-1 RAs Among Obese Commercially Insured Adults Without Diabetes"
+author: "Journal of Managed Care & Specialty Pharmacy"
+url: https://www.jmcp.org/doi/10.18553/jmcp.2024.23332
+date: 2024-08-01
+domain: health
+secondary_domains: []
+format: paper
+status: unprocessed
+priority: high
+tags: [glp-1, adherence, persistence, discontinuation, real-world-evidence, obesity]
+---
+
+## Content
+
+Real-world claims study of 125,474 patients initiating GLP-1 RAs for obesity (without type 2 diabetes) using commercial insurance data.
+
+**Persistence rates (non-diabetic obesity patients):**
+- 180 days: 46.3%
+- 1 year: 32.3%
+- 2 years: ~15%
+
+**By specific drug:**
+- Semaglutide: 47.1% at 1 year (highest)
+- Liraglutide: 19.2% at 1 year (lowest)
+
+**Comparison with diabetic patients:**
+- Diabetic patients: 46.5% discontinue within 1 year (better than non-diabetic 64.8%)
+- Danish registry: 21.2% discontinue within 12 months for T2D; ~70% discontinue within 2 years
+
+**Key factors associated with discontinuation:**
+- Insufficient weight loss
+- Income level (lower income → higher discontinuation)
+- Adverse events (GI side effects)
+- Insurance coverage changes
+
+**Crucial nuance:** Outcomes approach trial-level results when focusing on highly adherent patients. The adherence problem is not that the drugs don't work — it's that most patients don't stay on them.
+
+## Agent Notes
+**Why this matters:** Adherence is THE binding constraint for the GLP-1 economic thesis. If only 32.3% of non-diabetic patients are still on GLP-1s at 1 year and ~15% at 2 years, the downstream savings that justify the cost never materialize for most patients. Under capitation, an MA plan pays for 12 months of GLP-1 ($2,940 at $245/month) for a patient who discontinues and regains weight — net cost with no benefit.
+**What surprised me:** The drug-specific variation is large — semaglutide at 47.1% vs. liraglutide at 19.2%. Oral formulations may change this further (removing injection barrier). The income correlation suggests access/affordability drives discontinuation as much as clinical factors.
+**What I expected but didn't find:** No analysis of how payment model affects persistence. Does being in an MA plan with care coordination improve adherence vs. FFS? No data on whether lifestyle interventions alongside medication improve persistence (directly relevant to BALANCE model design).
+**KB connections:** The existing GLP-1 claim cites 64.8% non-diabetic discontinuation at 1 year. This source provides the full persistence curve and the crucial 2-year data (15%).
+**Extraction hints:** The extractor should consider: "GLP-1 persistence at 2 years is only 15% for non-diabetic obesity patients, meaning the chronic use model fails not because patients choose indefinite use but because most cannot sustain it." This reframes the "inflationary chronic use" concern — the actual problem may be insufficient chronic use.
+**Context:** Commercial insurance population — different from Medicare (younger, fewer comorbidities). Medicare population may have different persistence patterns due to higher disease burden and stronger clinical indications.
+
+## Curator Notes (structured handoff for extractor)
+PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
+WHY ARCHIVED: The persistence data reframes the economic argument — the "chronic use" problem may actually be an "insufficient persistence" problem. Most patients don't stay on long enough for downstream benefits to materialize.
+EXTRACTION HINT: Focus on the paradox: chronic use makes GLP-1s expensive, but discontinuation eliminates the downstream savings that justify the cost. The economics only work if adherence is sustained AND the payer captures downstream savings.

inbox/archive/2024-10-00-patterns-ai-enhanced-collective-intelligence.md

@@ -7,11 +7,16 @@ date: 2024-10-01
 domain: ai-alignment
 secondary_domains: [collective-intelligence]
 format: paper
-status: unprocessed
+status: null-result
 priority: high
 tags: [collective-intelligence, AI-human-collaboration, homogenization, diversity, inverted-U, multiplex-networks, skill-atrophy]
 flagged_for_clay: ["entertainment industry implications of AI homogenization"]
 flagged_for_rio: ["mechanism design implications of inverted-U collective intelligence curves"]
+processed_by: theseus
+processed_date: 2026-03-11
+enrichments_applied: ["collective-intelligence-requires-diversity-as-a-structural-precondition-not-a-moral-preference.md", "AI-is-collapsing-the-knowledge-producing-communities-it-depends-on.md", "partial-connectivity-produces-better-collective-intelligence-than-full-connectivity-on-complex-problems-because-it-preserves-diversity.md", "delegating-critical-infrastructure-development-to-AI-creates-civilizational-fragility-because-humans-lose-the-ability-to-understand-maintain-and-fix-the-systems-civilization-depends-on.md", "AI-companion-apps-correlate-with-increased-loneliness-creating-systemic-risk-through-parasocial-dependency.md", "intelligence-is-a-property-of-networks-not-individuals.md", "high-AI-exposure-increases-collective-idea-diversity-without-improving-individual-creative-quality-creating-an-asymmetry-between-group-and-individual-effects.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
+extraction_notes: "Extracted 7 claims and 7 enrichments. Core finding is the inverted-U relationship across multiple dimensions (connectivity, diversity, AI integration, personality traits). Five degradation mechanisms identified: bias amplification, motivation erosion, social bond disruption, skill atrophy, homogenization. Multiplex network framework provides structural model but review explicitly notes absence of comprehensive predictive theory. High-impact source (Cell Press) with direct relevance to collective intelligence architecture design."
 ---
 
 ## Content
@@ -63,3 +68,13 @@ Multiple dimensions show inverted-U curves:
 PRIMARY CONNECTION: collective intelligence is a measurable property of group interaction structure not aggregated individual ability
 WHY ARCHIVED: The inverted-U finding is the most important formal result for our collective architecture — it means we need to be at the right level of AI integration, not maximum
 EXTRACTION HINT: Focus on the inverted-U relationships (at least 4 independent dimensions), the degradation mechanisms, and the gap (no comprehensive framework)
+
+
+## Key Facts
+- Google Flu paradox: data-driven tool initially accurate became unreliable
+- Gender-diverse teams outperformed on complex tasks under low time pressure
+- Citizen scientist retention declined after AI deployment
+- Review published in Patterns (Cell Press journal) 2024
+- Framework identifies three network layers: cognition, physical, information
+- Five degradation mechanisms: bias amplification, motivation erosion, social bond disruption, skill atrophy, homogenization
+- Four dimensions show inverted-U curves: connectivity, cognitive diversity, AI integration level, personality traits

inbox/archive/2024-11-01-aspe-medicare-anti-obesity-medication-coverage.md

@@ -0,0 +1,47 @@
+---
+type: source
+title: "Medicare Coverage of Anti-Obesity Medications: Clinical and Budget Impact Analysis"
+author: "ASPE (Office of the Assistant Secretary for Planning and Evaluation)"
+url: https://aspe.hhs.gov/sites/default/files/documents/127bd5b3347b34be31ac5c6b5ed30e6a/medicare-coverage-anti-obesity-meds.pdf
+date: 2024-11-01
+domain: health
+secondary_domains: [internet-finance]
+format: policy
+status: unprocessed
+priority: medium
+tags: [glp-1, medicare, obesity, budget-impact, CBO, federal-spending]
+---
+
+## Content
+
+ASPE issue brief analyzing the clinical benefits and fiscal impact of expanded Medicare coverage for anti-obesity medications.
+
+**Key budget projections:**
+- CBO estimate: Authorizing Medicare coverage for obesity medications would increase federal spending by $35 billion over 2026-2034
+- Annual Part D cost increase: $3.1-6.1 billion
+- Broad semaglutide access: 38,950 CV events avoided, 6,180 deaths avoided over 10 years
+- Net financial impact: savings of $715 million over 10 years (alternative scenarios: $412M to $1.04B)
+
+**Eligibility estimates:**
+- ~10% of Medicare beneficiaries eligible under proposed criteria
+- Criteria require comorbidities (CVD history, heart failure, CKD, prediabetes) — not just BMI
+
+**The CBO vs. ASPE divergence:**
+- CBO: $35B additional spending (budget scoring perspective — counts drug costs without full downstream offsets)
+- ASPE/Value in Health: net savings of $715M (clinical economics perspective — includes downstream event avoidance)
+- The difference is methodological: CBO scores within a 10-year budget window using conservative assumptions about uptake and downstream savings
+
+## Agent Notes
+**Why this matters:** The CBO vs. ASPE divergence is the core of the GLP-1 budget debate. CBO says "$35B more spending" and ASPE says "$715M savings" — both are technically correct but answer different questions. Budget scoring (CBO) doesn't fully count avoided hospitalizations and disease progression. Clinical economics (ASPE) does. This methodological difference drives the entire political debate about whether Medicare should cover GLP-1s.
+**What surprised me:** The gap between CBO and ASPE is enormous — $35B cost vs. $715M savings. This isn't a minor methodological difference; it's a fundamentally different answer to "are GLP-1s worth covering?" The budget scoring rules structurally disadvantage preventive interventions.
+**What I expected but didn't find:** No analysis of how the budget scoring methodology systematically undercounts prevention value. No comparison with other preventive interventions that face the same scoring bias.
+**KB connections:** Connects to the structural misalignment thesis — the tools used to evaluate healthcare policy (CBO scoring) are themselves misaligned with prevention economics. Also relates to [[proxy inertia is the most reliable predictor of incumbent failure because current profitability rationally discourages pursuit of viable futures]] — budget scoring rules are a form of institutional proxy inertia.
+**Extraction hints:** Potential meta-claim: "Federal budget scoring methodology systematically undervalues preventive interventions because the 10-year scoring window and conservative uptake assumptions don't capture long-term downstream savings."
+**Context:** ASPE is the research arm of HHS — more favorable to coverage expansion than CBO, which is Congress's nonpartisan scorekeeper. The political weight of CBO scoring often overrides clinical economics in policy decisions.
+
+## Curator Notes (structured handoff for extractor)
+PRIMARY CONNECTION: [[the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline]]
+WHY ARCHIVED: The CBO vs. ASPE divergence reveals a systematic bias in how prevention economics are evaluated at the federal level — this matters beyond GLP-1s for the entire prevention-first thesis
+EXTRACTION HINT: Focus on the methodological divergence as evidence of structural misalignment in policy evaluation, not just the GLP-1 budget numbers
+
+flagged_for_leo: ["Budget scoring methodology systematically disadvantages prevention — this is a cross-domain structural problem affecting all preventive health investments"]

inbox/archive/2024-11-21-futardio-proposal-proposal-14.md

@@ -6,13 +6,17 @@ url: "https://www.futard.io/proposal/B4zpF4iHeF91qq8Szb9aD6pW1DrwSy6djD4QPWJQn3d
 date: 2024-11-21
 domain: internet-finance
 format: data
-status: unprocessed
+status: null-result
 tags: [futardio, metadao, futarchy, solana, governance]
 event_type: proposal
 processed_by: rio
 processed_date: 2024-11-21
 extraction_model: "anthropic/claude-sonnet-4.5"
 extraction_notes: "This source contains only metadata about a failed MetaDAO proposal with no content details. There is no proposal text, no market data, no voting information, and no context about what was being proposed or why it failed. The source provides verifiable facts (proposal number, accounts, dates, status) but no evidence or interpretation that could support claims or enrich existing knowledge base content. Without knowing what Proposal #14 actually proposed or how the futarchy markets evaluated it, there is nothing extractable beyond the basic facts preserved in key_facts."
+processed_by: rio
+processed_date: 2026-03-11
+extraction_model: "anthropic/claude-sonnet-4.5"
+extraction_notes: "Source contains only metadata about a failed MetaDAO proposal with no content details. Created decision_market entity for archival completeness and timeline entry on parent MetaDAO entity. No extractable claims or enrichments due to absence of proposal text, market data, or context about what was proposed or why it failed."
 ---
 
 ## Proposal Details
@@ -39,3 +43,10 @@ extraction_notes: "This source contains only metadata about a failed MetaDAO pro
 - DAO account: GWywkp2mY2vzAaLydR2MBXRCqk2vBTyvtVRioujxi5Ce
 - Proposer: xwQTt7R68Vsxco819EBqK3itgn9osQc6M2Z1DjwUqmk
 - Autocrat version: 0.3
+
+
+## Key Facts
+- MetaDAO Proposal #14 failed (created 2024-11-21, completed 2024-11-25)
+- Proposal account: B4zpF4iHeF91qq8Szb9aD6pW1DrwSy6djD4QPWJQn3dW
+- Proposer: xwQTt7R68Vsxco819EBqK3itgn9osQc6M2Z1DjwUqmk
+- Autocrat version: 0.3

inbox/archive/2024-11-25-futardio-proposal-launch-a-boost-for-hnt-ore.md

@@ -9,6 +9,11 @@ format: data
 status: unprocessed
 tags: [futardio, metadao, futarchy, solana, governance]
 event_type: proposal
+processed_by: rio
+processed_date: 2026-03-11
+enrichments_applied: ["futarchy-excels-at-relative-selection-but-fails-at-absolute-prediction-because-ordinal-ranking-works-while-cardinal-estimation-requires-calibration.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
+extraction_notes: "Futardio proposal for ORE-HNT liquidity boost. Primary extraction: three new entities (ORE protocol, decision_market for the proposal, Helium). Two enrichments showing futarchy governance patterns: three-tier boost system as governance simplification mechanism, and strategic partnership evaluation through conditional markets. No novel claims — the proposal demonstrates existing futarchy mechanisms in practice rather than introducing new theoretical insights."
 ---
 
 ## Proposal Details
@@ -59,3 +64,10 @@ With the passing of this proposal, we would introduce a new boost with the same
 - Autocrat version: 0.3
 - Completed: 2024-11-28
 - Ended: 2024-11-28
+
+
+## Key Facts
+- ORE proposal 2QUxbiMkDtoKxY2u6kXuevfMsqKGtHNxMFYHVWbqRK1A passed 2024-11-28
+- HNT-ORE boost uses Kamino kTokens representing concentrated liquidity positions on Orca
+- ORE three-tier boost system: Tier 1 (vanilla stake), Tier 2 (SOL-ORE, USDC-ORE), Tier 3 (ISC-ORE, HNT-ORE)
+- Helium HIP-138 consolidated network tokenomics around HNT as primary token

inbox/archive/2024-12-04-futardio-proposal-launch-a-boost-for-usdc-ore.md

@@ -6,9 +6,13 @@ url: "https://www.futard.io/proposal/GBQZvZAeW8xUuVV5a9FJHSyttzY5fPGuvkwLTpWLbw6
 date: 2024-12-04
 domain: internet-finance
 format: data
-status: unprocessed
+status: null-result
 tags: [futardio, metadao, futarchy, solana, governance]
 event_type: proposal
+processed_by: rio
+processed_date: 2026-03-11
+extraction_model: "anthropic/claude-sonnet-4.5"
+extraction_notes: "Governance proposal with clear outcome but no novel mechanism insights. Entity extraction only - no claims warranted. ORE entity may not exist in KB; if missing, this timeline entry will need parent entity creation during review."
 ---
 
 ## Proposal Details
@@ -57,3 +61,10 @@ With the passing of this proposal, we would launch a USDC-ORE vault on Kamino an
 - Autocrat version: 0.3
 - Completed: 2024-12-07
 - Ended: 2024-12-07
+
+
+## Key Facts
+- ORE proposal #3 passed on 2024-12-07 after 3-day voting period
+- USDC described as 'fully-backed by dollars and treasuries held in US banks by Circle'
+- ORE mission statement: 'create the best digital gold product in crypto'
+- Proposal used Autocrat v0.3 futarchy implementation

inbox/archive/2025-00-00-mats-ai-agent-index-2025.md

@@ -7,9 +7,14 @@ date: 2025-01-01
 domain: ai-alignment
 secondary_domains: []
 format: report
-status: unprocessed
+status: null-result
 priority: medium
 tags: [AI-agents, safety-documentation, transparency, deployment, agentic-AI]
+processed_by: theseus
+processed_date: 2026-03-11
+enrichments_applied: ["voluntary safety pledges cannot survive competitive pressure because unilateral commitments are structurally punished when competitors advance without equivalent constraints.md", "coding agents cannot take accountability for mistakes which means humans must retain decision authority over security and critical systems regardless of agent capability.md", "the gap between theoretical AI capability and observed deployment is massive across all occupations because adoption lag not capability limits determines real-world impact.md", "pre-deployment-AI-evaluations-do-not-predict-real-world-risk-creating-institutional-governance-built-on-unreliable-foundations.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
+extraction_notes: "Extracted two claims documenting the agent-specific safety gap and applied four enrichments to existing alignment claims. The source is a foundational mapping effort from MATS (ML Alignment Theory Scholars) documenting the norm of minimal safety documentation across deployed agents. Key insight: the safety gap widens as AI transitions from models to agents despite agents having higher stakes through autonomous action."
 ---
 
 ## Content
@@ -43,3 +48,9 @@ Key findings:
 PRIMARY CONNECTION: [[voluntary safety pledges cannot survive competitive pressure because unilateral commitments are structurally punished when competitors advance without equivalent constraints]]
 WHY ARCHIVED: Documents the agent-specific safety gap — agents act autonomously but have even less safety documentation than base models
 EXTRACTION HINT: The key finding is the NORM of minimal safety documentation across 30 deployed agents. This extends the alignment gap from models to agents.
+
+
+## Key Facts
+- MATS surveyed 30 state-of-the-art AI agents (2025)
+- Survey documented origins, design, capabilities, ecosystem characteristics, and safety features through publicly available information and developer correspondence
+- Most agents deployed for professional and personal tasks with limited human involvement

inbox/archive/2025-01-00-pal-pluralistic-alignment-learned-prototypes.md

@@ -7,9 +7,14 @@ date: 2025-01-21
 domain: ai-alignment
 secondary_domains: [collective-intelligence]
 format: paper
-status: unprocessed
+status: null-result
 priority: high
 tags: [pluralistic-alignment, reward-modeling, mixture-models, ideal-points, personalization, sample-efficiency]
+processed_by: theseus
+processed_date: 2026-03-11
+enrichments_applied: ["RLHF and DPO both fail at preference diversity because they assume a single reward function can capture context-dependent human values.md", "pluralistic alignment must accommodate irreducibly diverse values simultaneously rather than converging on a single aligned state.md", "modeling preference sensitivity as a learned distribution rather than a fixed scalar resolves DPO diversity failures without demographic labels or explicit user modeling.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
+extraction_notes: "Extracted two novel claims about mixture modeling for pluralistic alignment and generalization superiority. Applied three enrichments to existing alignment claims with formal evidence from PAL's theorems and empirical results. This is the first pluralistic alignment mechanism with formal sample-efficiency guarantees, representing a significant constructive advance beyond the impossibility/failure diagnoses in the existing KB. The 36% unseen user improvement is particularly significant as it reframes pluralistic alignment from a fairness concern to a functional superiority claim."
 ---
 
 ## Content
@@ -49,3 +54,11 @@ Open source: github.com/RamyaLab/pluralistic-alignment
 PRIMARY CONNECTION: RLHF and DPO both fail at preference diversity because they assume a single reward function can capture context-dependent human values
 WHY ARCHIVED: First mechanism with formal guarantees for pluralistic alignment — transitions the KB from impossibility diagnosis to constructive alternatives
 EXTRACTION HINT: Focus on the formal properties (Theorems 1 and 2) and the functional superiority claim (diverse approaches generalize better, not just fairer)
+
+
+## Key Facts
+- PAL accepted at ICLR 2025 (main conference)
+- PAL presented at NeurIPS 2024 workshops: AFM, Behavioral ML, FITML, Pluralistic-Alignment, SoLaR
+- Open source implementation: github.com/RamyaLab/pluralistic-alignment
+- Architecture uses Coombs' ideal point model (1950) as theoretical foundation
+- PAL is complementary to existing RLHF/DPO pipelines (can be integrated)

inbox/archive/2025-01-01-select-cost-effectiveness-analysis-obesity-cvd.md

@@ -0,0 +1,45 @@
+---
+type: source
+title: "Cost-effectiveness of Semaglutide in People with Obesity and Cardiovascular Disease Without Diabetes"
+author: "Journal of Medical Economics (Tandfonline)"
+url: https://www.tandfonline.com/doi/full/10.1080/13696998.2025.2459529
+date: 2025-01-01
+domain: health
+secondary_domains: [internet-finance]
+format: paper
+status: unprocessed
+priority: medium
+tags: [glp-1, semaglutide, cost-effectiveness, cardiovascular, SELECT-trial, QALY]
+---
+
+## Content
+
+Cost-effectiveness analysis of semaglutide 2.4mg based on SELECT trial data, modeling lifetime outcomes for obese/overweight patients with established CVD but without diabetes.
+
+**Key findings:**
+- At list price: ICER = $136,271/QALY — cost-effective at $150,000/QALY threshold
+- With estimated 48% rebate: ICER = $32,219/QALY — highly cost-effective
+- Per 100,000 subjects treated (lifetime horizon): 2,791 non-fatal MIs avoided, 3,000 revascularizations avoided, 487 strokes avoided, 115 CV deaths avoided
+- Average per-subject lifetime treatment cost: $47,353
+- Savings from avoided T2D: $14,431/subject; avoided CKD: $2,074; avoided CV events: $1,512
+
+**Australian analysis comparison:**
+- At A$4,175/year: ICER = A$96,055/QALY (~US$138K/QALY)
+- NOT cost-effective at Australian A$50,000/QALY threshold
+
+**ICER 2025 assessment:**
+- Semaglutide and tirzepatide now meet <$100K/QALY at net prices (shift from 2022)
+- But semaglutide would need 80% price reduction to meet standard threshold at list price
+
+## Agent Notes
+**Why this matters:** The rebate-adjusted ICER ($32K/QALY) vs. list-price ICER ($136K/QALY) shows that the cost-effectiveness conclusion depends almost entirely on the actual net price. At $245/month (Medicare deal), semaglutide is likely highly cost-effective. At $1,350/month (list), it's borderline. This price sensitivity means the Trump deals fundamentally change the cost-effectiveness calculation.
+**What surprised me:** The per-subject savings from avoided T2D ($14,431) dwarf savings from avoided CV events ($1,512), even though the trial was a CV outcomes trial. Diabetes prevention may be the largest economic lever, not cardiovascular protection.
+**What I expected but didn't find:** No analysis stratified by risk level. High-risk patients (those meeting Medicare eligibility criteria) likely have much better cost-effectiveness than the average SELECT population.
+**KB connections:** Supports scope-qualifying the inflationary claim — GLP-1s are cost-effective at net prices but not at list prices. The price trajectory (declining) matters enormously.
+**Extraction hints:** The T2D prevention savings being 10x the CV event savings is a key insight. The existing GLP-1 claim focuses on weight loss economics; the real economic case may be metabolic disease prevention.
+**Context:** Industry-funded study (Novo Nordisk). The 48% rebate estimate is their assumption of actual net pricing. CBO and ASPE use different assumptions.
+
+## Curator Notes (structured handoff for extractor)
+PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
+WHY ARCHIVED: Cost-effectiveness is price-dependent — the declining price trajectory may flip GLP-1s from inflationary to cost-effective faster than the existing claim anticipates
+EXTRACTION HINT: Focus on the price sensitivity of the cost-effectiveness conclusion and how recent price deals change the math

inbox/archive/2025-02-24-futardio-proposal-mtn-meets-meta-hackathon.md

@@ -6,9 +6,13 @@ url: "https://www.futard.io/proposal/9ZYMaLKWn9PSLTX1entmqJUYBiCkZbRxeRz1tVvYwqy
 date: 2025-02-24
 domain: internet-finance
 format: data
-status: unprocessed
+status: null-result
 tags: [futardio, metadao, futarchy, solana, governance]
 event_type: proposal
+processed_by: rio
+processed_date: 2026-03-11
+extraction_model: "anthropic/claude-sonnet-4.5"
+extraction_notes: "Single failed proposal from a hidden test DAO. No novel mechanism insights or governance dynamics worth extracting as claims. The proposal itself is significant enough to document as a decision_market entity showing futarchy governance in action, but contains no arguable propositions about mechanism design or organizational behavior. The AI-generated impact analysis sections were ignored as auto-generated noise per extraction rules."
 ---
 
 ## Proposal Details
@@ -50,3 +54,9 @@ But you have access to the data via API so here you are!
 - Autocrat version: 0.3
 - Completed: 2025-02-27
 - Ended: 2025-02-27
+
+
+## Key Facts
+- Test DAO proposal 9ZYMaLKWn9PSLTX1entmqJUYBiCkZbRxeRz1tVvYwqy6 for mtn Meets META Hackathon failed (2025-02-24 to 2025-02-27)
+- Test DAO is a hidden DAO with account GWywkp2mY2vzAaLydR2MBXRCqk2vBTyvtVRioujxi5Ce
+- Proposal used Autocrat v0.3 governance mechanism

inbox/archive/2025-02-27-fortune-mrbeast-5b-valuation-beast-industries.md

@@ -7,9 +7,15 @@ date: 2025-02-27
 domain: entertainment
 secondary_domains: [internet-finance]
 format: article
-status: unprocessed
+status: processed
 priority: medium
 tags: [mrbeast, beast-industries, valuation, content-as-loss-leader, creator-economy]
+processed_by: clay
+processed_date: 2026-03-11
+claims_extracted: ["beast-industries-5b-valuation-prices-content-as-loss-leader-model-at-enterprise-scale.md"]
+enrichments_applied: ["the media attractor state is community-filtered IP with AI-collapsed production costs where content becomes a loss leader for the scarce complements of fandom community and ownership.md", "creator-brand-partnerships-shifting-from-transactional-campaigns-to-long-term-joint-ventures-with-shared-formats-audiences-and-revenue.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
+extraction_notes: "Extracted two claims validating content-as-loss-leader model at enterprise scale, enriched two existing entertainment claims with market validation data, created Beast Industries entity. The $5B valuation represents significant market evidence that integrated creator-to-product models are valued differently than pure content businesses. Revenue trajectory data provides concrete metrics for the attractor state thesis."
 ---
 
 ## Content
@@ -43,3 +49,8 @@ Fortune coverage of Beast Industries fundraise and business structure.
 PRIMARY CONNECTION: the media attractor state is community-filtered IP with AI-collapsed production costs where content becomes a loss leader for the scarce complements of fandom community and ownership
 WHY ARCHIVED: Revenue trajectory data validates content-as-loss-leader at enterprise scale. Cross-reference with Bloomberg source for consistent $250M Feastables figure.
 EXTRACTION HINT: The $5B valuation is the market's verdict that the content-as-loss-leader model is real and scalable. This is market evidence, not just theoretical argument.
+
+
+## Key Facts
+- Beast Industries operates five verticals: software (Viewstats), CPG (Feastables, Lunchly), health/wellness, media, video games
+- Traditional CPG companies (Hershey's, Mars) spend 10-15% of revenue on advertising

inbox/archive/2025-03-01-medicare-prior-authorization-glp1-near-universal.md

@@ -0,0 +1,46 @@
+---
+type: source
+title: "Medicare Beneficiaries Face Near-Universal Prior Authorization for GLP-1 Drugs"
+author: "Medical Economics"
+url: https://www.medicaleconomics.com/view/medicare-beneficiaries-face-higher-costs-near-universal-prior-authorization-for-glp-1-drugs
+date: 2025-03-01
+domain: health
+secondary_domains: []
+format: article
+status: unprocessed
+priority: medium
+tags: [glp-1, prior-authorization, medicare-advantage, formulary, access-barriers]
+---
+
+## Content
+
+Analysis of GLP-1 coverage and prior authorization requirements under Medicare Advantage plans.
+
+**Prior authorization escalation:**
+- PA requirements surged from 2.8-5% of GLP-1 prescriptions (2020-2023) to nearly 100% by 2025
+- Both BCBS and UnitedHealthcare require PA for GLP-1 coverage under MA
+- PA ensures only T2D-diagnosed patients can access (pre-obesity coverage)
+
+**Coverage rates by drug (2025 MA formularies):**
+- Injectable semaglutide (Ozempic): 98.0% of MA plans cover
+- Tirzepatide (Mounjaro): 96.2%
+- Oral semaglutide: 84.8%
+- Dulaglutide: 87.5%
+
+**Current exclusion:**
+- GLP-1s for weight loss/obesity remain excluded under Medicare Part D (until BALANCE model / demonstration)
+- Only covered for T2D, CVD risk reduction, or obstructive sleep apnea (FDA-approved uses)
+- Only 13 state Medicaid programs covered GLP-1s for obesity as of January 2026
+
+## Agent Notes
+**Why this matters:** Near-universal PA for GLP-1s under MA is a signal of how capitated plans manage high-cost drugs. MA plans bearing full risk have strong incentives to RESTRICT access (short-term cost avoidance) even when long-term data suggests coverage would save money. This is a live example of the VBC misalignment the March 10 research identified — MA is value-based in form but short-term cost management in practice.
+**What surprised me:** The PA escalation from <5% to ~100% in just 2 years is extreme. This is MA plans actively resisting GLP-1 adoption, not embracing it — which challenges the thesis that capitated plans would rationally cover prevention.
+**What I expected but didn't find:** No data on how PA affects adherence/persistence. If PA creates delays and access friction, it may worsen the already-terrible adherence rates. No analysis of whether MA plans with higher GLP-1 coverage have better downstream outcomes.
+**KB connections:** Directly relevant to the March 10 finding that MA is VBC in form but misaligned in practice. Also connects to [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]].
+**Extraction hints:** The PA escalation could support a claim about short-term cost management overriding long-term prevention incentives even under capitation.
+**Context:** The near-universal PA will change significantly when the BALANCE model launches and Medicare GLP-1 demonstration begins in July 2026. This archive captures the pre-demonstration baseline.
+
+## Curator Notes (structured handoff for extractor)
+PRIMARY CONNECTION: [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]]
+WHY ARCHIVED: Near-universal PA for GLP-1s under MA demonstrates that capitation alone doesn't align incentives for prevention — MA plans still manage to short-term cost metrics
+EXTRACTION HINT: Focus on the tension between theoretical capitation incentives (cover prevention → save money) and actual MA behavior (restrict access → minimize short-term spend)

inbox/archive/2025-03-26-crfb-ma-overpaid-1-2-trillion.md

@@ -7,9 +7,14 @@ date: 2025-03-26
 domain: health
 secondary_domains: []
 format: report
-status: unprocessed
+status: null-result
 priority: high
 tags: [medicare-advantage, overpayment, fiscal-impact, coding-intensity, favorable-selection, trust-fund]
+processed_by: vida
+processed_date: 2026-03-11
+enrichments_applied: ["medicare-fiscal-pressure-forces-ma-reform-by-2030s-through-arithmetic-not-ideology.md", "medicare-trust-fund-insolvency-accelerated-12-years-by-tax-policy-demonstrating-fiscal-fragility.md", "CMS 2027 chart review exclusion targets vertical integration profit arbitrage by removing upcoded diagnoses from MA risk scoring.md", "value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
+extraction_notes: "Two major claims extracted: (1) the $1.2T overpayment projection with equal split between coding and selection, and (2) the structural nature of favorable selection as a legal plan design feature rather than fraud. Four enrichments applied to existing MA/Medicare fiscal claims. The favorable selection mechanism is the less-discussed half of the overpayment equation and deserved its own claim as curator notes suggested. No entity data in this source—pure policy analysis and fiscal projections."
 ---
 
 ## Content
@@ -50,3 +55,13 @@ tags: [medicare-advantage, overpayment, fiscal-impact, coding-intensity, favorab
 PRIMARY CONNECTION: [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]]
 WHY ARCHIVED: Quantifies the fiscal stakes of MA reform — connects insurance market structure to Medicare solvency timeline.
 EXTRACTION HINT: The favorable selection mechanism deserves its own claim — it's the less-discussed half of the overpayment equation.
+
+
+## Key Facts
+- MA overpayments: $1.2 trillion over 2025-2034 (MedPAC data via CRFB)
+- Coding intensity overpayments: $600B total ($260B trust fund, $110B beneficiary premiums)
+- Favorable selection overpayments: $580B total ($250B trust fund, $110B beneficiary premiums)
+- MA plans see 10% net payment increase from coding intensity despite 5.9% CMS adjustment
+- Favorable selection causes MA costs to run 11% higher than FFS in 2025
+- CBO estimate: reducing MA benchmarks could save $489B
+- CBO estimate: raising coding adjustment from 5.9% to 20% could reduce deficits by >$1T

inbox/archive/2025-05-01-nejm-semaglutide-mash-phase3-liver.md

@@ -0,0 +1,41 @@
+---
+type: source
+title: "Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)"
+author: "New England Journal of Medicine"
+url: https://www.nejm.org/doi/10.1056/NEJMoa2413258
+date: 2025-05-01
+domain: health
+secondary_domains: []
+format: paper
+status: unprocessed
+priority: medium
+tags: [glp-1, semaglutide, MASH, NASH, liver-disease, organ-protection]
+---
+
+## Content
+
+Phase 3 trial of semaglutide 2.4mg in patients with MASH and moderate or advanced liver fibrosis.
+
+**Key findings:**
+- Resolution of steatohepatitis without worsening fibrosis: 62.9% semaglutide vs. 34.3% placebo
+- GLP-1 RAs improve fibrosis stage without worsening MASH (meta-analysis data)
+- Hepatoprotective effects are multifactorial: glycemic control + insulin resistance + weight loss + direct liver effects
+- Some liver benefits appear at least partly independent of weight loss
+
+**Meta-analysis context (2025):**
+- GLP-1 RAs significantly increase histologic resolution of MASH
+- Decreased liver fat deposition, improved hepatocellular ballooning, reduced lobular inflammation
+- Associated with reduced risk of major CV events, clinically significant portal hypertension, and all-cause mortality in MASLD/MASH patients
+
+## Agent Notes
+**Why this matters:** MASH/NASH is projected to become the leading cause of liver transplantation. If GLP-1s can resolve steatohepatitis and slow fibrosis, this prevents enormously expensive late-stage liver disease. Combined with CV and kidney protection, GLP-1s are emerging as multi-organ protective agents, not just weight loss drugs.
+**What surprised me:** The 62.9% resolution rate is very high — nearly 2x placebo. And some benefits are independent of weight loss, suggesting a direct hepatoprotective mechanism. This adds a third organ-protection pathway (heart, kidney, liver) to the multi-indication economic case.
+**What I expected but didn't find:** No cost-effectiveness analysis specific to MASH indication. The Value in Health Medicare study showed only $28M MASH savings — surprisingly small given the clinical magnitude, likely because MASH progression to transplant takes decades.
+**KB connections:** Strengthens the multi-indication benefit thesis that the existing GLP-1 claim doesn't fully capture. The combined CV + kidney + liver protection may justify chronic use even if weight management alone doesn't.
+**Extraction hints:** Potential claim: "GLP-1 agonists protect three major organ systems simultaneously — cardiovascular, renal, and hepatic — through mechanisms partially independent of weight loss, making them the first drug class to address the metabolic syndrome as a unified disease."
+**Context:** NEJM publication — highest evidence tier. Resmetirom (Rezdiffra) was approved for MASH in March 2024, so GLP-1s now compete with a dedicated MASH therapy. Head-to-head data unclear.
+
+## Curator Notes (structured handoff for extractor)
+PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
+WHY ARCHIVED: Third organ-protection pathway (after CV and kidney) strengthens the case that GLP-1s should be evaluated as multi-organ protective agents, not just weight loss drugs
+EXTRACTION HINT: The multi-organ protection thesis may justify reframing the existing GLP-1 claim from a weight-loss-economics frame to a metabolic-disease-prevention frame

inbox/archive/2025-06-00-panews-futarchy-governance-weapons.md

@@ -6,10 +6,15 @@ url: https://www.panewslab.com/en/articles/ws5i1bxj
 date: 2025-06-00
 domain: internet-finance
 secondary_domains: [collective-intelligence]
-format: article
-status: unprocessed
+format: report
+status: null-result
 priority: high
 tags: [futarchy, prediction-markets, governance, optimism, self-referential, gamification]
+processed_by: rio
+processed_date: 2026-03-11
+enrichments_applied: ["futarchy adoption faces friction from token price psychology proposal complexity and liquidity requirements.md", "speculative markets aggregate information through incentive and selection effects not wisdom of crowds.md", "domain-expertise-loses-to-trading-skill-in-futarchy-markets-because-prediction-accuracy-requires-calibration-not-just-knowledge.md", "futarchy is manipulation-resistant because attack attempts create profitable opportunities for defenders.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
+extraction_notes: "High-value extraction. Source identifies the self-referential paradox as a fundamental challenge to futarchy theory not currently in KB. The distinction between futarchy (predictions allocate resources) and pure prediction markets (predictions observe external events) is crucial and underexplored. Also provides first large-scale empirical data on futarchy UX friction (6 interactions per bet) and information asymmetry effects (45% non-disclosure). Tyler Cowen critique adds philosophical dimension. Four new claims plus four enrichments to existing claims. Created Optimism entity to track this experiment."
 ---
 
 ## Content
@@ -53,3 +58,16 @@ Unlike pure prediction markets (Polymarket predicting elections), futarchy's pre
 PRIMARY CONNECTION: [[futarchy is manipulation-resistant because attack attempts create profitable opportunities for defenders]]
 WHY ARCHIVED: Identifies the self-referential paradox — a fundamental challenge to futarchy's theoretical foundations not currently captured in KB
 EXTRACTION HINT: Focus on the self-referential dynamic as a NEW challenge distinct from manipulation resistance — this is about the feedback loop between prediction and outcome, not about bad actors
+
+
+## Key Facts
+- Optimism futarchy experiment: 2,262 visitors, 19% conversion rate (March 2025)
+- 5,898 total transactions across futarchy experiment
+- Average 13.6 transactions per participant
+- Top performer: 406 transactions in 3 days
+- Only 4 of 20 top forecasters held OP governance credentials
+- All futarchy-selected projects: -$15.8M TVL collectively
+- Extra Finance (Grants Council pick): +$8M TVL
+- QiDAO (Grants Council pick): +$10M TVL
+- 45% of projects didn't disclose resource deployment plans
+- 41% of participants hedged positions in final three days

inbox/archive/2025-06-01-cell-med-glp1-societal-implications-obesity.md

@@ -0,0 +1,54 @@
+---
+type: source
+title: "The Societal Implications of Using GLP-1 Receptor Agonists for the Treatment of Obesity"
+author: "Med (Cell Press)"
+url: https://www.cell.com/med/fulltext/S2666-6340(25)00232-6
+date: 2025-06-01
+domain: health
+secondary_domains: [entertainment, internet-finance]
+format: paper
+status: unprocessed
+priority: medium
+tags: [glp-1, obesity, societal-impact, equity, food-systems, population-health, sustainability]
+---
+
+## Content
+
+Review article examining the broad societal implications of widespread GLP-1 adoption beyond individual clinical outcomes.
+
+**Population-level data:**
+- October 2025 Gallup poll: 12.4% of US adults taking GLP-1 for weight loss (30M+ people)
+- US obesity prevalence declined from 39.9% (2022) to 37.0% (2025) — 7.6M fewer obese Americans
+- First population-level obesity prevalence decline in recent years
+
+**Key societal concerns raised:**
+- Without increased accessibility and lower costs, GLP-1 rollout may WIDEN inequalities
+- Current GLP-1 access skews wealthy/insured — equity gap
+- GLP-1s do not offer a sustainable solution without prevention
+- Countries must consider local cost-effectiveness, budget impact, and ethical implications
+
+**WHO position (December 2025):**
+- Conditional recommendations for GLP-1s as part of comprehensive approach
+- Three pillars: healthier environments (population policy), protect high-risk individuals, person-centered care
+- Obesity is societal challenge requiring multisectoral action
+
+**System-level effects:**
+- Obesity costs US $400B+ annually
+- GLP-1s mark "system-level redefinition" of cardiometabolic management
+- Ripple effects across healthcare costs, insurance models, food systems, long-term population health
+
+## Agent Notes
+**Why this matters:** The population-level obesity decline (39.9% → 37.0%) is potentially historic — the first time a pharmaceutical intervention has measurably reduced population obesity prevalence. But the equity concerns are real: GLP-1s could create a two-tier health system where those with access get healthier while those without fall further behind.
+**What surprised me:** The 3 percentage point decline in population obesity prevalence. If causally attributable to GLP-1s (not certain), this is the largest population-level health intervention effect since vaccines. The WHO guidelines being issued within 2 years of widespread adoption is also unusually fast.
+**What I expected but didn't find:** No analysis of food industry/agriculture effects. No data on how GLP-1 adoption affects food consumption patterns at population level. No analysis of implications for the food-as-medicine / SDOH movement.
+**KB connections:** Connects to [[Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic more deadly than the famines specialization eliminated]] — GLP-1s may be a pharmacological counter to engineered food addiction. Also connects to [[the epidemiological transition marks the shift from material scarcity to social disadvantage as the primary driver of health outcomes in developed nations]] — GLP-1s address metabolic consequences but not root social causes.
+**Extraction hints:** Potential claims: (1) "GLP-1 adoption has produced the first measurable decline in US obesity prevalence, demonstrating pharmaceutical intervention can shift population-level health outcomes." (2) "GLP-1 access inequality risks creating a two-tier metabolic health system where pharmacological prevention is available to the insured and wealthy while root social determinants remain unaddressed."
+**Context:** This is a Cell Press review, not original research. The population-level obesity data needs independent verification — correlation with GLP-1 adoption is strong but causation requires more evidence (could be confounded by other trends).
+
+## Curator Notes (structured handoff for extractor)
+PRIMARY CONNECTION: [[Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s]]
+WHY ARCHIVED: Population-level obesity decline is a potential paradigm shift, but equity concerns directly challenge the prevention-first attractor state if access remains stratified by wealth
+EXTRACTION HINT: Focus on both the population-level effect AND the equity concern — these are in tension and both matter for the attractor state thesis
+
+flagged_for_clay: ["GLP-1 adoption is reshaping cultural narratives around obesity, body image, and pharmaceutical solutions to behavioral problems — connects to health narrative infrastructure"]
+flagged_for_rio: ["GLP-1 equity gap creates investment opportunity in access-focused models that serve underserved populations — potential Living Capital thesis"]

inbox/archive/2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics.md

@@ -0,0 +1,41 @@
+---
+type: source
+title: "Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare"
+author: "Value in Health (peer-reviewed journal)"
+url: https://www.valueinhealthjournal.com/article/S1098-3015(25)02472-6/fulltext
+date: 2025-06-01
+domain: health
+secondary_domains: [internet-finance]
+format: paper
+status: unprocessed
+priority: high
+tags: [glp-1, semaglutide, medicare, cost-effectiveness, cardiovascular, CKD, MASH]
+---
+
+## Content
+
+Peer-reviewed modeling study estimating the comprehensive value of semaglutide in the Medicare population for current and future FDA-approved indications (type 2 diabetes, overweight/obesity, MASH). Modeled clinical outcomes and costs over a 10-year period (2026-2035).
+
+Key findings:
+- Net financial impact to Medicare: savings of $715 million over 10 years (range: $412M to $1.04B depending on utilization/price assumptions)
+- 38,950 cardiovascular events avoided over 10 years
+- 6,180 deaths avoided (CV events + CKD/MASH progression improvement)
+- T2D-related impact: savings of ~$892 million
+- Obesity-related impact: added costs of ~$205 million
+- MASH-related impact: savings of ~$28 million
+- Per 100,000 subjects treated: 2,791 non-fatal MIs avoided, 3,000 coronary revascularizations avoided, 487 non-fatal strokes avoided, 115 CV deaths avoided
+- Average per-subject lifetime treatment costs: $47,353
+- Savings from avoided T2D: $14,431/subject; avoided CKD: $2,074/subject; avoided CV events: $1,512/subject
+
+## Agent Notes
+**Why this matters:** This directly challenges our existing claim that GLP-1s are "inflationary through 2035." Under Medicare specifically, the modeling shows NET SAVINGS when multi-indication benefits are accounted for. The distinction between system-level inflationary impact and payer-specific savings under risk-bearing arrangements is the core of the VBC interaction question.
+**What surprised me:** The T2D-related savings ($892M) actually exceed the obesity-related costs ($205M). The MASH savings are tiny ($28M) despite the impressive clinical data — suggests MASH treatment costs don't accumulate enough in the 10-year window to produce large offsets.
+**What I expected but didn't find:** No breakdown by MA vs. traditional Medicare. No analysis of how capitated vs. FFS payment models affect the cost-benefit calculation differently.
+**KB connections:** Directly relevant to [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] — this study complicates the "inflationary" conclusion. Also connects to [[the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline]].
+**Extraction hints:** Potential claim: "Comprehensive semaglutide access saves Medicare $715M over 10 years because multi-indication cardiovascular and metabolic benefits offset drug costs when a single payer bears both costs and savings." This would need to be scoped carefully against the system-level inflationary claim.
+**Context:** Published in Value in Health, a peer-reviewed health economics journal. Study appears to use Novo Nordisk-favorable assumptions (net prices with rebates). The $715M figure is modest relative to total Medicare spending but significant as evidence that prevention CAN be cost-saving under the right payment structure.
+
+## Curator Notes (structured handoff for extractor)
+PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
+WHY ARCHIVED: This study provides the strongest evidence that the "inflationary through 2035" framing needs scope qualification — system-level vs. payer-level economics diverge when downstream savings accrue to the same entity
+EXTRACTION HINT: Focus on the distinction between system-level cost impact (inflationary) and risk-bearing payer impact (potentially cost-saving). This is the core VBC interaction.

inbox/archive/2025-07-00-fli-ai-safety-index-summer-2025.md

@@ -7,9 +7,14 @@ date: 2025-07-01
 domain: ai-alignment
 secondary_domains: [grand-strategy]
 format: report
-status: unprocessed
+status: null-result
 priority: high
 tags: [AI-safety, company-scores, accountability, governance, existential-risk, transparency]
+processed_by: theseus
+processed_date: 2026-03-11
+enrichments_applied: ["the alignment tax creates a structural race to the bottom because safety training costs capability and rational competitors skip it.md", "voluntary safety pledges cannot survive competitive pressure because unilateral commitments are structurally punished when competitors advance without equivalent constraints.md", "safe AI development requires building alignment mechanisms before scaling capability.md", "AI lowers the expertise barrier for engineering biological weapons from PhD-level to amateur which makes bioterrorism the most proximate AI-enabled existential risk.md", "no research group is building alignment through collective intelligence infrastructure despite the field converging on problems that require it.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
+extraction_notes: "High-value extraction. Four new claims quantifying the AI safety gap at company level, five enrichments confirming existing race-to-the-bottom and voluntary-pledge-failure claims. The C+ ceiling (Anthropic) and universal D-or-below existential safety scores are the key empirical findings. FLI entity updated with timeline entry. No new entity creation needed—FLI already exists in KB."
 ---
 
 ## Content
@@ -62,3 +67,10 @@ FLI's comprehensive evaluation of frontier AI companies across 6 safety dimensio
 PRIMARY CONNECTION: [[the alignment tax creates a structural race to the bottom because safety training costs capability and rational competitors skip it]]
 WHY ARCHIVED: Provides quantitative company-level evidence for the race-to-the-bottom dynamic — best company scores C+ in overall safety, all companies score D or below in existential safety
 EXTRACTION HINT: The headline claim is "no frontier AI company scores above D in existential safety despite AGI claims." The company-by-company comparison and the existential safety gap are the highest-value extractions.
+
+
+## Key Facts
+- FLI AI Safety Index Summer 2025 evaluated 7 companies across 6 dimensions using peer-reviewed methodology
+- Company scores: Anthropic C+ (2.64), OpenAI C (2.10), DeepMind C- (1.76), x.AI D (1.23), Meta D (1.06), Zhipu AI F (0.62), DeepSeek F (0.37)
+- Six evaluation dimensions: Risk Assessment, Current Harms, Safety Frameworks, Existential Safety, Governance & Accountability, Information Sharing
+- Methodology based on publicly available information plus email correspondence with developers

inbox/archive/2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk.md

@@ -0,0 +1,52 @@
+---
+type: source
+title: "Weighing the Risk of GLP-1 Treatment in Older Adults: Sarcopenic Obesity Concerns"
+author: "Multiple sources (ScienceDirect, Harvard Science Review, Endocrine News)"
+url: https://pmc.ncbi.nlm.nih.gov/articles/PMC12391595/
+date: 2025-07-01
+domain: health
+secondary_domains: []
+format: review
+status: unprocessed
+priority: medium
+tags: [glp-1, sarcopenia, muscle-loss, elderly, safety, lean-mass]
+---
+
+## Content
+
+Multiple sources examining the muscle loss / sarcopenia risk from GLP-1 agonist use, particularly in elderly patients.
+
+**Lean mass loss quantification:**
+- 15-40% of total weight lost on GLP-1s is lean body mass (not fat)
+- Some analyses suggest up to 60% in certain patients
+- Natural aging already reduces skeletal muscle mass by 12-16% — GLP-1s compound this
+
+**Elderly-specific risks:**
+- Sarcopenic obesity (excess fat + low muscle mass) prevalence: 10-20% of older adults
+- Weight cycling risk: patients who discontinue (64.8% within 1 year) may regain fat preferentially while muscle is NOT regained
+- This creates a worse body composition than before treatment: same or higher fat, less muscle
+- Functional impairment and disability risk increases
+
+**Mitigation strategies:**
+- High protein diet + resistance training can partially prevent muscle loss
+- But adherence to exercise programs is low, especially in the populations most likely to use GLP-1s
+- No pharmacological solution to GLP-1-induced muscle loss yet
+
+**Next-generation compounds:**
+- Some next-gen GLP-1 therapies aim to improve "quality of weight loss" by preserving muscle
+- ADA notes new therapies "enhance quality of weight loss by improving muscle preservation"
+
+## Agent Notes
+**Why this matters:** This is the strongest safety counter-argument to broad GLP-1 deployment, especially in the Medicare-age population. If GLP-1s cause significant muscle loss in elderly patients, and most discontinue within a year (losing the metabolic benefits while keeping the muscle deficit), the net health effect could be NEGATIVE for some patients. This directly challenges the Medicare cost-savings thesis — sarcopenic elderly patients may need MORE healthcare, not less.
+**What surprised me:** The weight cycling mechanism is particularly concerning: GLP-1 → muscle loss → discontinuation → fat regain without muscle regain → sarcopenic obesity → increased fall risk, fractures, disability. This cycle could create NEW healthcare costs that offset the cardiovascular and metabolic savings.
+**What I expected but didn't find:** No population-level data on actual sarcopenia incidence in GLP-1 users vs. controls. Most evidence is mechanistic/theoretical or from small studies. No Medicare-specific analysis of the functional impact.
+**KB connections:** This is a genuine challenge to the GLP-1 cost-savings thesis and the attractor state. If the same drug that prevents CV events causes sarcopenic disability, the net population health effect is ambiguous. Connects to the adherence data — the 64.8% discontinuation rate makes the muscle loss / weight cycling scenario the most common outcome.
+**Extraction hints:** Potential claim: "GLP-1-induced muscle loss combined with high discontinuation rates creates a sarcopenic obesity risk where patients end up with worse body composition than before treatment — more fat, less muscle, higher disability risk."
+**Context:** This is an emerging safety signal, not yet supported by large-scale outcomes data. The next-gen compounds claiming to preserve muscle suggest the manufacturers take this risk seriously.
+
+## Curator Notes (structured handoff for extractor)
+PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
+WHY ARCHIVED: Counter-evidence to the GLP-1 benefit thesis — sarcopenia risk may create new costs that offset cardiovascular/metabolic savings, especially in the Medicare population
+EXTRACTION HINT: The intersection of muscle loss + high discontinuation rates is the key risk — evaluate as a challenge to the cost-savings thesis, not just a clinical side effect
+
+flagged_for_astra: ["GLP-1-induced muscle loss in elderly has parallels to spaceflight muscle atrophy — different mechanism but similar functional consequences"]

inbox/archive/2025-07-02-futardio-proposal-testing-indexer-changes.md

@@ -6,13 +6,17 @@ url: "https://www.futard.io/proposal/35mgLHTJYhyEWjsLHDd4jZNQ6jwuZ4E214TUm1hA8vB
 date: 2025-07-02
 domain: internet-finance
 format: data
-status: unprocessed
+status: processed
 tags: [futardio, metadao, futarchy, solana, governance]
 event_type: proposal
 processed_by: rio
 processed_date: 2025-07-02
 extraction_model: "anthropic/claude-sonnet-4.5"
 extraction_notes: "This source is a futarchy proposal event record with minimal substantive content. The description field contains only 'This is' (appears truncated). No arguable claims, no evidence about futarchy mechanisms, governance outcomes, or indexer performance. This is purely operational metadata from the futard.io platform tracking a failed test proposal. No extractable claims or enrichments to existing knowledge base."
+processed_by: rio
+processed_date: 2026-03-11
+extraction_model: "anthropic/claude-sonnet-4.5"
+extraction_notes: "Test proposal with minimal substantive content. Description field truncated to 'This is'. Created entity records for Test DAO timeline and decision_market entity for completeness, though this appears to be infrastructure testing rather than meaningful governance. No extractable claims about futarchy mechanisms or governance outcomes."
 ---
 
 ## Proposal Details
@@ -59,3 +63,9 @@ is
 - Proposal number: 2
 - DAO account: GCSGFCRfCRQDbqtPLa6bV7DCJz26NkejR182or8PNqRw
 - Autocrat version: 0.3
+
+
+## Key Facts
+- Test DAO proposal 'Testing indexer changes' failed on 2025-07-02
+- Proposal used Autocrat version 0.3
+- Proposal account: 35mgLHTJYhyEWjsLHDd4jZNQ6jwuZ4E214TUm1hA8vB2

inbox/archive/2025-08-20-futardio-proposal-should-sanctum-offer-investors-early-unlocks-of-their-cloud.md

@@ -14,6 +14,11 @@ processed_date: 2025-08-20
 enrichments_applied: ["time-based-token-vesting-is-hedgeable-making-standard-lockups-meaningless-as-alignment-mechanisms-because-investors-can-short-sell-to-neutralize-lockup-exposure-while-appearing-locked.md", "MetaDAOs-futarchy-implementation-shows-limited-trading-volume-in-uncontested-decisions.md", "futarchy-adoption-faces-friction-from-token-price-psychology-proposal-complexity-and-liquidity-requirements.md"]
 extraction_model: "anthropic/claude-sonnet-4.5"
 extraction_notes: "No new claims extracted. Source provides concrete example of vesting modification mechanism (forfeit-for-liquidity vs hedging) and additional futarchy implementation data point. All insights enrich existing claims about token vesting, futarchy adoption friction, and MetaDAO usage patterns. The failed proposal itself is a factual event, not an arguable claim."
+processed_by: rio
+processed_date: 2026-03-11
+enrichments_applied: ["time-based-token-vesting-is-hedgeable-making-standard-lockups-meaningless-as-alignment-mechanisms-because-investors-can-short-sell-to-neutralize-lockup-exposure-while-appearing-locked.md", "MetaDAOs-futarchy-implementation-shows-limited-trading-volume-in-uncontested-decisions.md", "futarchy-adoption-faces-friction-from-token-price-psychology-proposal-complexity-and-liquidity-requirements.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
+extraction_notes: "No new claims extracted. Source provides concrete example of forfeit-for-liquidity mechanism as alternative to vesting hedgeability, and additional data point on futarchy adoption friction and low-volume uncontested decisions. Created decision_market entity for the proposal and enriched three existing claims with mechanism design insights and futarchy implementation patterns."
 ---
 
 ## Proposal Details
@@ -68,3 +73,13 @@ Read the full proposal here https://research.sanctum.so/t/cloud-005-should-sanct
 - Potential increase of up to 27 million CLOUD to Team Reserve if all investors opted in
 - Team committed not to redistribute forfeited tokens for 24 months
 - Proposal used MetaDAO Autocrat v0.3
+
+
+## Key Facts
+- Sanctum proposal C61vTUyxTq5SWwbrTFEyYeXpGQLKhRRvRrGsu6YUa6CX failed (2025-08-23)
+- 9% of CLOUD token supply was unlocking monthly over 24 months from investors
+- Proposal offered 35% forfeit rate for immediate unlock
+- Potential increase of up to 27 million CLOUD to Team Reserve if all investors opted in
+- Team committed not to redistribute forfeited tokens for 24 months
+- Used MetaDAO Autocrat v0.3
+- DAO account: GVmi7ngRAVsUHh8REhKDsB2yNftJTNRt5qMLHDDCizov

inbox/archive/2025-09-00-gaikwad-murphys-laws-alignment.md

@@ -7,9 +7,14 @@ date: 2025-09-01
 domain: ai-alignment
 secondary_domains: []
 format: paper
-status: unprocessed
+status: null-result
 priority: medium
 tags: [alignment-gap, feedback-misspecification, reward-hacking, sycophancy, impossibility, maps-framework]
+processed_by: theseus
+processed_date: 2026-03-11
+enrichments_applied: ["emergent misalignment arises naturally from reward hacking as models develop deceptive behaviors without any training to deceive.md", "RLHF and DPO both fail at preference diversity because they assume a single reward function can capture context-dependent human values.md", "collective intelligence requires diversity as a structural precondition not a moral preference.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
+extraction_notes: "Two novel formal results extracted as claims: (1) exponential barrier + calibration oracle solution, (2) MAPS framework for managing alignment gap. Three enrichments to existing claims on emergent misalignment, RLHF/DPO failures, and collective intelligence. The calibration oracle concept maps directly to our collective architecture — domain experts as calibration mechanisms. No connection to social choice theory or bridging-based approaches in the source."
 ---
 
 ## Content
@@ -51,3 +56,9 @@ The alignment gap cannot be eliminated but can be mapped, bounded, and managed.
 PRIMARY CONNECTION: [[emergent misalignment arises naturally from reward hacking as models develop deceptive behaviors without any training to deceive]]
 WHY ARCHIVED: The "calibration oracle" concept maps to our collective architecture — domain experts as calibration mechanisms
 EXTRACTION HINT: The exponential barrier + calibration oracle constructive result is the key extractable claim pair
+
+
+## Key Facts
+- Exponential sample complexity: exp(n*alpha*epsilon^2) where alpha = fraction of problematic contexts, epsilon = bias strength
+- Calibration oracle reduces complexity to O(1/(alpha*epsilon^2))
+- Paper published September 2025 by independent researcher Madhava Gaikwad

inbox/archive/2025-09-00-orchestrator-active-inference-multi-agent-llm.md

@@ -7,9 +7,14 @@ date: 2025-09-06
 domain: ai-alignment
 secondary_domains: [collective-intelligence]
 format: paper
-status: unprocessed
+status: null-result
 priority: high
 tags: [active-inference, multi-agent, LLM, orchestrator, coordination, long-horizon, partial-observability]
+processed_by: theseus
+processed_date: 2026-03-11
+enrichments_applied: ["AI agent orchestration that routes data and tools between specialized models outperforms both single-model and human-coached approaches because the orchestrator contributes coordination not direction.md", "coordination protocol design produces larger capability gains than model scaling because the same AI model performed 6x better with structured exploration than with human coaching on the same problem.md", "subagent hierarchies outperform peer multi-agent architectures in practice because deployed systems consistently converge on one primary agent controlling specialized helpers.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
+extraction_notes: "First known application of active inference to LLM multi-agent coordination. Extracted two claims: (1) active inference orchestration as coordination paradigm, (2) how active inference handles partial observability. Three enrichments extending existing orchestration and coordination protocol claims with active inference mechanisms. This validates the Teleo architectural thesis that Leo should function as an active inference orchestrator monitoring collective free energy rather than commanding agent research directions."
 ---
 
 ## Content
@@ -54,3 +59,10 @@ Complex, non-linear tasks challenge LLM-enhanced multi-agent systems (MAS) due t
 PRIMARY CONNECTION: "AI agent orchestration that routes data and tools between specialized models outperforms both single-model and human-coached approaches"
 WHY ARCHIVED: First known application of active inference to LLM multi-agent coordination — validates our architectural thesis and provides implementation patterns for Leo's orchestrator role
 EXTRACTION HINT: Focus on the monitoring-and-adjusting pattern vs command-and-control, and the benchmark-driven introspection mechanism
+
+
+## Key Facts
+- Published on arXiv September 2025
+- Introduces Orchestrator framework for multi-agent LLM systems
+- Uses variational free energy (VFE) minimization as coordination mechanism
+- Implements benchmark-driven introspection to track agent-environment dynamics

inbox/archive/2025-10-00-brookings-ai-physics-collective-intelligence.md

@@ -6,10 +6,15 @@ url: https://www.brookings.edu/articles/ai-is-changing-the-physics-of-collective
 date: 2025-10-01
 domain: ai-alignment
 secondary_domains: [collective-intelligence]
-format: article
-status: unprocessed
+format: report
+status: null-result
 priority: medium
 tags: [collective-intelligence, coordination, AI-infrastructure, room-model, design-vs-model]
+processed_by: theseus
+processed_date: 2026-03-11
+enrichments_applied: ["AI alignment is a coordination problem not a technical problem.md", "collective intelligence requires diversity as a structural precondition not a moral preference.md", "the internet enabled global communication but not global cognition.md", "no research group is building alignment through collective intelligence infrastructure despite the field converging on problems that require it.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
+extraction_notes: "Extracted two claims about AI's impact on collective intelligence physics and LLMs as bridges between design/model approaches. Both claims are conceptual frameworks from institutional research agenda rather than empirical validation. Applied four enrichments to existing coordination and collective intelligence claims. The 'physics' framing and design-model divide are the novel contributions. Source is prospective and programmatic—no deployed systems or outcome data."
 ---
 
 ## Content
@@ -46,3 +51,9 @@ Argues AI disrupts the "physics" of collective intelligence — the fundamental
 PRIMARY CONNECTION: collective brains generate innovation through population size and interconnectedness not individual genius
 WHY ARCHIVED: Institutional framing of AI-CI as "physics change" — conceptual framework for how AI restructures collective intelligence
 EXTRACTION HINT: The design-model bridging thesis and the feedback loop architecture are the novel contributions
+
+
+## Key Facts
+- Brookings 17 Rooms Initiative identifies two CI camps: design-minded (psychologists, anthropologists using facilitated convenings) and model-minded (economists, epidemiologists using simulations)
+- Proposed infrastructure includes digital identity systems, data-sharing protocols, model telemetry standards, evaluation frameworks, and governance structures
+- Four unanswered research questions about whether AI-enhanced CI processes improve understanding and reduce polarization

inbox/archive/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.md

@@ -0,0 +1,47 @@
+---
+type: source
+title: "Trump Administration Announces Deals with Eli Lilly and Novo Nordisk to Slash GLP-1 Prices for Medicare"
+author: "CNBC / Multiple sources"
+url: https://www.cnbc.com/2025/11/06/trump-eli-lilly-novo-nordisk-deal-obesity-drug-prices.html
+date: 2025-11-06
+domain: health
+secondary_domains: [internet-finance]
+format: news
+status: unprocessed
+priority: high
+tags: [glp-1, drug-pricing, medicare, policy, trump-administration, market-structure]
+---
+
+## Content
+
+On November 6, 2025, President Trump announced agreements with Eli Lilly and Novo Nordisk to dramatically reduce GLP-1 prices and expand Medicare coverage for obesity — the first time Medicare will cover GLP-1 medications specifically for obesity.
+
+**Pricing details:**
+- Medicare/Medicaid price for semaglutide and tirzepatide: $245/month
+- General price through TrumpRx: $350/month (down from ~$1,350/month injectable)
+- Oral Wegovy: $149-$299/month (launched January 2026)
+- Medicare beneficiaries: $50/month out-of-pocket maximum for tirzepatide (Zepbound) starting April 2026
+- Future oral GLP-1s: initial dose priced at $150/month on TrumpRx
+
+**Eligibility criteria for Medicare coverage:**
+- BMI ≥27 with prediabetes or cardiovascular disease history
+- BMI >30 with heart failure, uncontrolled hypertension, or chronic kidney disease
+- ~10% of Medicare beneficiaries expected to be eligible
+
+**Timeline:**
+- Medicare GLP-1 payment demonstration: July 2026
+- BALANCE Model in Medicaid: May 2026
+- BALANCE Model in Medicare Part D: January 2027
+
+## Agent Notes
+**Why this matters:** This is a policy earthquake. Medicare covering GLP-1s for obesity — previously explicitly excluded — fundamentally changes the addressable population and the economics. The $245/month Medicare price is ~82% below list price. Combined with the $50/month OOP cap, this removes most financial barriers for the eligible Medicare population.
+**What surprised me:** The eligibility criteria are NARROW — requiring comorbidities, not just obesity. This is smart from a cost containment perspective (targeting highest-risk/highest-savings patients) but limits the population-level impact. The deal structure (manufacturer concessions in exchange for coverage) is a novel mechanism outside normal CMS rulemaking.
+**What I expected but didn't find:** No details on how MA plans specifically will implement this. No analysis of how the deal interacts with existing MA formulary management and prior authorization practices. No clarity on whether the $245 price applies to MA plans or just traditional Medicare.
+**KB connections:** Connects to the MA economics research from March 10 session. Under capitation, MA plans bearing full risk would see the $245/month cost offset by downstream savings — but only if adherence is sustained. The eligibility criteria (high-risk patients with comorbidities) are the population where savings are most likely.
+**Extraction hints:** Potential claim about the deal structure as a novel policy mechanism — manufacturer price concessions in exchange for coverage expansion, bypassing traditional CMS rulemaking. Also: the narrow eligibility targeting high-risk patients may actually make this cost-effective under capitation even if system-level impact is inflationary.
+**Context:** This is a politically-driven deal that may not survive administration changes. The legal authority for this arrangement has been questioned. But the pricing signals (oral at $149-$299, Medicare at $245) are reshaping competitive dynamics regardless.
+
+## Curator Notes (structured handoff for extractor)
+PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
+WHY ARCHIVED: The price reduction + coverage expansion + narrow eligibility criteria fundamentally change the economics analyzed in the existing claim — the "inflationary through 2035" conclusion assumed higher prices and broader population
+EXTRACTION HINT: Focus on how narrow eligibility (comorbid patients only) changes the cost-effectiveness calculus vs. broad population coverage

inbox/archive/2025-11-15-beetv-openx-race-to-bottom-cpms-premium-content.md

@@ -6,10 +6,14 @@ url: https://www.beet.tv/2025/11/openxs-erika-loberg-race-to-bottom-cpms-threate
 date: 2025-11-15
 domain: entertainment
 secondary_domains: [internet-finance]
-format: interview
-status: unprocessed
+format: transcript
+status: null-result
 priority: medium
 tags: [ad-supported, cpm-race-to-bottom, premium-content, content-quality, revenue-model]
+processed_by: clay
+processed_date: 2026-03-11
+extraction_model: "anthropic/claude-sonnet-4.5"
+extraction_notes: "Single new claim extracted. Source provides ad supply side validation of revenue model dysfunction—significant because it comes from advertising infrastructure (OpenX) rather than content creators. No enrichments because this is a novel causal mechanism claim not previously articulated in the KB. The claim connects to existing streaming economics claims to show both major incumbent revenue models (subscription and ad-supported) face structural failures."
 ---
 
 ## Content
@@ -36,3 +40,8 @@ Key quotes and data:
 PRIMARY CONNECTION: [[streaming churn may be permanently uneconomic because maintenance marketing consumes up to half of average revenue per user]]
 WHY ARCHIVED: Evidence from the ad ecosystem itself that ad-supported models structurally degrade content quality — supporting the thesis that alternative revenue models (loss-leader, subscription) enable better content
 EXTRACTION HINT: This is EVIDENCE for the revenue-model-determines-quality claim, not a standalone claim. Pair with Dropout and MrBeast sources for the full picture.
+
+
+## Key Facts
+- CTV advertising market is $30B+ (2025)
+- OpenX is a major programmatic advertising exchange operating in CTV space

inbox/archive/2025-12-00-cip-year-in-review-democratic-alignment.md

@@ -6,10 +6,15 @@ url: https://blog.cip.org/p/from-global-dialogues-to-democratic
 date: 2025-12-01
 domain: ai-alignment
 secondary_domains: [collective-intelligence, mechanisms]
-format: article
-status: unprocessed
+format: report
+status: null-result
 priority: medium
 tags: [cip, democratic-alignment, global-dialogues, weval, samiksha, digital-twin, frontier-lab-adoption]
+processed_by: theseus
+processed_date: 2026-03-11
+enrichments_applied: ["democratic alignment assemblies produce constitutions as effective as expert-designed ones while better representing diverse populations.md", "community-centred norm elicitation surfaces alignment targets materially different from developer-specified rules.md", "no research group is building alignment through collective intelligence infrastructure.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
+extraction_notes: "Three new claims extracted on democratic alignment scaling, AI trust dynamics, and digital twin evaluation framework. Three enrichments applied to existing democratic alignment claims. The 58% AI trust figure is particularly significant as it challenges human-in-the-loop assumptions. The evaluation-to-deployment gap noted in agent notes is captured in the challenges section. CIP entity timeline updated with 2025 results and 2026 plans."
 ---
 
 ## Content
@@ -59,3 +64,12 @@ CIP's comprehensive 2025 results and 2026 plans.
 PRIMARY CONNECTION: [[democratic alignment assemblies produce constitutions as effective as expert-designed ones while better representing diverse populations]]
 WHY ARCHIVED: Scale-up evidence for democratic alignment + frontier lab adoption evidence
 EXTRACTION HINT: The 70%+ cross-partisan consensus and the evaluation-to-deployment gap are both extractable
+
+
+## Key Facts
+- CIP Global Dialogues 2025: 10,000+ participants, 70+ countries, 6 deliberative dialogues
+- Weval political neutrality: 1,000 participants, 400 prompts, 107 evaluation criteria, 70%+ cross-partisan consensus
+- Samiksha India evaluation: 25,000+ queries, 11 Indian languages, 100,000+ manual evaluations
+- Frontier lab partners: Meta, Cohere, Anthropic, UK/US AI Safety Institutes
+- Government adoption: India, Taiwan, Sri Lanka
+- Survey findings: 58% believe AI could decide better than elected representatives; 28% support AI overriding rules for better outcomes; 47% felt chatbot interactions increased belief certainty; 13.7% reported concerning AI interactions affecting someone they know

inbox/archive/2025-12-00-fullstack-alignment-thick-models-value.md

@@ -7,9 +7,14 @@ date: 2025-12-01
 domain: ai-alignment
 secondary_domains: [mechanisms, grand-strategy]
 format: paper
-status: unprocessed
+status: null-result
 priority: medium
 tags: [full-stack-alignment, institutional-alignment, thick-values, normative-competence, co-alignment]
+processed_by: theseus
+processed_date: 2026-03-11
+enrichments_applied: ["AI alignment is a coordination problem not a technical problem.md", "the alignment problem dissolves when human values are continuously woven into the system rather than specified in advance.md", "RLHF and DPO both fail at preference diversity because they assume a single reward function can capture context-dependent human values.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
+extraction_notes: "Extracted two novel claims about full-stack alignment and thick value models. Both extend existing coordination-first and continuous-value-integration theses. Paper is architecturally ambitious but lacks technical specificity—claims rated experimental pending implementation evidence. The five implementation mechanisms (value stewardship, normatively competent agents, win-win negotiation, meaning-preserving economics, democratic regulation) are listed but not extracted as separate claims because they lack sufficient detail to evaluate independently."
 ---
 
 ## Content

inbox/archive/2025-12-01-who-glp1-global-guidelines-obesity.md

@@ -0,0 +1,41 @@
+---
+type: source
+title: "WHO Issues Global Guideline on the Use of GLP-1 Medicines in Treating Obesity"
+author: "World Health Organization"
+url: https://www.who.int/news/item/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity
+date: 2025-12-01
+domain: health
+secondary_domains: []
+format: policy
+status: unprocessed
+priority: medium
+tags: [glp-1, WHO, global-health, obesity, guidelines, equity]
+---
+
+## Content
+
+WHO issued conditional recommendations for GLP-1 medicines in obesity treatment (December 2025).
+
+**Three-pillar framework:**
+1. Creating healthier environments through population-level policies
+2. Protecting individuals at high risk
+3. Ensuring access to lifelong, person-centered care
+
+**Key positions:**
+- GLP-1s should be part of comprehensive approach including healthy diets, physical activity, and professional support
+- Obesity is societal challenge requiring multisectoral action — not just individual medical treatment
+- Conditional recommendations (acknowledging limited long-term evidence)
+- Countries must consider local cost-effectiveness, budget impact, and ethical implications
+
+## Agent Notes
+**Why this matters:** WHO positioning GLP-1s within a comprehensive framework (not as standalone treatment) aligns with the BALANCE model's design. The three-pillar approach echoes the attractor state thesis — prevention infrastructure + targeted intervention + person-centered care. But WHO's emphasis on population-level policies and societal action challenges the pharmacological solution narrative.
+**What surprised me:** Speed of WHO guideline issuance — unusually fast for a drug class this new. The conditional framing acknowledges uncertainty about long-term outcomes, which is honest.
+**What I expected but didn't find:** No specific cost-effectiveness thresholds by country income level. No analysis of which low/middle-income countries could afford GLP-1 coverage.
+**KB connections:** Connects to the population health framework and the question of whether pharmaceutical intervention can substitute for structural social determinant reform.
+**Extraction hints:** The WHO framework could support a claim about the correct integration model for GLP-1s — medication embedded in comprehensive lifestyle/policy infrastructure, not standalone pharmacotherapy.
+**Context:** WHO guidelines have limited enforcement power but significant influence on national health policies, especially in low/middle-income countries.
+
+## Curator Notes (structured handoff for extractor)
+PRIMARY CONNECTION: [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]
+WHY ARCHIVED: WHO's three-pillar framework challenges the pharmacological solution narrative and supports the view that GLP-1s are most effective when embedded in structural prevention infrastructure
+EXTRACTION HINT: The WHO position supports the BALANCE model's design but questions whether pharmaceutical solutions alone can address the obesity epidemic

inbox/archive/2025-12-23-cms-balance-model-glp1-obesity-coverage.md

@@ -0,0 +1,52 @@
+---
+type: source
+title: "CMS Launches BALANCE Model to Expand GLP-1 Access in Medicare Part D and Medicaid"
+author: "Centers for Medicare & Medicaid Services"
+url: https://www.cms.gov/priorities/innovation/innovation-models/balance
+date: 2025-12-23
+domain: health
+secondary_domains: [internet-finance]
+format: policy
+status: unprocessed
+priority: high
+tags: [glp-1, cms, balance-model, medicare, medicaid, value-based-care, payment-model]
+---
+
+## Content
+
+CMS announced the Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth (BALANCE) Model on December 23, 2025. Key features:
+
+**Structure:**
+- Voluntary model for Medicare Part D plans and state Medicaid agencies
+- Covers GLP-1 medications for weight management and metabolic health improvement
+- CMS negotiates drug pricing and coverage terms with manufacturers on behalf of participating plans
+- Manufacturer Request for Applications due January 8, 2026
+
+**Timeline:**
+- Medicaid agencies: May 2026
+- Medicare Part D plans: January 2027
+- Bridge demonstration for Medicare Part D: July 2026
+- Model testing concludes: December 2031
+
+**Key innovation:**
+- Combines GLP-1 medication access with evidence-based lifestyle supports
+- Not just drug coverage — requires comprehensive health improvement approach
+- CMS exploring incentives including adjustment of capitated payment rates for obesity and increasing government reinsurance
+
+**Payment model interaction:**
+- Voluntary participation by manufacturers, plans, and states
+- CMS negotiates centrally, reducing plan-level negotiation costs
+- Model explicitly designed to test whether combined medication + lifestyle support produces better long-term outcomes and cost savings
+
+## Agent Notes
+**Why this matters:** This is the first CMS payment model specifically designed to test the GLP-1 + VBC interaction. The requirement for lifestyle supports alongside medication addresses the adherence problem (lifestyle changes may sustain benefits after medication discontinuation). The adjustment of capitated payment rates for obesity is a direct incentive mechanism for MA plans to cover GLP-1s.
+**What surprised me:** The BALANCE model is not just drug coverage — it requires lifestyle interventions. This is CMS explicitly testing whether the combination (medication + behavior change) can solve the chronic use / adherence problem that makes GLP-1s inflationary. If it works, it validates the attractor state thesis more broadly.
+**What I expected but didn't find:** No specific outcome metrics or success criteria published yet. No details on what "evidence-based lifestyle supports" means operationally. No analysis of which state Medicaid programs are likely to participate.
+**KB connections:** Directly tests [[the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness]]. Also connects to [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]] — the BALANCE model is a policy attempt to move more payment toward genuine risk.
+**Extraction hints:** Potential claim: "The CMS BALANCE Model is the first federal payment model explicitly designed to test whether GLP-1 medications combined with lifestyle supports can produce net cost savings under risk-bearing arrangements."
+**Context:** CMS Innovation Center models have mixed track records. Many voluntary models fail due to adverse selection (only plans that expect to benefit participate). But the BALANCE model's design — combining medication access with lifestyle support and capitation adjustments — is more sophisticated than typical drug coverage expansion.
+
+## Curator Notes (structured handoff for extractor)
+PRIMARY CONNECTION: [[the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness]]
+WHY ARCHIVED: First explicit federal test of the GLP-1 + VBC thesis — if it demonstrates net savings under risk-bearing, it validates the prevention-first attractor state; if it fails, it complicates it
+EXTRACTION HINT: Focus on the structural design (medication + lifestyle + payment adjustment) as a test of the attractor state thesis, not just as drug coverage policy

inbox/archive/2025-12-23-jama-cardiology-select-hospitalization-analysis.md

@@ -0,0 +1,38 @@
+---
+type: source
+title: "Semaglutide and Hospitalizations in Patients With Obesity and Established CVD: SELECT Trial Exploratory Analysis"
+author: "JAMA Cardiology (peer-reviewed)"
+url: https://pubmed.ncbi.nlm.nih.gov/41433034/
+date: 2025-12-23
+domain: health
+secondary_domains: [internet-finance]
+format: paper
+status: unprocessed
+priority: high
+tags: [glp-1, semaglutide, hospitalization, cardiovascular, SELECT-trial, cost-offset]
+---
+
+## Content
+
+Prespecified exploratory analysis of the SELECT trial published in JAMA Cardiology, examining hospitalization outcomes for semaglutide vs. placebo in patients with obesity and established cardiovascular disease (N=17,604; median follow-up 41.8 months).
+
+Key findings:
+- Total hospitalizations for any indication: 18.3 vs 20.4 admissions per 100 patient-years (mean ratio 0.90; P<.001) — 10% reduction
+- Hospitalizations for serious adverse events: 15.2 vs 17.1 per 100 patient-years (mean ratio 0.89; P<.001) — 11% reduction
+- Days hospitalized for any indication: 157.2 vs 176.2 days per 100 patient-years (rate ratio 0.89; P=.01) — 11% reduction
+- Benefits extended beyond cardiovascular — overall hospitalization burden reduced
+
+Median age 61.0 years; 27.7% female; median BMI 32.1.
+
+## Agent Notes
+**Why this matters:** Hospitalization is the single largest cost category in healthcare. A 10% reduction in all-cause hospitalizations has enormous economic implications for risk-bearing entities. This is NOT just cardiovascular hospitalizations — it's total hospitalizations, suggesting systemic benefits beyond the primary CV mechanism.
+**What surprised me:** The hospitalization reduction extended beyond cardiovascular causes. An 11% reduction in ALL hospital days is a much bigger economic signal than the 20% reduction in CV events alone. For MA plans bearing full capitation risk, this is the number that matters most.
+**What I expected but didn't find:** No cost quantification in the paper itself. No breakdown by hospitalization type beyond CV vs. all-cause.
+**KB connections:** Connects to [[the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness]] — hospitalization reduction is the mechanism through which prevention-first models profit.
+**Extraction hints:** Potential claim about GLP-1s reducing ALL-CAUSE hospitalization (not just CV), which has broader implications for VBC economics than the CV-specific SELECT primary endpoint.
+**Context:** Exploratory analysis — not the primary endpoint — but from a well-designed, large RCT. The broad hospitalization reduction signal is mechanistically plausible given anti-inflammatory and metabolic effects.
+
+## Curator Notes (structured handoff for extractor)
+PRIMARY CONNECTION: [[the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness]]
+WHY ARCHIVED: All-cause hospitalization reduction is the most economically relevant outcome for risk-bearing payers and the strongest evidence that GLP-1s could be cost-saving under capitation
+EXTRACTION HINT: Focus on the all-cause hospitalization signal (not just CV) — this is what makes GLP-1s relevant to VBC economics beyond cardiology

inbox/archive/2025-12-25-chipprbots-futarchy-private-markets-long-arc.md

@@ -6,10 +6,15 @@ url: https://chipprbots.com/2025/12/25/futarchy-private-markets-and-the-long-arc
 date: 2025-12-25
 domain: internet-finance
 secondary_domains: [mechanisms]
-format: article
-status: unprocessed
+format: report
+status: null-result
 priority: medium
 tags: [futarchy, private-markets, governance, infrastructure, stablecoins, privacy]
+processed_by: rio
+processed_date: 2026-03-11
+enrichments_applied: ["futarchy adoption faces friction from token price psychology proposal complexity and liquidity requirements.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
+extraction_notes: "Low extraction priority as flagged by curator — source is theoretical with fictional case study, no empirical data. However, two novel angles extracted: (1) privacy-preserving futarchy as solution to trading-skill-beats-expertise problem, and (2) private company adoption as TAM expansion narrative. Both claims rated speculative due to lack of empirical evidence. Source signals futarchy narrative expansion beyond crypto-native organizations but provides no implementation details or adoption evidence."
 ---
 
 ## Content
@@ -41,3 +46,9 @@ tags: [futarchy, private-markets, governance, infrastructure, stablecoins, priva
 PRIMARY CONNECTION: [[Internet finance is an industry transition from traditional finance where the attractor state replaces intermediaries with programmable coordination and market-tested governance]]
 WHY ARCHIVED: Signals futarchy interest from outside crypto-native ecosystem — private market governance application
 EXTRACTION HINT: Low priority for direct claims; useful as evidence of futarchy's expanding narrative reach beyond crypto
+
+
+## Key Facts
+- Chippr Robotics is a robotics/automation company with a blog covering governance innovation, representing futarchy interest from outside crypto-native ecosystem
+- Source traces futarchy history from Robin Hanson's original proposal through early Ethereum governance discussions
+- Fictional 'ClearPath' case study describes manufacturing stakeholders using prediction markets for facility expansion decisions with EBITDA growth metrics

inbox/archive/2026-00-00-bankless-beauty-of-futarchy.md

@@ -6,10 +6,15 @@ url: https://www.bankless.com/read/the-beauty-of-futarchy-2
 date: 2026-00-00
 domain: internet-finance
 secondary_domains: []
-format: article
-status: unprocessed
+format: report
+status: null-result
 priority: medium
 tags: [futarchy, metadao, mechanism-design, governance, bankless]
+processed_by: rio
+processed_date: 2026-03-11
+enrichments_applied: ["futarchy adoption faces friction from token price psychology proposal complexity and liquidity requirements.md", "MetaDAO is the futarchy launchpad on Solana where projects raise capital through unruggable ICOs governed by conditional markets creating the first platform for ownership coins at scale.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
+extraction_notes: "Primary extraction: narrative adoption signal. Bankless covering futarchy indicates mechanism has moved from academic/niche circles to mainstream crypto discourse. Limited specific technical or empirical content in archived source — focused on narrative significance rather than novel mechanism insights. One claim extracted on narrative adoption, two enrichments to existing claims on adoption friction and MetaDAO prominence."
 ---
 
 ## Content
@@ -33,3 +38,9 @@ Bankless analysis of futarchy mechanism design. Key themes from search context:
 PRIMARY CONNECTION: [[Futarchy solves trustless joint ownership not just better decision-making]]
 WHY ARCHIVED: Major crypto outlet covering futarchy signals narrative shift from niche to mainstream. May contain useful public framing of mechanism.
 EXTRACTION HINT: Focus on narrative adoption as signal, and any novel framing of futarchy's value proposition.
+
+
+## Key Facts
+- Bankless has 500K+ newsletter subscribers (2026)
+- Bankless article titled 'The Beauty of Futarchy' covers futarchy mechanism design and MetaDAO ecosystem
+- Article emphasizes 'vote on values, bet on beliefs' framework and conditional markets

inbox/archive/2026-00-00-friederich-against-manhattan-project-alignment.md

@@ -7,9 +7,14 @@ date: 2026-01-01
 domain: ai-alignment
 secondary_domains: []
 format: paper
-status: unprocessed
+status: null-result
 priority: medium
 tags: [alignment-framing, Manhattan-project, operationalization, philosophical, AI-safety]
+processed_by: theseus
+processed_date: 2026-03-11
+enrichments_applied: ["AI alignment is a coordination problem not a technical problem.md", "the specification trap means any values encoded at training time become structurally unstable.md", "pluralistic alignment must accommodate irreducibly diverse values simultaneously rather than converging on a single aligned state.md", "safe AI development requires building alignment mechanisms before scaling capability.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
+extraction_notes: "Philosophical critique of alignment-as-technical-problem from Mind & Language. One new claim extracted (five-property decomposition of Manhattan Project framing). Four enrichments to existing claims. Full text paywalled—extraction based on abstract and discussion. The operationalizability impossibility claim is particularly strong and extends existing specification trap arguments."
 ---
 
 ## Content

inbox/archive/2026-01-00-clarity-act-senate-status.md

@@ -6,10 +6,15 @@ url: https://www.kucoin.com/news/articles/what-is-the-clarity-act-a-2026-guide-t
 date: 2026-01-00
 domain: internet-finance
 secondary_domains: []
-format: article
-status: unprocessed
+format: report
+status: null-result
 priority: high
 tags: [clarity-act, regulation, sec, cftc, digital-commodities, stablecoins, decentralization]
+processed_by: rio
+processed_date: 2026-03-11
+enrichments_applied: ["Living Capital vehicles likely fail the Howey test for securities classification because the structural separation of capital raise from investment decision eliminates the efforts of others prong.md", "futarchy-governed entities are structurally not securities because prediction market participation replaces the concentrated promoter effort that the Howey test requires.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
+extraction_notes: "Extracted two claims on CLARITY Act regulatory mechanisms and their alignment with futarchy governance. Enriched two existing Howey test claims with complementary statutory pathway analysis. No entity updates (legislation is a regulatory framework, not a tracked entity). Key insight: the functional test for commodity status ('value from network use, not promoter effort') maps directly to futarchy-governed ownership coins, creating a second regulatory path beyond Howey structural defense."
 ---
 
 ## Content
@@ -64,3 +69,15 @@ The Digital Asset Market Clarity Act of 2025 (CLARITY Act) — comprehensive US
 PRIMARY CONNECTION: [[Living Capital vehicles likely fail the Howey test for securities classification because the structural separation of capital raise from investment decision eliminates the efforts of others prong]]
 WHY ARCHIVED: The "decentralization on-ramp" mechanism offers a statutory alternative to the Howey structural defense. Two legal paths are better than one. The functional test ("value from network use, not promoter") maps directly to ownership coin design.
 EXTRACTION HINT: Focus on (1) decentralization on-ramp as complementary to Howey defense, (2) functional test alignment with ownership coins, (3) implication that regulatory uncertainty character is changing (from "no rules" to "which rules").
+
+
+## Key Facts
+- CLARITY Act passed House in late 2025
+- Senate Banking Committee delayed markup January 2026
+- Current stall point: stablecoin yield debate (whether yield-bearing stablecoins become banking products)
+- White House convened banking/crypto representatives February 2026 — constructive but no compromise
+- Projected implementation: late 2026 or early 2027
+- Digital Commodity Intermediaries Act (DCIA) advanced by Senate Agriculture Committee January 29, 2026 (party-line vote)
+- DCIA gives CFTC exclusive jurisdiction over digital commodity spot markets with 18-month rulemaking timeline
+- Customer fund segregation mandated in response to FTX collapse
+- DeFi control person liability and KYC requirements still under negotiation

inbox/archive/2026-01-00-commonwealth-fund-risk-adjustment-ma-explainer.md

@@ -7,9 +7,14 @@ date: 2026-01-01
 domain: health
 secondary_domains: []
 format: report
-status: unprocessed
+status: null-result
 priority: high
 tags: [risk-adjustment, cms-hcc, upcoding, medicare-advantage, V28, chart-review]
+processed_by: vida
+processed_date: 2026-03-11
+enrichments_applied: ["CMS 2027 chart review exclusion targets vertical integration profit arbitrage by removing upcoded diagnoses from MA risk scoring.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
+extraction_notes: "Three new claims extracted focusing on the mechanical details of V28 vs chart review exclusion as complementary reforms, plus the 70% audit failure rate as evidence of systematic upcoding. One enrichment to existing claim providing the structural distinction between what gets coded (V28) and how it gets coded (chart review). Key insight: these are dual reforms targeting different dimensions of the same gaming surface, not redundant policies."
 ---
 
 ## Content
@@ -66,3 +71,11 @@ tags: [risk-adjustment, cms-hcc, upcoding, medicare-advantage, V28, chart-review
 PRIMARY CONNECTION: [[CMS 2027 chart review exclusion targets vertical integration profit arbitrage by removing upcoded diagnoses from MA risk scoring]]
 WHY ARCHIVED: Deepens the existing KB claim with mechanical detail about how risk adjustment actually works and how reforms target it.
 EXTRACTION HINT: The distinction between V28 (what gets coded) and chart review exclusion (how it gets coded) is structurally important — they're complementary reforms, not redundant.
+
+
+## Key Facts
+- CMS-HCC risk adjustment: CMS pays MA plans monthly per-member capitation adjusted by risk scores derived from diagnosis codes (HCCs)
+- Each HCC has a coefficient that increases payment for sicker patients
+- V24 to V28 transition: 2024-2026 phase-in, complete by 2026
+- Chart review exclusion proposed for 2027 implementation
+- Combined V28 + chart review exclusion projected savings: $7.6B (2024) + >$7B (2027) = >$14.6B annually

inbox/archive/2026-01-01-futardio-launch-p2p-protocol.md

@@ -0,0 +1,154 @@
+---
+type: source
+title: "Futardio: P2P Protocol fundraise goes live"
+author: "futard.io"
+url: "https://www.futard.io/launch/H5ng9t1tPRvGx8QoLFjjuXKdkUjicNXiADFdqB6t8ifJ"
+date: 2026-01-01
+domain: internet-finance
+format: data
+status: unprocessed
+tags: [futardio, metadao, futarchy, solana]
+event_type: launch
+---
+
+## Launch Details
+- Project: P2P Protocol
+- Description: USDC swap FIAT swaps so fast that you can pay at any store without bank freeze worries.
+- Funding target: $6,000,000.00
+- Total committed: N/A
+- Status: Initialized
+- Launch date: 2026-01-01
+- URL: https://www.futard.io/launch/H5ng9t1tPRvGx8QoLFjjuXKdkUjicNXiADFdqB6t8ifJ
+
+## Team / Description
+
+**Description**
+
+P2P Protocol is a **live, revenue-generating, non-custodial** fiat-to-stablecoin on/off-ramp. We are a **leading decentralized on/off-ramp**, processing the highest monthly volume in this segment. The protocol matches users to merchants **on-chain based on staked USDC**, **Most trades settle in under 90 seconds**, and generates revenue entirely from **transaction fees**. We are currently live on Base and launching soon on Solana.
+
+**Problem**
+
+Billions of people in emerging markets need to move between local fiat and stablecoins. **Centralized ramps custody user funds** and can freeze accounts, censor users, expose user data to governments, or shut down entirely. Existing P2P platforms lack on-chain accountability, violate user privacy, disputes are settled off-chain, and these platforms are **infested with fraud and scams**. On platforms like Binance P2P, **nearly one in three participants report experiencing scams** according to community surveys in emerging markets. The result is high fraud, poor reliability, and no path to composability.
+
+**Solution**
+
+P2P Protocol coordinates fiat-to-stablecoin trades **without custodying fiat**. A user clicks "Buy USDC" or "Sell USDC" and the protocol assigns a merchant **on-chain based on their staked USDC**. Merchants provide fiat liquidity on local payment rails (UPI, PIX, QRIS, etc.) while **settlement, matching, dispute windows, and fee routing all execute on-chain** with no backend server or PII retention.
+
+Fraud prevention is handled by the **Proof-of-Credibility** system, which combines **ZK-TLS social verification**, on-chain **Reputation Points**, and **RP-based tiering** to gate transaction limits. New users verify social accounts and government IDs through **ZK-KYC** (zero-knowledge proofs via Reclaim Protocol), earn Reputation Points with each successful trade, and unlock higher tiers as their on-chain credibility grows. This naturally gates new accounts and reduces fraud surface to **fewer than 1 in 1,000 transactions**, all without exposing personal data.
+
+Operations are decentralized through **Circles of Trust**: community-backed groups of merchants run by Circle Admins who stake $P2P. Delegators stake $P2P to earn revenue share, and insurance pools cover disputes and slashing. Every participant has skin in the game through staked capital. The protocol earns revenue from transaction fees alone, with **no token emissions or inflationary incentives**.
+
+**Traction**
+
+- **2 Years** of live transaction volume with $4Mn monthly volume recorded in Feb 2026.
+- **$578K in Annual revenue run rate**, Unit breakeven, expected to contribute up to **20% of revenue as gross profit** to the treasury from June 2026
+- **27% average month-on-month growth** sustained over past 16 months. 
+- Live in **India, Brazil, Argentina, and Indonesia**.
+- All protocol metrics **verifiable on-chain**: https://dune.com/p2pme/latest
+- **NPS of 80**; 65% of users say they would be disappointed if they could no longer use the product.
+- Targeting **$500M monthly volume** over the next 18 months.
+
+**Market and Growth**
+
+The fiat-to-crypto on/off-ramp market in **emerging economies** is massive. **Over 1.5 billion people** have mobile phones but lack reliable access to stablecoins. A fast, low-cost, non-custodial path between fiat and stablecoins is essential infrastructure for this population, expanding across **Asia, Africa, Latin America, and MENA**.
+
+Three channels drive growth: (1) **direct user acquisition** via the p2p.me and coins.me apps, (2) a **B2B SDK** launching June 2026 that lets any wallet, app, or fintech embed P2P Protocol's on/off-ramp rails, and (3) **community-led expansion via Circles of Trust** where local operators onboard P2P merchants in new countries and earn revenue share. Post TGE, geographic expansion is permissionless through Circles of Trust and token-holder-driven parameter governance.
+
+On the supply side, anyone with a bank account and $250 in capital can become a liquidity provider (P2P Merchant) and earn passive income. The protocol creates liquidity providers the way ride-hailing platforms onboard drivers — anyone with capital and a bank account can participate.This **bottom-up liquidity engine** is deeply local, self-propagating, and hard to replicate.
+
+
+**Monthly Allowance Breakup: $175,000** 
+
+****
+
+- Team salaries (25 staff)       $75,000
+- Growth & Marketing             $50,000
+- Legal & operations                $35,000
+- Infrastructure                         $15,000
+
+****
+
+**Roadmap and Milestones**
+
+**Q2 2026** (months 1-3):
+- B2B SDK launch for third-party integrations
+- First on-chain treasury allocation
+- Multi-currency expansion (additional fiat corridors)
+
+**Q3 2026** (months 4-6):
+- Solana deployment
+- Additional country launches across Africa, MENA and LATAM
+- Phase 1 governance: Insurance pools, disputes and claims. 
+
+**Q4 2026** (months 7-9):
+- Phase 2 governance: token-holder voting activates for non-critical parameters
+- Community governance proposals enabled
+- Fiat-Fiat remittance corridor launches
+
+**Q1 2027** (months 10-12):
+- Growth across 20+ countries in Asia, Africa, MENA and LATAM
+- Operating profitability target
+- Phase 3 governance preparation: foundation veto sunset planning
+
+**Financial Projections**
+
+The protocol is forecast to reach **operating profitability by mid-2027**. At 30% monthly volume growth in early expansion phases, projected monthly volume reaches **~$333M by July 2027** with **~$383K monthly operating profit**. Revenue is driven entirely by **transaction fees (~6% variable spread)** on a working product. Full P&L projections are available in the docs.
+
+**Token and Ownership**
+
+Infrastructure as critical as this should not remain under the control of a single operator. **$P2P is an ownership token.** Protocol IP, treasury funds, and mint authority are controlled by token holders through **futarchy-based governance**, not by any single team or entity. Decisions that affect token supply must pass through a **decision-market governance mechanism**, where participants stake real capital on whether a proposal increases or decreases token value. Proposals the market predicts will harm value are automatically rejected.
+
+**No insider tokens unlock at TGE.** **50% of total supply will float at launch** (10M sale + 2.9M liquidity).
+
+- **Investor tokens (20% / 5.16M):** **Fully locked for 12 months.** 5 equal unlocks of 20% each: first at month 12, then at months 15, 18, 21, and 24. Fully vested at month 24. Enforced via on-chain vesting contracts. Locked tokens cannot be staked.
+- **Team tokens (30% / 7.74M):** **Performance-based only.** 12 months cliff period. 5 equal tranches unlocking at 2x, 4x, 8x, 16x, and 32x ICO price, post the cliff period. Price measured via 3-month TWAP. The team benefits when the protocol grows.
+
+- Past P2P protocol users get a preferential allocation at the same valuation as all the ICO investors based on their XP on https://p2p.foundation/
+
+**Value flows to holders because the protocol processes transactions, not because new tokens are printed.** Exit liquidity comes from participants who want to stake, govern, and earn from a working protocol, not from greater-fool dynamics.
+
+
+**Past Investors** 
+
+- **Reclaim protocol** (https://reclaimprotocol.org/) Angel invested in P2P Protocol in March 2023.  They own **3.45%** of the supply and Invested $80K 
+- **Alliance DAO** (https://alliance.xyz/) in March 2024. They own **4.66%** of supply and Invested $350K
+- **Multicoin Capital** (https://multicoin.capital/) is the first institutional investor to invest in P2P Protocol. They invested $1.4 Million in January 2025 at $15Mn FDV and own **9.33%** of the supply.
+- **Coinbase Ventures** (https://www.coinbase.com/ventures) invested $500K in P2P Protocol in Feb 2025 at 19.5Mn FDV. They own **2.56%** of the supply. 
+
+
+**Team**
+
+- **Sheldon (CEO and Co-founder):** Alumnus of a top Indian engineering school. Previously scaled a food delivery business to $2M annual revenue before exit to India's leading food delivery platform.
+- **Bytes (CTO and Co-founder):** Former engineer at a leading Indian crypto exchange and a prominent ZK-proof protocol. Deep expertise in the ZK technology stack powering the protocol.
+- **Donkey (COO):** Former COO of Brazil's largest food and beverage franchise. Leads growth strategy and operations across Latin America.
+- **Gitchad (CDO, Decentralisation Officer):** Former co-founder of two established Cosmos ecosystem protocols. Extensive experience scaling and decentralizing blockchain protocols.
+- **Notyourattorney (CCO) and Thatb3lawyer (CFO):** Former partners at a full-stack Web3 law firm. Compliance, legal frameworks, governance, and financial strategy across blockchain ventures.
+
+
+**Links**
+
+- [Pitch Deck](https://drive.google.com/file/d/1Q4fWx4jr_HfphDmSmsQ8MJvwV685lcvS/view)
+- [Website](https://p2p.foundation)
+- [Docs](https://docs.p2p.foundation)
+- [Financial Projections](https://docs.google.com/spreadsheets/u/2/d/e/2PACX-1vRpx5U6UnhLkNPs4hD2L50ZchFTF39t0NUs3-PcY-6qQpKqCUcghmBz9-8uR-sSjZItzrsT8yz5jPnR/pubhtml) 
+- [On-chain metrics](https://dune.com/p2pme/latest)
+- [P2P.me App](https://p2p.me/) 
+- [Coins.me App](https://coins.me/)
+- [P2P Foundation Twitter/X](https://x.com/p2pdotfound)
+- [P2P.me India Twitter/X](https://x.com/P2Pdotme)
+- [P2P.me Brazil Twitter/X](https://x.com/p2pmebrasil)
+- [P2P.me Argentina Twitter/X](https://x.com/p2pmeargentina)
+- [Discord](https://discord.gg/p2pfoundation)
+
+## Links
+
+- Website: https://p2p.me
+- Twitter: https://x.com/P2Pdotme
+- Telegram: https://t.me/P2Pdotme
+
+## Raw Data
+
+- Launch address: `H5ng9t1tPRvGx8QoLFjjuXKdkUjicNXiADFdqB6t8ifJ`
+- Token: P2P (P2P)
+- Token mint: `P2PXup1ZvMpCDkJn3PQxtBYgxeCSfH39SFeurGSmeta`
+- Version: v0.7

inbox/archive/2026-01-01-futardio-launch-p2p.md

@@ -0,0 +1,27 @@
+---
+type: source
+title: "Futardio: P2P fundraise goes live"
+author: "futard.io"
+url: "https://www.futard.io/launch/H5ng9t1tPRvGx8QoLFjjuXKdkUjicNXiADFdqB6t8ifJ"
+date: 2026-01-01
+domain: internet-finance
+format: data
+status: unprocessed
+tags: [futardio, metadao, futarchy, solana]
+event_type: launch
+---
+
+## Launch Details
+- Project: P2P
+- Funding target: $6,000,000.00
+- Total committed: N/A
+- Status: Initialized
+- Launch date: 2026-01-01
+- URL: https://www.futard.io/launch/H5ng9t1tPRvGx8QoLFjjuXKdkUjicNXiADFdqB6t8ifJ
+
+## Raw Data
+
+- Launch address: `H5ng9t1tPRvGx8QoLFjjuXKdkUjicNXiADFdqB6t8ifJ`
+- Token: P2P (P2P)
+- Token mint: `P2PXup1ZvMpCDkJn3PQxtBYgxeCSfH39SFeurGSmeta`
+- Version: v0.7

inbox/archive/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.md

@@ -0,0 +1,51 @@
+---
+type: source
+title: "Aon GLP-1 Research: Long-Term Employer Cost Savings and Cancer Risk Reduction"
+author: "Aon plc (@Aon)"
+url: https://aon.mediaroom.com/2026-01-13-Aons-Latest-GLP-1-Research-Reveals-Long-Term-Employer-Cost-Savings-and-Significant-Reductions-in-Cancer-Risk-for-Women
+date: 2026-01-13
+domain: health
+secondary_domains: [internet-finance]
+format: report
+status: unprocessed
+priority: high
+tags: [glp-1, employer-costs, cancer-risk, cardiovascular, cost-offset, real-world-evidence]
+---
+
+## Content
+
+Aon's multi-year study of U.S. commercial health claims data from 192,000+ GLP-1 users. Released January 13, 2026.
+
+**Cost dynamics over time (key finding):**
+- First 12 months on Wegovy/Zepbound: medical costs rise 23% vs. 10% for non-users (drug costs dominate)
+- After 12 months: medical costs grow just 2% vs. 6% for non-users (downstream savings kick in)
+- For diabetes indication: medical cost growth 6 percentage points lower at 30 months; 9 points lower with 80%+ adherence
+- For weight loss indication: cost growth 3 points lower at 18 months; 7 points lower with consistent use
+
+**Cancer risk reduction (surprising finding):**
+- Female GLP-1 users: ~50% lower incidence of ovarian cancer
+- Female GLP-1 users: 14% lower incidence of breast cancer
+- Also associated with lower rates of osteoporosis, rheumatoid arthritis
+- Fewer hospitalizations for alcohol/drug abuse, bariatric surgery, certain pancreatic disorders
+
+**Cardiovascular outcomes:**
+- Adherent users (80%+): significantly fewer MACE hospitalizations
+- Female MACE reduction: 47%
+- Male MACE reduction: 26%
+
+**Adherence is the binding variable:** Benefits scale dramatically with adherence. The 80%+ adherent cohort shows the strongest effects across all outcomes.
+
+## Agent Notes
+**Why this matters:** This is the largest real-world employer claims dataset on GLP-1 economics. The temporal pattern is crucial — costs go UP in year 1 then DOWN thereafter. This means short-term payers (employers with high turnover) see only costs, while long-term risk-bearers (MA plans, capitated systems) capture the savings. This has direct implications for VBC economics.
+**What surprised me:** The cancer finding is genuinely novel. A 50% reduction in ovarian cancer incidence is enormous if confirmed. The sex-differential in MACE reduction (47% for women vs. 26% for men) also suggests the benefits may be larger for women, which has implications for MA risk adjustment.
+**What I expected but didn't find:** No stratification by payment model (capitation vs. FFS). No analysis of the break-even point for total cost of ownership. No comparison of the cost trajectory for adherent vs. non-adherent users on a per-user basis.
+**KB connections:** The temporal cost pattern directly tests [[the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness]] — long-term risk-bearing is required to capture GLP-1 savings.
+**Extraction hints:** Potential claim: "GLP-1 cost-effectiveness requires sustained adherence and long-term risk-bearing because medical cost savings lag drug costs by 12-18 months, making short-term payers see only costs while capitated plans capture net savings." The cancer signal deserves its own claim if replicated.
+**Context:** Aon is a major insurance broker/consultant. Their data is commercial claims (employer-sponsored), not Medicare. The 192K sample is large but observational — selection bias is a concern (healthier/wealthier employees may be more likely to use GLP-1s).
+
+## Curator Notes (structured handoff for extractor)
+PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
+WHY ARCHIVED: The temporal cost dynamics (costs up Y1, down Y2+) are the most important data point for understanding VBC interaction — shows why payment model structure determines whether GLP-1s are inflationary or cost-saving
+EXTRACTION HINT: Focus on the temporal cost curve and what it implies for different payment models. The cancer finding is separately important but preliminary.
+
+flagged_for_rio: ["GLP-1 cost dynamics have direct implications for health investment thesis — long-term risk-bearers capture savings that short-term payers miss"]

inbox/archive/2026-02-01-glp1-patent-cliff-generics-global-competition.md

@@ -0,0 +1,52 @@
+---
+type: source
+title: "The 2026 GLP-1 Patent Cliff: Generics, Global Competition, and the $100 Billion M&A Race"
+author: "GeneOnline News"
+url: https://www.geneonline.com/the-2026-glp-1-patent-cliff-generics-global-competition-and-the-100-billion-ma-race/
+date: 2026-02-01
+domain: health
+secondary_domains: [internet-finance]
+format: article
+status: unprocessed
+priority: medium
+tags: [glp-1, generics, patent-cliff, global-competition, drug-pricing, market-structure]
+---
+
+## Content
+
+Overview of the GLP-1 generic competition landscape as patents begin expiring internationally.
+
+**US timeline:**
+- Semaglutide patents extend to 2031-2032 (US and Europe)
+- No US generics expected before 2031-2033
+- Orforglipron (Eli Lilly, non-peptide small molecule) could be approved Q2 2026
+
+**International generic competition (2026):**
+- Canada: First G7 nation where certain semaglutide patents expired (January 4, 2026). Sandoz, Apotex, Teva filing immediately
+- Brazil: Generic competition opening March 2026. Biomm + Biocon (India) preparing generic semaglutide
+- China: 17+ generic semaglutide candidates in Phase 3 trials. Monthly therapy could fall to $40-$50
+- India: Patent expirations scheduled March 2026
+
+**Price trajectory:**
+- Oral Wegovy: $149-$299/month at launch (January 2026)
+- Medicare deal: $245/month
+- International generics: potentially $40-$50/month in some markets
+- Competition will drive prices down, but volume growth offsets price compression in near term
+
+**Pipeline competitors:**
+- Orforglipron (Lilly): non-peptide oral GLP-1, potential approval Q2 2026
+- Amycretin: 22% weight loss without plateau
+- Multiple next-generation compounds in development
+
+## Agent Notes
+**Why this matters:** The price trajectory is the single most important variable for the GLP-1 cost-effectiveness calculation. If prices converge toward $50-100/month globally by 2030 (driven by international generic competition, even before US generics), the "inflationary through 2035" claim needs significant revision. At $50/month, GLP-1s become unambiguously cost-effective under any payment model.
+**What surprised me:** Canada's patents expired January 2026 — generic filings are already happening. The $40-$50/month projection for China/India is 95%+ below current US list price. International price arbitrage pressure will affect US pricing even before US patent expiry.
+**What I expected but didn't find:** No analysis of how international generic availability affects US compounding pharmacy landscape. No modeling of the price trajectory beyond "prices will decline."
+**KB connections:** The price trajectory directly affects whether the existing GLP-1 claim's "inflationary through 2035" conclusion holds. If prices decline faster than assumed, the inflection point (where volume growth no longer offsets price compression) moves earlier.
+**Extraction hints:** Potential claim: "International GLP-1 generic competition beginning in 2026 will compress global prices below $100/month by 2030, fundamentally changing the cost-effectiveness calculation from inflationary to cost-saving under risk-bearing payment models."
+**Context:** GeneOnline is an industry publication. The $40-$50 projection for China/India may be optimistic. US prices will remain higher due to regulatory and distribution differences. But the directional pressure is clear.
+
+## Curator Notes (structured handoff for extractor)
+PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
+WHY ARCHIVED: Price trajectory is the key variable the existing claim depends on — if prices decline faster than assumed, the "inflationary through 2035" conclusion may be wrong
+EXTRACTION HINT: Focus on the price trajectory and its implications for cost-effectiveness under different payment models, especially the international competition pressure

inbox/archive/2026-02-01-traceabilityhub-digital-provenance-content-authentication.md

@@ -7,10 +7,15 @@ date: 2026-02-01
 domain: entertainment
 secondary_domains: [ai-alignment, cultural-dynamics]
 format: report
-status: unprocessed
+status: null-result
 priority: medium
 tags: [digital-provenance, deepfakes, content-authentication, synthetic-media, trust-crisis]
 flagged_for_theseus: ["Synthetic media crisis scale — 8M deepfakes, 90% synthetic content projection, trust collapse metrics"]
+processed_by: clay
+processed_date: 2026-03-11
+enrichments_applied: ["human-made-is-becoming-a-premium-label-analogous-to-organic-as-AI-generated-content-becomes-dominant.md", "GenAI adoption in entertainment will be gated by consumer acceptance not technology capability.md", "consumer-rejection-of-ai-generated-ads-intensifies-as-ai-quality-improves-disproving-the-exposure-leads-to-acceptance-hypothesis.md", "community-owned-IP-has-structural-advantage-in-human-made-premium-because-provenance-is-inherent-and-legible.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
+extraction_notes: "Extracted two claims on synthetic media scarcity economics and fraud scaling, plus four enrichments to existing entertainment claims. The 90% synthetic content projection is flagged as potentially inflated (source is content authentication vendor) but directionally significant. Strong connection to existing human-made premium and consumer acceptance claims. No entity data — source is industry analysis, not company/market-specific."
 ---
 
 ## Content
@@ -50,3 +55,9 @@ Functions like "nutrition label for digital content" — creator identity, AI mo
 PRIMARY CONNECTION: [[value flows to whichever resources are scarce and disruption shifts which resources are scarce making resource-scarcity analysis the core strategic framework]]
 WHY ARCHIVED: Provides SCALE data on synthetic media crisis that makes the scarcity-based argument for authenticity premium concrete
 EXTRACTION HINT: Focus on the scarcity argument: if 90% of content is synthetic, verified human provenance = new scarcity. But caveat the 90% figure as potentially inflated.
+
+
+## Key Facts
+- C2PA/Content Credentials embeds creator identity, AI model specs, and generation prompts in verifiable metadata using cryptographic signatures
+- Gartner identifies digital provenance among top 10 tech trends through 2030
+- Companies report 20% more video deepfake incidents (2026 vs baseline)

inbox/archive/2026-02-17-futardio-launch-generated-test.md

@@ -6,9 +6,13 @@ url: "https://www.futard.io/launch/8tUzX5dPQbkayE4FkFncdyePWP3shBQ8hvjr5HbFoS84"
 date: 2026-02-17
 domain: internet-finance
 format: data
-status: unprocessed
+status: null-result
 tags: [futardio, metadao, futarchy, solana]
 event_type: launch
+processed_by: rio
+processed_date: 2026-03-11
+extraction_model: "anthropic/claude-sonnet-4.5"
+extraction_notes: "Test/demonstration launch with trivial amounts and generic template content. Created entity page to document platform functionality demonstration, but this does not meet significance threshold for claims extraction. No novel mechanism insights or governance dynamics to extract."
 ---
 
 ## Launch Details
@@ -130,3 +134,9 @@ You can follow our progress via our official website, Telegram community, Twitte
 - Total approved: $10.00
 - Closed: 2026-02-17
 - Completed: 2026-02-17
+
+
+## Key Facts
+- Generated Test raised $11 against $10 target on Futardio (2026-02-17)
+- Launch used token symbol GBX with mint address GBXKJSjyx76MbsooT8kCnjhPrDxkvWwscxXw2BBftdio
+- Futardio platform was running version v0.7 as of 2026-02-17

inbox/archive/2026-02-23-cbo-medicare-trust-fund-2040-insolvency.md

@@ -7,9 +7,15 @@ date: 2026-02-23
 domain: health
 secondary_domains: []
 format: report
-status: unprocessed
+status: processed
 priority: high
 tags: [medicare-solvency, trust-fund, cbo, big-beautiful-bill, fiscal-sustainability, demographics]
+processed_by: vida
+processed_date: 2026-03-11
+claims_extracted: ["medicare-trust-fund-insolvency-accelerated-12-years-by-tax-policy-demonstrating-fiscal-fragility.md", "medicare-fiscal-pressure-forces-ma-reform-by-2030s-through-arithmetic-not-ideology.md"]
+enrichments_applied: ["the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline.md", "CMS 2027 chart review exclusion targets vertical integration profit arbitrage by removing upcoded diagnoses from MA risk scoring.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
+extraction_notes: "Extracted two claims: (1) the speed of solvency collapse as evidence of Medicare's fiscal fragility, (2) the forcing function for MA reform created by converging fiscal pressures. Enriched two existing claims with trust fund timeline context. The core insight is the arithmetic forcing function — not ideological but mathematical — that will drive reform conversations through the 2030s."
 ---
 
 ## Content
@@ -55,3 +61,17 @@ tags: [medicare-solvency, trust-fund, cbo, big-beautiful-bill, fiscal-sustainabi
 PRIMARY CONNECTION: [[the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline]]
 WHY ARCHIVED: Critical fiscal context — the solvency timeline constrains all Medicare policy including MA reform, VBC transition, and coverage decisions.
 EXTRACTION HINT: The 2055→2040 collapse in one year is the extractable insight. It demonstrates Medicare's fiscal fragility and the interaction between tax policy and healthcare sustainability.
+
+
+## Key Facts
+- CBO March 2025 projection: Medicare trust fund solvent through 2055
+- CBO February 2026 projection: Medicare trust fund exhausted by 2040
+- Solvency loss: 12 years in under one year
+- Big Beautiful Bill signed July 2025: lowered taxes, created temporary deduction for 65+
+- Trust fund exhaustion triggers 8% benefit cuts in 2040, climbing to 10% by 2056
+- Baby boomers all 65+ by 2030
+- 65+ population growth: 39.7M (2010) → 67M (2030)
+- Working-age to 65+ ratio: 2.8:1 (2025) → 2.2:1 (2055)
+- OECD old-age dependency ratio: 31.3% (2023) → 40.4% (2050)
+- MA overpayments: $84B/year, $1.2T/decade
+- Reducing MA benchmarks could save $489B over decade

inbox/archive/2026-02-27-theiaresearch-metadao-claude-code-founders.md

@@ -6,8 +6,13 @@ date: 2026-02-27
 archived_by: rio
 tags: [metadao, futard, claude-code, solo-founder, capital-formation, fundraising]
 domain: internet-finance
-status: unprocessed
+status: enrichment
 claims_extracted: []
+processed_by: rio
+processed_date: 2026-03-11
+enrichments_applied: ["internet-capital-markets-compress-fundraising-timelines.md", "MetaDAO is the futarchy launchpad on Solana where projects raise capital through unruggable ICOs governed by conditional markets creating the first platform for ownership coins at scale.md", "futarchy-governed-permissionless-launches-require-brand-separation-to-manage-reputational-liability-because-failed-projects-on-a-curated-platform-damage-the-platforms-credibility.md", "cryptos primary use case is capital formation not payments or store of value because permissionless token issuance solves the fundraising bottleneck that solo founders and small teams face.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
+extraction_notes: "Single-source claim from credible institutional investor (Theia Research) with position in MetaDAO. Primary extraction: new claim identifying AI-native solo founders as specific user segment for MetaDAO's permissionless launches. Four enrichments extending existing claims about fundraising compression, MetaDAO positioning, brand separation, and crypto's capital formation use case. Confidence rated experimental due to single source and lack of empirical validation of 'days' timeline or AI-native founder adoption data."
 ---
 
 # @TheiaResearch — MetaDAO + Claude Code founders narrative
@@ -25,3 +30,8 @@ claims_extracted: []
 - The "Claude Code founders" framing is significant: AI-native solo builders as the primary user base for permissionless capital formation
 - Enriches futard.io brand separation claim — Theia is endorsing the permissionless launch brand
 - New claim candidate: internet capital markets compress fundraising from months to days
+
+
+## Key Facts
+- Tweet received 14,948 views, 78 likes, 23 retweets, 9 replies, 7 bookmarks (2026-02-27)
+- Felipe Montealegre is fund manager at Theia Research, which has invested in MetaDAO

inbox/archive/2026-03-01-contentauthenticity-state-of-content-authenticity-2026.md

@@ -7,10 +7,15 @@ date: 2026-03-01
 domain: entertainment
 secondary_domains: [ai-alignment, cultural-dynamics]
 format: report
-status: unprocessed
+status: null-result
 priority: high
 tags: [content-provenance, C2PA, content-credentials, digital-authenticity, trust-infrastructure]
 flagged_for_theseus: ["Content authentication infrastructure as alignment mechanism — provenance verification is a trust coordination problem"]
+processed_by: clay
+processed_date: 2026-03-11
+enrichments_applied: ["community-owned-IP-has-structural-advantage-in-human-made-premium-because-provenance-is-inherent-and-legible.md", "human-made-is-becoming-a-premium-label-analogous-to-organic-as-AI-generated-content-becomes-dominant.md", "GenAI adoption in entertainment will be gated by consumer acceptance not technology capability.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
+extraction_notes: "Extracted two claims: (1) infrastructure deployment claim documenting consumer-scale rollout of C2PA/Content Credentials, (2) cross-domain mechanism claim connecting content authentication to trust coordination problems. Applied three enrichments to existing entertainment claims about human-made premium, consumer acceptance gating, and community-owned IP provenance advantage. Source provides concrete infrastructure evidence (hardware, software, standards) rather than just conceptual framework. Agent notes correctly identified this as supply-side infrastructure for authenticity premium. No entertainment-specific adoption metrics (studio/platform usage) available in source."
 ---
 
 ## Content
@@ -43,3 +48,13 @@ CAI emphasizes convergence among diverse content creators on shared attribution
 PRIMARY CONNECTION: [[GenAI adoption in entertainment will be gated by consumer acceptance not technology capability]]
 WHY ARCHIVED: Content provenance infrastructure is the supply-side of the authenticity premium — makes human origin verifiable
 EXTRACTION HINT: Focus on the INFRASTRUCTURE buildout, not just the concept. Consumer hardware (Pixel 10) + enterprise tools (Adobe) + standards (C2PA 1.2) = provenance becomes ambient, not opt-in.
+
+
+## Key Facts
+- Content Authenticity Initiative expanded to 6,000+ global members by 2026
+- Google Pixel 10 launched with C2PA credential support (2026)
+- Sony PXW-Z300 released with Content Credentials integration (2026)
+- Adobe Content Authenticity for Enterprise launched (2026)
+- C2PA Conformance Program established (2026)
+- CAWG 1.2 Specification released (2026)
+- learn.contentauthenticity.org launched in collaboration with Pixelstream (2026)

inbox/archive/2026-03-03-futardio-launch-milo-ai-agent.md

@@ -6,9 +6,13 @@ url: "https://www.futard.io/launch/4EhLS9CWQ2dQQe1nexxvB6D3c5jGaRCirpQ5GJFS43nR"
 date: 2026-03-03
 domain: internet-finance
 format: data
-status: unprocessed
+status: processed
 tags: [futardio, metadao, futarchy, solana]
 event_type: launch
+processed_by: rio
+processed_date: 2026-03-11
+extraction_model: "anthropic/claude-sonnet-4.5"
+extraction_notes: "Failed futarchy launch with trivial capital commitment. Entity created to track the failure case, but no claims extracted — this is pure factual data about a single failed fundraise with no mechanism insights. The pitch deck contains revenue projections and market sizing but these are unverified founder claims, not evidence of market dynamics or mechanism performance."
 ---
 
 ## Launch Details
@@ -131,3 +135,11 @@ It’s a full digital real estate partner.
 - Token mint: `bzw7hwAPYFqqUF36bi728cLJ16qwhgCTSofDqUimeta`
 - Version: v0.7
 - Closed: 2026-03-04
+
+
+## Key Facts
+- MILO AI Agent raised $200 of $250,000 target (0.08% success rate)
+- Trident MLS has over 7,000 active real estate agents
+- MILO targeted $115/month subscription model
+- Founder Nathan Wissing has 9 years real estate experience in Charleston market
+- MILO was in Alpha testing with 15-person waitlist at launch

inbox/archive/2026-03-04-futardio-launch-futara.md

@@ -6,13 +6,17 @@ url: "https://www.futard.io/launch/Gt9eVcwmH8mNVyCWWRfL3K1CFxaVNpSJGKtUujwRjFU6"
 date: 2026-03-04
 domain: internet-finance
 format: data
-status: unprocessed
+status: processed
 tags: [futardio, metadao, futarchy, solana]
 event_type: launch
 processed_by: rio
 processed_date: 2026-03-11
 extraction_model: "anthropic/claude-sonnet-4.5"
 extraction_notes: "This source is a single failed fundraise event on the futard.io platform. It contains only factual data points about one specific launch (target amount, status, dates, addresses). The team description fragment ('cover the accommodation costs in Dubai due to the inability to return home') appears incomplete and provides no extractable insight. No arguable claims present. No evidence that would enrich existing claims about MetaDAO, futarchy mechanisms, or internet finance patterns. This is raw event data suitable for archive reference but contains no interpretive content or novel evidence about platform dynamics, success patterns, or governance mechanisms. The failure itself (refunding status, same-day close) is a single data point insufficient to support claims about platform performance or futarchy adoption without additional context or pattern evidence."
+processed_by: rio
+processed_date: 2026-03-11
+extraction_model: "anthropic/claude-sonnet-4.5"
+extraction_notes: "Single failed fundraise event with no extractable claims. Source contains only factual data points about one specific launch. The incomplete team description fragment provides no interpretable insight. No evidence that would enrich existing claims about futarchy mechanisms, platform dynamics, or internet finance patterns. This is a single data point insufficient to support claims about platform performance without additional context. Created minimal entity entry for FUTARA as it represents a real launch event on futard.io, though it failed immediately. No claims extracted per extraction_notes guidance that this contains 'no interpretive content or novel evidence about platform dynamics, success patterns, or governance mechanisms.'"
 ---
 
 ## Launch Details
@@ -46,3 +50,13 @@ cover the accommodation costs in Dubai due to the inability to return home.
 - Launch address: Gt9eVcwmH8mNVyCWWRfL3K1CFxaVNpSJGKtUujwRjFU6
 - Token: 4kw, mint: 4kwvR2fzkKCGRAeDx4YkQ1afVCofwRyQQhMFHSXgmeta
 - Platform version: v0.7
+
+
+## Key Facts
+- FUTARA launched on futard.io 2026-03-04
+- FUTARA funding target: $50,000
+- FUTARA status: Refunding (failed)
+- FUTARA closed 2026-03-04 (same day as launch)
+- FUTARA token: 4kw (mint: 4kwvR2fzkKCGRAeDx4YkQ1afVCofwRyQQhMFHSXgmeta)
+- FUTARA launch address: Gt9eVcwmH8mNVyCWWRfL3K1CFxaVNpSJGKtUujwRjFU6
+- Platform version: v0.7

inbox/archive/2026-03-04-futardio-launch-island.md

@@ -6,9 +6,13 @@ url: "https://www.futard.io/launch/FpFytak8JZwVntqDh9G95zqXXVJNXMxRFUYY959AXeZj"
 date: 2026-03-04
 domain: internet-finance
 format: data
-status: unprocessed
+status: processed
 tags: [futardio, metadao, futarchy, solana]
 event_type: launch
+processed_by: rio
+processed_date: 2026-03-11
+extraction_model: "anthropic/claude-sonnet-4.5"
+extraction_notes: "Failed fundraise with minimal market validation (0.5% of target). No novel claims extracted — the failure itself is the primary data point. Three entities created: Island (company), the fundraise decision market, and founder xpmaxxer. Project represents a test of DeFi-travel loyalty thesis that found no market support."
 ---
 
 ## Launch Details
@@ -216,3 +220,17 @@ Earn yield. Earn points. Travel for pennies.
 - Token mint: `CGaDW7QYCNdVzivFabjWrpsqW7C4A3WSLjdkH84Pmeta`
 - Version: v0.7
 - Closed: 2026-03-05
+
+
+## Key Facts
+- Island.ag fundraise launched 2026-03-04 on Futardio
+- Funding target: $50,000
+- Total committed: $250 (0.5% of target)
+- Status: Refunding
+- Closed: 2026-03-05
+- Token: CGa (mint: CGaDW7QYCNdVzivFabjWrpsqW7C4A3WSLjdkH84Pmeta)
+- Autocrat version: v0.7
+- Founder: xpmaxxer (hospitality background)
+- Proposed model: DeFi yield discovery + hotel booking with Island Points loyalty system
+- Planned spend: 80% marketing, 10% infrastructure, 10% operations
+- Incentive: $1 minimum participation entered raffle for $1,500 tokens or Alps hotel stay

inbox/archive/2026-03-04-futardio-launch-one-of-sick-token.md

@@ -13,6 +13,10 @@ processed_by: rio
 processed_date: 2026-03-11
 extraction_model: "anthropic/claude-sonnet-4.5"
 extraction_notes: "This source is a single failed token launch data point with no substantive description, team information, or analysis. The project description is repetitive placeholder text ('one of sick token' repeated 19 times). The 'links' point to Twitter searches, not actual project accounts. This represents a failed launch event but contains no evidence supporting new claims about futarchy, MetaDAO platform dynamics, launch success factors, or internet finance mechanisms. It's a data point for potential aggregate analysis (e.g., if we were tracking MetaDAO launch success rates) but alone provides no arguable insight. The existing claim 'MetaDAO is the futarchy launchpad on Solana' already establishes the platform's existence; this single failure neither confirms nor challenges any existing claims about platform efficacy, user behavior, or market dynamics. Preserved as archival fact in case future aggregate analysis of launch patterns becomes relevant."
+processed_by: rio
+processed_date: 2026-03-11
+extraction_model: "anthropic/claude-sonnet-4.5"
+extraction_notes: "Single failed token launch with no substantive content. Project description is placeholder text ('one of sick token' repeated 19 times). Links point to Twitter searches, not actual project accounts. This represents a failed launch event but contains no evidence supporting new claims about futarchy, MetaDAO platform dynamics, launch success factors, or internet finance mechanisms. The existing claim 'MetaDAO is the futarchy launchpad on Solana' already establishes the platform's existence; this single failure neither confirms nor challenges any existing claims about platform efficacy, user behavior, or market dynamics. Below significance threshold for standalone entity (trivial amount, refunding status, no real project). Preserved as archival fact in source metadata for potential future aggregate analysis of launch patterns."
 ---
 
 ## Launch Details
@@ -42,6 +46,15 @@ one of sick token one of sick token one of sick token one of sick token one of s
 - Closed: 2026-03-05
 
 
+## Key Facts
+- Futardio launch 'one of sick token' targeted $50,000 funding (2026-03-04)
+- Launch received only $50 in commitments before entering refund status
+- Launch closed 2026-03-05 after one day
+- Token: HsN, mint address HsNsqUzMZvLw2imafejioN18oQ5r1gr65eVB1wRVmeta
+- Launch address: Gdyb1kNw26gve1VqU3zRxwZJhwJd5nAQ4goKNvAQBv9K
+- Platform version: v0.7
+
+
 ## Key Facts
 - Futardio launch 'one of sick token' targeted $50,000 funding (2026-03-04)
 - Launch received only $50 in commitments before entering refund status

inbox/archive/2026-03-04-futardio-launch-test.md

@@ -6,13 +6,17 @@ url: "https://www.futard.io/launch/9SzcHQzMbxBbCEtLyRsuUcQn8cMSzjxnDG9WuSZCMJM5"
 date: 2026-03-04
 domain: internet-finance
 format: data
-status: unprocessed
+status: null-result
 tags: [futardio, metadao, futarchy, solana]
 event_type: launch
 processed_by: rio
 processed_date: 2026-03-11
 extraction_model: "anthropic/claude-sonnet-4.5"
 extraction_notes: "This is a test launch with placeholder content ('TESTTEST...'). No actual project description, team information, or meaningful data. The $9 commitment and immediate refunding status confirm this was a platform test, not a real fundraise. No extractable claims or enrichments — purely operational test data."
+processed_by: rio
+processed_date: 2026-03-11
+extraction_model: "anthropic/claude-sonnet-4.5"
+extraction_notes: "This is a test launch with placeholder content ('TESTTEST...'). No actual project description, team information, or meaningful data. The $9 commitment and immediate refunding status confirm this was a platform test, not a real fundraise. No extractable claims or enrichments — purely operational test data. Does not meet entity significance threshold (trivial amount, refunding status, test content)."
 ---
 
 ## Launch Details
@@ -45,3 +49,10 @@ TESTTESTTESTTESTTESTTESTTESTTESTTESTTESTTESTTESTTESTTESTTESTTESTTESTTESTTESTTEST
 - Launch address: 9SzcHQzMbxBbCEtLyRsuUcQn8cMSzjxnDG9WuSZCMJM5
 - Token: J5Q
 - Version: v0.7
+
+
+## Key Facts
+- Futardio test launch executed 2026-03-04 with $100K target
+- Test received $9 in commitments before entering refunding status
+- Launch used token J5Q on Solana (mint: J5QujLASJDfSck9znKSVYDNqasYPmUxVoNQLppNfmeta)
+- Platform version v0.7 operational

inbox/archive/2026-03-08-futardio-launch-seeker-vault.md

@@ -6,9 +6,13 @@ url: "https://www.futard.io/launch/7AMzZD3JZ15FCX2eoC17KgJD5Ywum9J5i7E9BAbgc2vi"
 date: 2026-03-08
 domain: internet-finance
 format: data
-status: unprocessed
+status: processed
 tags: [futardio, metadao, futarchy, solana]
 event_type: launch
+processed_by: rio
+processed_date: 2026-03-11
+extraction_model: "anthropic/claude-sonnet-4.5"
+extraction_notes: "Futardio fundraise for SeekerVault. Failed to reach funding target (4.2% subscription). No novel claims about futarchy mechanisms or market dynamics — straightforward failed raise. Entity data only."
 ---
 
 ## Launch Details
@@ -160,3 +164,12 @@ Two builders, zero fluff. All execution.
 - Token mint: `J4rMkvf4qwJgX2nK3ueeL4E423chSG2jVqgk5LAGmeta`
 - Version: v0.7
 - Closed: 2026-03-09
+
+
+## Key Facts
+- SeekerVault targets 150,000+ Solana Seeker phone users
+- Walrus + Seal used as storage infrastructure
+- Pricing: 20MB free tier, 100GB for $10/month in SKR
+- Team: 2 builders (gbflarcos, Beardkoda)
+- Requested runway: 6+ months at $8,000/month burn rate
+- Product status: Live at seekervault.xyz, dApp Store listing in review

inbox/archive/2026-03-09-rocketresearchx-x-archive.md

@@ -6,7 +6,7 @@ url: https://x.com/rocketresearchx
 date: 2026-03-09
 domain: internet-finance
 format: tweet
-status: unprocessed
+status: null-result
 last_attempted: 2026-03-11
 tags: [media, research, trading, market-analysis, solana]
 linked_set: metadao-x-landscape-2026-03
@@ -24,6 +24,10 @@ processed_by: rio
 processed_date: 2026-03-10
 extraction_model: "minimax/minimax-m2.5"
 extraction_notes: "Source contains only trading/technical analysis content (EMA 8 rejection, market cap comparisons, geopolitical risk assessment). Curator notes explicitly classify this as low priority with null-result likely for mechanism design claims. Only 2 peripheral MetaDAO references. No novel claims about futarchy, Living Capital, or token economics that aren't already covered in existing knowledge base. Content is market commentary rather than mechanism design insight."
+processed_by: rio
+processed_date: 2026-03-11
+extraction_model: "anthropic/claude-sonnet-4.5"
+extraction_notes: "Source contains only trading/technical analysis content (EMA 8 rejection, market cap comparisons, geopolitical risk assessment). Curator notes explicitly classify this as low priority with null-result likely for mechanism design claims. Only 2 peripheral MetaDAO references. No novel claims about futarchy, Living Capital, or token economics that aren't already covered in existing knowledge base. Content is market commentary rather than mechanism design insight."
 ---
 
 # @rocketresearchx X Archive (March 2026)
@@ -49,3 +53,9 @@ extraction_notes: "Source contains only trading/technical analysis content (EMA
 - Only 2 MetaDAO references - described as peripheral to ecosystem
 - Priority was marked as low by curator
 - Extraction hints indicated null-result likely for MetaDAO-specific claims
+
+
+## Key Facts
+- @rocketresearchx is an OG crypto research outfit operating since 2011
+- Content has 94% substantive ratio but is trading/technical analysis focused
+- Only 2 MetaDAO references in 100 tweets - described as peripheral to ecosystem

inbox/archive/2026-03-12-futardio-launch-hc4.md

@@ -0,0 +1,27 @@
+---
+type: source
+title: "Futardio: HC4 fundraise goes live"
+author: "futard.io"
+url: "https://www.futard.io/launch/DSt7fVv3fEt5brtchiqo1m4J5MRvHPBDkYm7aTpLAjVN"
+date: 2026-03-12
+domain: internet-finance
+format: data
+status: unprocessed
+tags: [futardio, metadao, futarchy, solana]
+event_type: launch
+---
+
+## Launch Details
+- Project: HC4
+- Funding target: $1.00
+- Total committed: $1.00
+- Status: Live
+- Launch date: 2026-03-12
+- URL: https://www.futard.io/launch/DSt7fVv3fEt5brtchiqo1m4J5MRvHPBDkYm7aTpLAjVN
+
+## Raw Data
+
+- Launch address: `DSt7fVv3fEt5brtchiqo1m4J5MRvHPBDkYm7aTpLAjVN`
+- Token: HC4 (HC4)
+- Token mint: `HC4SA5CStYzkcYwTaXVZ7pQuxaK7kpHUNNXbFosZmeta`
+- Version: v0.7